CONFIDENTIAL –FOIA Exemptions Apply in U.S. 1
Status: Approved ,Date: 4 June 2021Janssen Research & Development *
Clinical Protocol
A Phase 2b, Randomized, Double -blind, Placebo- controlled, Parallel -group, Multicenter 
Protocol to Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately 
to Severely Active Crohn’s Disease
TRIDENT
Protocol 64304500CRD2001; Phase 2b
AMENDMENT 7
JNJ-64304500
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen 
Biologics, BV; Janssen -Cilag International NV; Janssen, Inc; Janssen Infectious Diseases BVBA; Janssen 
Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout 
the protocol to represent these various legal entities; the sponsor is identified on the Contact [CONTACT_23756].
This study will be conducted under US Food & Drug Administration IND regulations (21 CFR Part 312).
EudraCT NUMBER: 2016 -000634 -21
Status: Approved
Date: 4 June 2021
Prepared by: [CONTACT_12945] & Development, LLC
EDMS number :EDMS- ERI-117774163:9 .0
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements .
Confidentiality Statement
The information provided herein contains Company trade secrets, commercial or financial information that the Company 
customarily holds close and treats as confidential. The information is be ing provided under the assurance that the recipi[INVESTIGATOR_23754], regulations, rules, protective orders or otherwise .
[STUDY_ID_REMOVED]
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 2
Approved , Date: [ADDRESS_1241385] OF IN -TEXT T ABLES A ND FIGURES ................................ ................................ ................................ 6
PROTOCOL A MENDMENTS ................................ ................................ ................................ ....................... 7
SYNOPSIS ................................ ................................ ................................ ................................ .................. 57
TIME AND EVENTS SCHE DULE: PA RT I ................................ ................................ ................................ 65
TIME AND EVENTS SCHE DULE: PA RT II M AIN S TUDY PHA SE................................ .......................... 69
TIME AND EVENTS SCHE DULE: PA RT II LONG -TERM  EXTENSION ................................ ................... 74
TIME AND EVENTS SCHE DULE: PA RT II LONG -TERM  EXTENSION ................................ ................... 76
ABBREVIA TIONS ................................ ................................ ................................ ................................ ......77
1. INTRODUCTION ................................ ................................ ................................ ................................ 79
1.1. Nonclinical Studies ................................ ................................ ................................ ......................... 80
1.2. Clinical Studies ................................ ................................ ................................ ............................... 80
1.2.1. Rheumatoid Arthritis ................................ ................................ ................................ ................... 80
1.2.2. Crohn’s Disease ................................ ................................ ................................ ......................... 80
2. OBJECTIVES, ENDPOINT S, AND HYPOTHESIS ................................ ................................ ........... 83
2.1. Objectives and Endpoints ................................ ................................ ................................ .............. 83
2.1.1. Objectives ................................ ................................ ................................ ................................ ...83
2.1.2. Endpoints ................................ ................................ ................................ ................................ ....83
2.2. Hypothesis ................................ ................................ ................................ ................................ .....85
3. STUDY DESIGN A ND RA TIONA LE................................ ................................ ................................ .85
3.1. Overview of Study Design ................................ ................................ ................................ .............. 85
3.1.1. Part I................................ ................................ ................................ ................................ ........... 90
3.1.2. Part II................................ ................................ ................................ ................................ .......... 90
3.1.3. Interim Analysis ................................ ................................ ................................ .......................... 91
3.1.4. Part II Long -Term Extension ................................ ................................ ................................ ....... 91
3.2. Study Design Rationale ................................ ................................ ................................ .................. 93
3.2.1. Choice of JNJ -64304500 Dose for Placebo Nonresponders ................................ ...................... 93
3.2.2. Efficacy  Assessments ................................ ................................ ................................ ................. 94
3.2.3. Pharmacokinetic Assessments ................................ ................................ ................................ ...94
3.2.4. Immunogenicity Assessments ................................ ................................ ................................ ....94
3.2.5. Pharmacodynamic Assessments ................................ ................................ ............................... 94
3.2.6. DNA and Biomarker Collection ................................ ................................ ................................ ...95
3.2.7. Control, Randomization, and Blinding ................................ ................................ ........................ 95
3.2.8. Dose Selection ................................ ................................ ................................ ............................ 96
[IP_ADDRESS]. JNJ-64304500 ................................ ................................ ................................ ......................... 96
[IP_ADDRESS]. Ustekinumab ................................ ................................ ................................ ............................ [ADDRESS_1241386] POPUL ATION................................ ................................ ................................ .................. 99
4.1. Inclusion Criteria ................................ ................................ ................................ .......................... 100
4.2. Exclusion Criteria ................................ ................................ ................................ ......................... 104
4.3. Prohibitions and Restrictions ................................ ................................ ................................ ....... 107
5. TREA TMENT A LLOCA TION AND BLINDING ................................ ................................ ............... 108
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 3
Approved , Date: 4 June [ZIP_CODE].1. Treatment Allocation ................................ ................................ ................................ .................... 108
5.2. Blinding ................................ ................................ ................................ ................................ ........ 108
6. DOSA GE A ND A DMINISTR ATION................................ ................................ ................................ 110
6.1. Part I ................................ ................................ ................................ ................................ ............. 110
6.2. Part II ................................ ................................ ................................ ................................ ............ 110
6.3. Part II Long -term Extension ................................ ................................ ................................ ......... 111
7. TREA TMENT COMPLIA NCE ................................ ................................ ................................ .......... 112
8. PRESTUDY A ND CONCOMI TANT THERA PY................................ ................................ .............. 113
8.1. Concomitant Medications ................................ ................................ ................................ ............. 113
8.1.1. Corticosteroid Tapering ................................ ................................ ................................ ............ 114
8.2. Prohibited Medications ................................ ................................ ................................ ................. 114
9. STUDY EVA LUATIONS ................................ ................................ ................................ .................. 115
9.1. Study Procedures ................................ ................................ ................................ ......................... 115
9.1.1. Overview ................................ ................................ ................................ ................................ ...115
9.1.2. Screening Period ................................ ................................ ................................ ...................... 115
9.1.3. Double -Blind Treatment Period ................................ ................................ ................................ 116
9.1.4. Final Efficacy and Safety Follow -up Visit ................................ ................................ .................. 117
9.2. Efficacy  Evaluations ................................ ................................ ................................ ..................... 117
9.2.1. Crohn’s Disease Activity Index ................................ ................................ ................................ .117
9.2.2. Bristol Stool Form Scale ................................ ................................ ................................ ........... 117
9.2.3. Abdominal Pain Numerical Rating Scale ................................ ................................ .................. 118
9.2.4. Patient’s Global Impression of Severity of Cr ohn’s Disease ................................ .................... 118
9.2.5. Patient’s Global Impression of Change of Severity of Crohn’s Disease ................................ ..118
9.2.6. C-Reactive Protein ................................ ................................ ................................ .................... 118
9.2.7. Fecal Lactoferrin and Calprotectin ................................ ................................ ............................ 118
9.2.8. Inflammatory  Bowel Disease Questionnaire ................................ ................................ ............. 119
9.2.9. 36-Item Short Form Health Survey ................................ ................................ ........................... 119
9.2.10. Fistula Assessment ................................ ................................ ................................ ................... 119
9.2.11. Endoscopic Endpoints ................................ ................................ ................................ .............. 119
9.2.12. Histologic Assessment ................................ ................................ ................................ .............. 120
9.3. Pharmacokinetics and Immunogenicity Evaluations ................................ ................................ ....120
9.3.1. Evaluations ................................ ................................ ................................ ............................... 120
9.3.2. Serum Concentration ................................ ................................ ................................ ................ 121
9.3.3. Immunogenicity Assessments (Antibodies to Study Agent) ................................ ..................... 121
9.4. Biom arker and Other Pharmacodynamic Evaluations ................................ ................................ .121
9.4.1. Serum -based Biomarkers ................................ ................................ ................................ ......... 121
9.4.2. Whole Blood -based Biomarkers ................................ ................................ ............................... 121
9.4.3. Biopsy -based Biomarkers ................................ ................................ ................................ ......... 122
9.4.4. NKG2D Receptor Occupancy ................................ ................................ ................................ ...122
9.4.5. Immunophenotypi[INVESTIGATOR_007] ................................ ................................ ................................ ................. 122
9.5. Pharmacogenomic (DNA) Evaluations ................................ ................................ ........................ [ADDRESS_1241387] COMPLETION/D ISCONTINUA TION OF ST UDY TREA TMENT/ WITHD RAWAL 
FROM THE STUDY ................................ ................................ ................................ ......................... 126
10.1. Completion ................................ ................................ ................................ ................................ ...126
10.2. Discontinuation of Study Treatment ................................ ................................ ............................. 127
10.3. Withdrawal From the Study ................................ ................................ ................................ .......... 129
10.4. Withdrawal From the Use of Research Samples ................................ ................................ ......... 129
10.5. Withdrawal From Pharmacogenomic Research Only ................................ ................................ ..130
11. STATISTICAL METHODS ................................ ................................ ................................ ............... 130
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 4
Approved , Date: 4 June 202111.1. Sample Size Determination ................................ ................................ ................................ ......... 131
11.1.1. Sample Size in Part I ................................ ................................ ................................ ................ 131
11.1.2. Sample Size in Part II ................................ ................................ ................................ ............... 132
11.2. Efficacy  Analyses ................................ ................................ ................................ ......................... 133
11.2.1. Part I ................................ ................................ ................................ ................................ ......... 133
[IP_ADDRESS]. Primary Endpoint Analysis ................................ ................................ ................................ .....133
[IP_ADDRESS]. Other Efficacy Endpoint Analy ses................................ ................................ ......................... 134
11.2.2. Part II ................................ ................................ ................................ ................................ ........ 135
[IP_ADDRESS]. Primary Endpoint Analysis ................................ ................................ ................................ .....135
[IP_ADDRESS]. Major Secondary Endpoint Analyses ................................ ................................ .................... 136
[IP_ADDRESS]. Other Efficacy Endpoint Analy ses................................ ................................ ......................... 137
11.3. Pharmacokinetic Analy ses................................ ................................ ................................ ........... 137
11.4. Immunogenicity Analyses ................................ ................................ ................................ ............ 138
11.5. Biom arker Analyses ................................ ................................ ................................ ..................... 138
11.6. Pharmacokinetic/Pharmacodynamic Analyses ................................ ................................ ............ 138
11.7. Pharmacogenomic Analyses ................................ ................................ ................................ ....... 138
11.8. Medical Resource Utilization ................................ ................................ ................................ ........ 139
11.9. Safety Analyses ................................ ................................ ................................ ........................... 139
11.10. Interim Analysis ................................ ................................ ................................ ............................ 139
11.11. Data Monitoring Committee ................................ ................................ ................................ ......... 140
12. ADVERSE EVENT REPORT ING................................ ................................ ................................ ....140
12.1. Definitions ................................ ................................ ................................ ................................ ....140
12.1.1. Adverse Event Definitions and Classifications ................................ ................................ ......... 140
12.1.2. Attribution Definitions ................................ ................................ ................................ ................ 142
12.1.3. Severity Criteria ................................ ................................ ................................ ........................ 142
[IP_ADDRESS]. Severity Criteria: General Categorical Descriptors ................................ ................................ 142
[IP_ADDRESS]. Severity Criteria Based on National Cancer Institute Common Terminology Criteria 
for Adverse Events Toxicity Grade ................................ ................................ ........................ [ADDRESS_1241388] ................................ ................. 149
16.2.3. Informed Consent ................................ ................................ ................................ ..................... 151
16.2.4. Privacy of Personal Data ................................ ................................ ................................ .......... 152
16.2.5. Long -Term Retention of S amples for Additional Future Research ................................ .......... 152
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 5
Approved , Date: 4 June 202116.2.6. Countr y Selection ................................ ................................ ................................ ..................... 153
17. ADM INISTRA TIVE REQUI REM ENTS ................................ ................................ ............................ 153
17.1. Protocol Amendments ................................ ................................ ................................ .................. 153
17.2. Regulatory Documentation ................................ ................................ ................................ .......... 153
17.2.1. Regulatory Approval/Notification ................................ ................................ .............................. [ADDRESS_1241389] Identification, Enrollment, and Screening Logs ................................ .............................. 154
17.4. Source Documentation ................................ ................................ ................................ ................. 155
17.5. Case Report Form Completion ................................ ................................ ................................ ....155
17.6. Data Quality Assurance/Quality Control ................................ ................................ ...................... [ADDRESS_1241390] Retention ................................ ................................ ................................ ......................... 156
17.8. Monitoring ................................ ................................ ................................ ................................ ....157
17.9. Study Com pletion/Termination ................................ ................................ ................................ .....158
17.9.1. Study Com pletion/End of Study ................................ ................................ ................................ [ADDRESS_1241391] OF A TTACHMENTS
Attachment 1: Definition of Inadequate Initial Response, Loss of Response, or Intolerance 
to TNF -Antagonist Therapi[INVESTIGATOR_014] (Infliximab, Adalimumab, or Certolizumab 
Pegol) or Vedolizumab ................................ ................................ ............................. 162
Attachment 2: Definitions of Inadequate Response to or Intolerance of Corticosteroids or 
AZA/6 -MP/MTX and Corticosteroid Dependence ................................ ..................... 167
Attachment 3: Tuberculin Skin Testing ................................ ................................ ............................ 169
Attachment 4: Crohn’s Disease Activity Index ................................ ................................ ................. 170
Attachment 5: Liver Safety Monitoring and Assessment ................................ ................................ .171
Attachment 6: Anticipated Events ................................ ................................ ................................ ....174
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 6
Approved , Date: [ADDRESS_1241392] OF IN -TEXT TA BLES A ND FIGURES
TABLES
Table 1: Time and Events Schedule, Part I ................................ ................................ ............................ 65
Table 2: Time and Events Schedule, Part II ................................ ................................ ........................... 69
Table 3: Time and Events Schedule, Long -term Extension Before Unblinding for JNJ -
64304500, Ustekinumab, and Placebo and After Unblinding for JNJ -64304500j.................... 74
Table 4: Time and Events Schedule, Long -term Extension Phase After Unblinding for 
Ustekinumab Subjects in Countries Where Ustekinumab Is Not Commercially 
Available ................................ ................................ ................................ ................................ ...76
Table 5: Predicted median serum JNJ -64304500 concentrations and NKG2D receptor 
occupancy after administration of the selected dose regimens of JNJ -64304500 ................... 97
Table 6: Power to detect a treatment difference and sample size combinations at an overall 
Type 1 error of 0.05 (2 -sided) for Part I ................................ ................................ .................. 132
Table 7: Power to detect a treatment difference and sample size combinations at an overall 
Type 1 error of 0.05 (2 -sided) for Part II ................................ ................................ ................. 133
FIGURES
Figure 1:Schematic representation of 64304500CRD2001 ................................ ................................ ....86
Figure 2:Schematic Overview of Part I of Study 64304500CRD2001 ................................ .................... 88
Figure 3: Schematic Overview of th e 64304500CRD2001 Part II (Including the Long -term 
Extension) ................................ ................................ ................................ ................................ .89
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 7
Approved , Date: 4 June 2021PROTOCOL A MENDMENTS
Protocol Version Issue Date
Original Protocol 17 March 2016
Amendment 1 14 June 2016
Amendment [LOCATION_006] -1 22 Sep tember 2016 (super seded by [CONTACT_11827] 2)
Amendment [ADDRESS_1241393] recent amendment. The changes to the protocol are 
indicated with an underline.
Amendment 7 (04June 2021 )
The overall reason for the amendment: Thestudy has been unblinded due to lack of sufficient efficacy of 
JNJ-64304500 based on the Part II Week 12 analysis .The unblinding occurred after all Part II subjects completed 
their Week 24 assessments. Subjects who w ere receiving JNJ-64304500 or placebo in the Part IIlong-term 
extension (LTE) w ere discon tinued. Subjects receiving ustekinumab in countries where ustekinumab is not
commercially available were continued in the LTE. To reduce the burden of the ustekinumab subjects who continue 
in the LTE, the laboratory assessments (including PK and immunogeni city) have been removed, and the 16 -week 
safety follow -uphas been removed due to the w ell-known safety profile of ustekinumab . 
Applicable 
Section(s)Description of Change(s)
Rationale: To update details around the subject unblinding in Part II of the study and the subsequent conduct of the 
LTE.
Synopsis; 
3.1.4, Part II Long -
Term  Extension ; 
6.3, Part II Long -
Term  ExtensionSubjects will continue to receive the same treatment regimen during the Part II LTE that 
they were receiving between Week 12 and Week 20 in the main study phase of Part II 
(placebo, high, middle, low dose JNJ-64304500 or ustekinumab). To maintain the study
blind, all patients, investigators, and sites will remain blinded to treatment allocation 
during the Part II LTE until the last subject in the Part II main study phase has completed 
the Week [ADDRESS_1241394] will receive his/her treatment allocation 
during the Part II LTE will depend upon his/h er Part II enrollment date. Therefore, a 
portion of subjects will complete the entire Part II LTE in a blinded fashion before study 
unblinding, while other subjects could be unblinded to treatment allocation during their 
participation in the Part II LTE.
On [ADDRESS_1241395] dose of study drug. For subjects who 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 8
Approved , Date: 4 June 2021Applicable 
Section(s)Description of Change(s)
remain in the Part II LTE at the time of study unblinding, continuation of study drug 
during the Part II LTE w ill be dependent upon treatment allocation, as follows:
JNJ-64304500 : Subjects receiving JNJ-[ADDRESS_1241396] dose of study drug .
Rationale: The 16 -week safety follow -up has been removed due to the w ell-known safety profile of ustekinumab.
Synopsis; 
3.1.4 Part II Long -
Term  Extension;
6.[ADDRESS_1241397] continues on ustekinumab in countries where commercial ustekinumab is not 
available or approved for adult Crohn’s disease, ustekinumab will continue to be provided 
to subjects through Week 72, followed by a final safety follow -up visit [ADDRESS_1241398] dose of ustekinumab .
Rationale: To reduce the burden of the ustekinumab subjects who continue in the LTE, the laboratory assessments 
(including PK and immunogenicity) have been removed.
Synopsis;
3.1.4 Part II Long -
Term  Extension;
6.3 Part II Long -term 
ExtensionAll subjects in the Part II LTE (before unblinding for JNJ-64304500, ustekinumab, and 
placebo and after unblinding for JNJ-64304500) will be assessed according to the Time & 
Events Schedule (Table 3, Table 4), which includes assessments, adverse events (AEs), 
laboratory analyses, and PK and immunogenicity samples. Ustekinumab subjects in the 
Part II LTE (after unblinding for ustekinumab subjects in countries where ustekinumab is 
not commercially available) will be assessed according to the Time & Events Schedule 
(Table ), which includes assessments and AEs.
Rationale: To update details around the subject unblinding in Part II of the study and the subsequent conduct of the 
LTE.
Section 5.[ADDRESS_1241399] assessments.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 9
Approved , Date: 4 June 2021Applicable 
Section(s)Description of Change(s)
Rationale: To reduce the burden of the ustekinumab subjects who continue in the LTE, the laboratory assessments 
(including PK and immunogenicity) have been removed.
Section 9.1.1 
Overvie wThe Time and Events Schedules summarize the frequency and timing of efficacy, PK, 
immunogenicity, PD, pharmacogenomic, medical resource utiliza tion, and safety 
measurements applicable to this study (Table 1, Table 2, Table 3 , Table 4 ).The Time and 
Events Schedules for the LTE after unblinding for ustekinumab subjects in countries 
where ustekinumab is not commercially available (Table 4) includes safety assessments.
Rationale: The [ADDRESS_1241400] study agent 
administration for all subjects who received JNJ -64304500 or ustekinumab. Follow ing the 
study unblinding, any remaining ustekinumab subjects in the LTE (in countries were 
ustekinumab is not commercially available) will not have a final safety visit due to the 
well-known safety profile of ustekinumab . If the investigator decides that the patient 
should continue ustekinumab treatment after completing the Part II LTE, the investigator 
or the subject’s treating physician is responsible for providing the subject w ith commercial 
ustekinumab, which should be administered according to the approved dosing regimen in 
each country. Refer to Section 3.1.4, Part II Long -Term  Extensi on, for details regarding 
the ustekinumab follow -up visit.
Rationale: The [ADDRESS_1241401] dose of study drug ( Table 3; Table 4 ). Subjects in th e Part 
II LTE on ustekinumab after unblinding will not require a safety follow -up visit.
Rationale: To update details around the subject unblinding in Part II of the study and the subsequent conduct of the 
LTE.
Table 4, Time and 
Events Schedule, 
Long -term Extension 
Phase After 
Unblinding for 
Ustekinumab Subjects 
in Countries Where 
Ustekinumab is Not 
Commercially 
AvailableEvery 16 Weeks column was removed. 
Final safety follow -up column w as removed.
Clinical laboratory assessments row s (hematology and chemistry) were removed. 
Pharm acokinetics/Immunogenicity rows (Study agen tserum concentration, assessment for 
antibody to study agent) were removed.
Footnote h was removed: Serum concentration of study agent and antibodies to study agent 
will be evaluat ed. One venous blood sample of sufficient volume should be collected (at 
visits where study intervention will be administered, blood samples should be collected 
prior to study intervention administration). Each serum sample w ill be divided into 3 
aliquots (1 each for serum concentration of study agent, antibodies to study agent and a 
back -up).
Footnote i w as rem oved: Pharmacokinetic and immunogenicity samples will be obtained 
only at the specified timepoints and when SAEs are reported by [CONTACT_4866].
Footnote j w as modified and updated to footnote h: Visits every 8 weeks may include 
scheduled visits at Weeks 32, 40, 48, 56, 64, and 72 , depending on when unblinding 
occurs. The final safety assessment should be performed at the final dosing visit.
Footno te k was removed: Visits every 16 weeks may include scheduled visits at Weeks 40, 
56, and 72, depending on when unblinding occurs.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 10
Approved , Date: 4 June 2021Applicable 
Section(s)Description of Change(s)
Rationale: Minor errors w ere noted . 
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
Amendment 6 (04February 2020 )
The overall reason for the amendment: To adjust the maximum proportions of Bio -NF subjects enrolled in 
Part II.
Applicable Section(s) Description of Change(s)
Rationale: The maximum proportion of Bio -NF subjects will be adjusted to 60% (from 50%), w hich will allow  for 
additional enrollment flexibility, based upon observed enrollment patterns in Part II. The maximum proportion of 
Bio-IR subjects will remain at 60%. The pro posed change should pose no risk to statistical pow er for Part II, as the 
power is based on overall population.
3.1, Overview  of 
Study DesignThe follow ing subsection was revised: 
It is anticipated that approximately 370to 420 subjects will be randomized overall across 
Part I and Part II:
Part Iwill study the safety and efficacy of a high dose regimen of JNJ-64304500 
compared with placebo and will enroll a minimum of 120 subjects and a maximum of 
170 subjects (Bio -IR and Bio -NF).
Part IIwill study the safety and efficacy of multiple -dose regimens of JNJ-64304500 
compared with placebo, with ustekinumab (STELARA®) as a reference arm. Part II 
will enroll approximately 250 subjects (the maximum proportion of either Bio-NF or 
Bio-IR subjects will be 60%).
3.1.2, Part II The last sentence in the first paragraph w as revised:
In Part II, 250 additional Bio -IR or Bio -NF subjects will be randomly assigned to receive 
placebo or 1 of 3 dose levels of JNJ -64304500 or ustekinumab in a ratio of 1:1:1:1:1 using 
permuted block randomization, stratified by [CONTACT_393379] ( ≤300 or >3 00), SNP -
positive status (yes or no), and Bio -IR status (yes or no). The m aximum proportion of 
either Bio -NF or Bio -IR subjects will be 60%.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 11
Approved , Date: 4 June 2021Applicable Section(s) Description of Change(s)
Rationale:   Footnotes in the Time and Events Schedule sfor the Part II Long -term Extension were revised to clarify 
that PK and immunogenicity samples will be collected at the timepoints shown in the schedule s; PK and 
immunogenicity samples collected at Week 24 are part of the main study, not part of the LTE . 
Table 3, Time and 
Events Schedule, 
Long -term Extension 
Before Unblinding for 
JNJ-64304500, 
Ustekinumab, and 
Placebo and After 
Unblinding for JNJ 
64304500jFootnote k was revised:
k. Pharm acokinetic and immunogenicity samples will be obtained only at the specified 
timepoints and when SAEs are reported by [CONTACT_4866].
Table 4, Time and 
Events Schedule, 
Long -term Extension 
Phase After 
Unblinding in 
Countries Where 
Ustekinumab is Not 
Commercially 
AvailableFootnote i w as revised:
i.Pharm acokinetic and immunogenicity samples will be obtained only at the specified 
timepoints and when SAEs are reported by [CONTACT_4866].
Rationale:   The specified time period for treatment with apheresis as an e xclusion criterion (5h)was inadvertently 
omitted in Protocol Amendment 5 and has been reinstated.
4.2, Exclusion 
Criteria5.Has received any of the following prescribed medications or therapi[INVESTIGATOR_887053]:
…
h.Treatment with apheresis (eg, Adacolumn apheresis) <3 w eeks before baseline .
Rationale: Minor errors w ere corrected. 
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
Amendment 5 (17January 2019 )
The overall reason for the amendment: The 3 main reasons for updating this protocol were to reduce the sample 
sizefor Part IIfrom 275 to 250 subjects, change the primary endpoint timing for Part II from Week 8 to Week 12,
based on the results from the previous Part I Week 12 analysis , and add a Part II long-term extension (LTE) to 
provide longer term study drug access to eligible subjects for up to [ADDRESS_1241402] been refined for clarification.
Applicable Section(s) Description of Change(s)
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 12
Approved , Date: 4 June 2021Rationale: A 52-weekLTE is being added toPart IIto provide longer -term study drug access to eligible subjects 
who are benefitting from therapy, and to obtain longer -term safety data for JNJ -64304500 .
Synopsis ; Section 
1.2.2 ,Crohn’s 
Disease;
Section 3.1, Overview 
of Study Design ;
Section 3.2,Study 
Design RationaleThe follow ing sentence was added:
A long-term extension (LTE) for Part II of the study was added to the protocol as part of 
Protocol Amendment 5. After Protocol Amendment 5is implemented, subjects who 
complete Part II Week [ADDRESS_1241403] completed Week 24 assessments 
prior to the implementati on of Protocol Amendment 5 will not be eligible to enroll in the
Part II LTE.
The follow ing sentence was added:
After Protocol Amendment [ADDRESS_1241404] completed Week 24 prior to the implementation of Protocol 
Amendment 5 will not be eligible to enroll in the Part II LTE .
Synopsis, Overview 
of Study DesignThe 2ndparagraph w as revised:
The duration of the study will be 38 weeks in Part I and 36weeks in Part II for subjects 
who do not enter the Part II LTE. The study duration includes study agent administration 
visits and a final efficacy and safety follow -up visit. Eligible subjects will only participate 
in Part I orPart II of the study.
The follow ing was added as the 3rdparagraph:
After Protocol Amendment 5 is implemented, subjects who complete Part II of the study 
through Week 24 and who may benefit from continued treatment in the opi[INVESTIGATOR_1070], will be eligible to enter the Part II LTE to receive up to 52 weeks of 
additional treatment.
Synopsis, Dosage and 
Administr ation, 
Long -term Extension; 
Section 6.3 ,Part II
Long -term ExtensionThe follow ing content was added:
After Protocol Amendment [ADDRESS_1241405] will be 
eligible to receive up to 52weeks of additional study drug (for a total of up to 72 w eeks of 
study drug in Part II). The first dose of study drug within the Part II LTE will be 
administered after the Week [ADDRESS_1241406] been completed. The dose may be 
administered on the same day as the Week 24 assessments, or may be administered on a 
later date, as long as the dose is administered within the Week 24 visit window .
Subjects will continue to receive the same treatment regimen during the Part II LTE that 
they were receiving between Week 12 and Week 20 in the main study phase of Part II 
(placebo, high, middle, low dose JNJ-64304500 or ustekinumab). To maintain the study 
blind, all patients, investigators, and sites will remain blinded to treatment allocation 
during the Part II LTE until the last subject in the Part II main study phase hascompleted 
the Week [ADDRESS_1241407]’s unblinding during the Part II LTE will depend 
upon his/her Part II enrollment date. Therefore, a portion of subjects will complete the 
entire Part II LTE in a blinded fashion before study unblinding, while other subjects could 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 13
Approved , Date: [ADDRESS_1241408] dose of study drug. For subjects that 
remain in the Part II LTE at the time of study unblinding, continuation of study drug 
during the Part II LTE w ill be dependent upon treatment allocation as follows:
JNJ-64304500: Subjects will continue to receive the same dose of 
JNJ-[ADDRESS_1241409] dose of study drug.
Placebo : Subjects receiving placebo who remain in the Part II LTE at the time of 
study unblinding will have their final safety follow -up visit subsequent to unblinding 
and will be discontinued from the study. No furth er follow -up visits will be 
performed.
Ustekinumab : Subjects receiving ustekinumab will continue to receive it during the 
Part II LTE until unblinding occurs. After unblinding, based on the treating 
physician’s clinical judgment , subjects may receive ustek inumab in a manner 
dependent on the country in which they are located:
If a subject is not continuing on ustekinumab after unblinding, the subject will 
need to return for a final safety follow -up visit that will be performed 16 weeks 
after the final dose o f study ustekinumab.
If a subject continues on ustekinumab in a country where commercial 
ustekinumab is available and approved forthe treatment ofadult Crohn’s 
disease, the treating physician is responsible for providing the subject with 
commercial ustek inum ab, which should be administered according to the 
approved dosing regim en in each country. The final safety follow -up visit 
should be performed after unblinding but before receiving the first dose of 
commercial ustekinumab.
If a subject continues on ustekinumab in countries where commercial 
ustekinumab is not available or approved for adult Crohn’s disease, 
ustekinumab will continue to be provided to subjects through Week 72, 
followed by a final safety follow -up visit [ADDRESS_1241410] dose of 
ustekinumab .
For eligible Part II subjects, participation in the Part II LTE is entirely voluntary. Eligible 
subjects who do not wish to enter the Part II LTE w ill complete the Part II Week 24 safety  
and efficacy assessments, follow ed by [CONTACT_887080] 36.
During the Part II LTE, all concomitant medications, including Crohn’s disease -specific 
medications (except for the prohibited medications listed in Section 8.2) may be 
administered at the discretion of the investigator.
All subjects in the Part II LTE will be assessed according to the Time & Events Schedule 
(Table 3, Table 4), which includes assessments, adverse events (AEs), laboratory analyses, 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 14
Approved , Date: 4 June 2021andPK and immunogenicity samples.
Synopsis, Efficacy 
Evaluations ; Section 
3.1, Overview  of 
Study Design; Section 
3.2.2, Efficacy 
AssessmentsThe follow ing sentence was added:
Efficacy evaluations will not be performed during the Part II LTE.
Table 2, Time and 
Events Schedule: Part 
IIMain Study PhaseUrine pregnancy test removed from Table 2 (Time and Events Schedule: Part II Main 
Study Phase) and added to Table 3 (Part II Long -term extension).
Footnotes b,c,d, and v updated :
b. Visit windows should be ±4 days for each visit up to and including Week 12; 
from Week 16 to end of study, visit window should be ± [ADDRESS_1241411] completed assessments at Week 24 and terminated after 
Week 24, the only assessments that should be perfor med at the early termination 
visit are those planned for the final efficacy and safety follow -upvisit. Subjects 
who discontinue study agent administration before Week 12(but have not 
terminated study participation) should complete the Week 12assessments and 
return for a final efficacy and safety follow -up visit approximately [ADDRESS_1241412] study agent administration. Subjects who discontinue study agent 
administration after Week 12(but have not terminated study participation) 
should complete the Week 24assessments and return for a final efficacy and 
safety follow -up visit approximately [ADDRESS_1241413] study agent administration. For subjects 
who com plete all visits and are not enrolling in the Part II LTE, this will occur at 
Week 36.
v. At all visits when study intervention will be administered, 1 blood sample should 
be collected prior to study intervention administration for evaluation of serum 
concentrations and/or antibodies to the study interventions. For the IV infusion 
related visit (Week 0), the SC study intervention should be administered first, 
followed by [CONTACT_16228]; another blood draw should be taken approximately 
60minutes after completion of the infusion for serum concentration 
measurement.
Footnote f added to Table 2.
Table 3 , Time and 
Events Schedule: Part 
II Long -Term  
ExtensionTime and Events Schedule: Time and Events Schedule, Long -term Extension Before 
Unblinding for JNJ-64304500, Ustekinumab, and Placebo and After Unblinding for 
JNJ-64304500 was added. 
Table 4, Time and 
Events Schedule: Part 
II Long -Term  
ExtensionTime and Events Schedule: Long -term Extension Phase After Unblinding in Countries 
Where Ustekinumab is Not Commercially Available was added.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 15
Approved , Date: 4 June 2021Section 3.1 ,Overview 
of Study DesignThe follow ing sentence was added to the eleventh paragraph:
After Protocol Amendment 5 is implemented, all subjects who complete Part II of the 
study through Week 24,and who may benefit from continued treatment in the opi[INVESTIGATOR_13046] ,are eligible to enter the Part II LTE and continue to receive treatment for 
up to 52weeks (Week 24 to Week 72), as described in Section 3.1.4. A schematic 
representation of the Part II LTE is shown in Figure 3 .
Section 3.1 ,Overview 
of Study DesignFigure 1, Schematic representation of 64304500CRD2001 was updated to include the 
Part II LTE.
Section 3.1 ,Overview 
of Study DesignFigure 3 , Schematic Overview of the 64304500CRD2001 Part II (Including the Long -term 
Extension ) was added.
Section 3.1.4 ,Long -
Term  ExtensionThe follow ing content was added:
After Protocol Amendment [ADDRESS_1241414] will be 
eligible to receive up to 52 weeks ofadditional study drug (for a total of up to 72 w eeks of 
study drug in Part II). The first dose of study drug within the Part II LTE will be 
administered after the Week [ADDRESS_1241415] been completed. The dose may be 
administered on the same day as theWeek 24 assessments, or may be administered on a 
later date, as long as the dose is administe red within the Week 24 visit window .
Subjects will continue to receive the same treatment regimen during the Part II LTE that 
they were receiving between Week 12 and Week 20 in the main study phase of Part II 
(placebo, high, middle, low dose JNJ-64304500 or ustekinumab). To maintain the study 
blind, all patients, investigators, and sites will remain blinded to treatment allocation 
during the Part II LTE until the last subject in the Part II main study phase hascompleted 
the Week [ADDRESS_1241416] will receive his/her treatment allocation 
during the Part II LTE will depend upon his/her Part II enrollment date. Therefore, a 
portion of subjects will complete the entire Part II LTE in a blinded fashion before study 
unblinding, while other subjects could be unblinded to treatment allocation during their 
participation in the Part II LTE.
Any subject who withdraws from the Part II LTE prior to study unblinding will return for a 
final safety follow -up visit [ADDRESS_1241417] dose ofstudy drug. For subjects that 
remain in the Part II LTE at the time of study unblinding, continuation of study drug 
during the Part II LTE w ill be dependent upon treatment allocation as follows:
JNJ-64304500 : Subjects will continue to receive the same dose of JNJ-[ADDRESS_1241418] dose of study drug.
Placebo : Subjects receiving placebo who remain in the Part II LTE at the time of 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 16
Approved , Date: [ADDRESS_1241419] their final safety follow -up visit subsequent to unblinding 
and will be discont inued from the study. No further follow -up visits will be 
performed.
Ustekinumab : Subjects receiving ustekinumab will continue to receive it during the 
Part II LTE until unblinding occurs. After unblinding, based on the treating 
physician’s clinical judgme nt, subjects may receive ustekinumab in a manner 
dependent on the country in which they are located:
oIf a subject is not continuing on ustekinumab after unblinding, the subject 
will need to return for a final safety follow -up visit that will be perform ed [ADDRESS_1241420] continues on ustekinumab in a country where commercial 
ustekinumab is available and approved for adult Crohn’s disease, the treating 
physician is responsible for providing the subject with commercial 
ustekinumab, which should be administered according to the approved 
dosing regimen in each country. The final safety follow -up visit should be 
performed after unblinding but before receiving the first dose of commercial 
ustekinumab.
oIf a subject continues on ustekinumab in countries where commercial 
ustekinumab is not available or approved for adult Crohn’s disease, 
ustekinumab will continue to be provided to subjects through Week 72, 
followed by a final safety follow-up visit [ADDRESS_1241421] dose of 
study drug.
For eligible Part II subjects, participation in the Part II LTE is entirely voluntary. Eligible 
subjects who do not wish to enter the Part II LTE w ill complete the Part II Week 24 safety  
and efficacy assessments, follow ed by [CONTACT_887080] 36.
During the Part II LTE, all concomitant medications, including Crohn’s disease -specific 
medications (except for the prohibited medications listed in Section 8.2) may be 
administered at the discretion of the inve stigator.
All subjects in the Part II LTE will be assessed according to the Time & Events Schedule 
(Table 3, Table 4), which includes assessments, AEs, laboratory analyses, and PK and 
immunogenicity samples.
Section 4.2, 
Exclusion CriteriaThe follow ing content was added to the end of this section:
Long -term  Extension Phase
After Protocol Amendment [ADDRESS_1241422] developed Crohn’s disease 
complications which may be anticipated to require surgery in the next [ADDRESS_1241423] eligibility for the LTE should 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 17
Approved , Date: [ADDRESS_1241424] bullet point was added:
Final DBL for Part I:Occurs when all Part I subjects have completed their final 
efficacy and safety visit or have terminated their study participation before the final 
efficacy and safety visit.
The four th bullet point was revised :
Week 12 DBL for Part II(final DBL for Part I occurs at the same time) :Occurs 
when all Part II subjects have completed their Week [ADDRESS_1241425] terminated their 
study participation before Week 12.
The six th bullet point was revised :
Final DBL for Part II: Occurs when all Part II subjects who entered the Part II LTE
have completed their final safety visit in the Part II LTE or have terminated their 
study participation before the final safety visit inthe Part II LTE .
The 3rdparagraph w as revised :
At the time of the interim analy sis lock for Part I, a limited number of sponsor personnel 
will become unblinded to treatment assignment. At the time of the Week [ADDRESS_1241426] 
assessments.
Section 8.1 ,
Concomitant 
MedicationsThe follow ing paragraph was added as the sixth paragraph in the section:
Subjects participating in the Part II LTE may continue receiving concom itant medications 
they were receiving at the time of Part II Week 24, including aminosalicylates, 
immunomodulatory agents (including 6-MP/AZA, MTX), enteral therapy ,and 
corticosteroids . During the Part II LTE, these medications may be initiated, discontinued, 
or dose adjusted at the investigator’s discretion.
Section 8.1.1, 
Corticosteroid 
TaperingThe fol lowing sentence was added as the 3rdparagraph :
During the Part II LTE, corticosteroids may be initiated, discontinued, or dose adjusted at 
the investigator’s discretion
Section 8.[ADDRESS_1241427] sentence in the section was revised :
Randomized subjects must not initiate any of the following prohibited medications at any 
time duri ng Part I, Part II ,or the Part II LTE:
Section 9.1.1,
Overvie wAdded reference to Table 3, Time and Events Schedule, Long -term Extension Before 
Unblinding for JNJ-64304500, Ustekinumab, and Placebo and After Unblinding for 
JNJ-64304500 and Table 4: Time and Events Schedule, Long-term Extension Phase After 
Unblinding i n Countries Where Ustekinumab is Not Commercially Available .
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 18
Approved , Date: [ADDRESS_1241428] paragraph w as updated:
The maximum amount of blood drawn from each subject in this study will be 
approximately 330mL.
Section 9.1.3, 
Double -Blind 
Treatment PeriodThe last sentence in this section was revised :
Each subject must be instructed to complete the CDAI diary card daily during the study, 
except during the Part II LTE.
Section 9.1.4 ,Final 
Efficacy and Safety 
Follow -up VisitThis section was revised :
Subjects in Part I and Part IIshould complete the final efficacy and safety follow -up visit 
approximately [ADDRESS_1241429] study agent administration (Table 1, Table 2). 
Subjects in Part II who are not continuing into the Part II LTE should complete the final 
efficacy and safety follow -up visit approximately 16 weeks after receiving the lastdose of 
study drug (Table 2). Subjects in the Part II LTE should complete the final safety follow -
up visit approximately [ADDRESS_1241430] dose of study drug 
(Table 3, Table 4). Placebo subjects who remain in the Part II LTE at the time of study
unblinding will have their final safety follow -upvisit subsequent to unblinding and will be 
discontinued from the study.
Section 10.1,
Com pletionThe original section was updated to become a subsection: Main Study Phase (Part I and 
Part II)
Thebullet points in the Main Study Phase (Part I and Part II) section were revised :
Subjects who discontinue study agent in Part Ibefore Week [ADDRESS_1241431] dose of study drug.
Subjects who discontinue study agent at or after Week [ADDRESS_1241432] dose of study drug.
Subjects who discontinue study agent inPart II before Week [ADDRESS_1241433] dose of study dru g.
Subjects who discontinue study agent at or after Week [ADDRESS_1241434] dose of study drug.
Anew subsection was added :
Long-term Extension Phase
A subject will be considered to have com pleted the long-term extension phase of the study 
if he or she has completed the final safety follow -up visit in the Part II LTE.
The final safety follow -up visit will occur approximately [ADDRESS_1241435]’s treating physician is 
responsible for providing the subject with comm ercial ustekinumab, which should be 
administered according to the approved dosing regimen in each country. Refer to 
Section 3.1.4, Part II Long -Term  Extension, for details regarding the ustekinumab follow -
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 19
Approved , Date: [ADDRESS_1241436] complet ed the extension phase of the study.
Rationale: The assumptions for the sample size calculations in Part II have been refined based on observed efficac y 
data from the Part I Week 12 analysis. The sample size for Part II has been reduced from 275 to 250 (reduction of 
25 subjects, or 5 subjects per arm). 
Synopsis ,Overview 
of Study DesignThe first paragraph, 4thsentence revised :
An additional 250subjects w ill be randomized in Part II.
Synopsis ,Statistical 
Methods, Sample Size 
DeterminationThe first paragraph was revised :
Sample size calculations for Part I (Bio-IR subjects and Bio-NF subjects combined) were 
determined by [CONTACT_676464] a significant difference in the change from baseline in 
the CDAI score at Week [ADDRESS_1241437]. 
Sample size calculations for Part II (Bio-IR and Bio-NF subjects) were determined by [CONTACT_887081] a dose-response signal for the change from baseline in the CDAI score at 
Week 12(primary endpoint in Part II) using the Multiple Com parison Procedures with 
modeling techniques (MCP -Mod) m ethod.
The third paragraph w as revised :
For Part II, assuming the mean CDAI change from baseline at Week 12is -111in the JNJ -
64304500 group and -51in the placebo group w ith a common SD of 102, 50 subjects per 
treatment group will provide a mean power of 85% to detect a dose -response signal based 
on [ADDRESS_1241438] sentence and the second bullet point of the se venth paragraph w as revised :
It is anticipated that approximately 370-420 subjects will be randomized overall across 
Part I and Part II:
Part II will study the safety and efficacy of multiple -dose regimens of JNJ -64304500 
compared with placebo, with ustekinumab (STELARA®) as a reference arm. Part II 
will enroll approximately 250 subjects (Bio-NF subjects will be no more than 50% 
and Bio -IR subject s will be no more than 60%).
Section 3.1.2, Part II The first sentence of the first paragraph w as re vised :
In Part II, 250additional Bio-IR or Bio-NF subjects will be randomly assigned to receive 
placebo or 1 of 3 dose levels of JNJ-64304500 or ustekinum ab in a ratio of 1:1:1:1:1 using 
permuted block random ization, stratified by [CONTACT_393379] (≤300 or >300), 
SNP-positive status (yes or no), and Bio -IR status (yes or no).
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 20
Approved , Date: 4 June 2021Section 11.1, Sample 
Size DeterminationThis section was revised :
Sample size calculations for Part I and Part IIwere determined by [CONTACT_676464] a 
significant difference in the change from baseline in the CDAI score at Week 8 (primary 
endpoint for Part I) betw een JNJ-[ADDRESS_1241439] a dose-response signal 
for the change from baseline in CDAI at Week 12 (primary endpoint for Part II) using the 
Multiple Comparison Procedures w ith modeling techniques (MCP -Mod) me thod.
Section 11.1.1,
Sample Size in Part IThe title of Table [ADDRESS_1241440] the sample size of Part I.
Section 11.1.2 ,
Sample Size in Part IIThe entire section was revised :
The assumptions for the sample size calculations in Part II were based on the Part I 
Week 12 analysis results . For Bio-IR subjects in Part I, the mean CDAI change from 
baseline at Week 12 was -30.9 (SD=85.15) and -77.4 (SD=103.68) for the placebo and 
JNJ-[ADDRESS_1241441] sin Part I, the mean CDAI change 
from baseline at Week 12 was -70.9 (SD=93.59) and -144.7 (SD=92.50) for the placebo 
and JNJ -64304500 groups, respectively.
For Part II, assuming the mean CDAI change from baseline at Week 12 is -111 in the 
JNJ-64304500 high dose group and -51 in the placebo group (these values are derived 
assuming a 1:1 ratio of Bio-IR and Bio-NF subjects) with a common SD of 102, 50 
subjects per treatment group will provide a mean power of 85% to detect a dose-response 
signal forthe chang e from baseline in CDAI at Week 12 based on 7 candidate 
dose-response models (to be detailed in the SAP) at an overall Type 1 error rateof 0.05 
(2-sided). Fifty subjects per treatment group will also provide 83% power to detect a 
treatment difference between the JNJ-[ADDRESS_1241442] dose and 
the placebo treatment group for change from baseline in CDAI at Week 12based on a 
2-sample t-testat a Type I error rate of 0.05 (2-sided; Table 7). This will result in a total 
sample size of 250 subjects in Part II (incorporating an additional 50 subjects for the 
ustekinumab treatment group).
Table [ADDRESS_1241443] the sample size in Part II.
Rationale: The timing for theprimary endpoint and major secondary endpoints for Part II (except for the 
endoscopy endpoint) will be m odified from  Week 8 to Week 12, based on the results from the pre vious Part I Week 
12 analysis. This change will also align the timing of the primary endpoint and major secondary endpoints to the 
planned Week 12 Part I I endoscopy endpoint. 
Synopsis ,Prim ary 
Endpoint s; Section 
2.1.2, Endpoints; 
Section 3.1 ,Overview 
of Study Design (9th
paragraph); Section 
[IP_ADDRESS], Primary 
Endpoint AnalysesThe pri mary endpoint was revised:
The primary endpoint for Part Iand Part IIis: Change from baseline in the CDAI score at 
Week 8.
The primary endpoint for Part II is: Change from baseline in the CDAI score at Week 12 .
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 21
Approved , Date: 4 June 2021Synopsis ,Major 
Secondary Endpoints ; 
Section 2.1.2, 
Endpoints; Section 
[IP_ADDRESS], Major 
Secondary Endpoint 
Analy sesThe major secondary endpoints were revised :
Clinical remission at Week 12 as measured by [CONTACT_82274] (CDAI <150).
Clinical response at Week 12as measured by [CONTACT_82274] (≥100 -point reduction from 
baseline in CDAI or CDAI <150).
Change in PRO -2 (the sum of the abdominal pain and stool frequency subscores of 
the CDAI score) from baseline at Week 12 .
Clinical remission at Week 12 as measured by [CONTACT_96553] -2 (PRO -2 <75).
Clinical response at Week 12as measured by [CONTACT_96553] -2 (≥50-point reduction from 
baseline in PRO -2 or PRO -2 <75).
Synopsis ,Efficacy 
AnalysesThe 4thparagraph w as revised :
The primary endpoint for Part II is also the change from baseline in the CDAI score at 
Week 12. A unified strategy that combines Multiple Comparison Procedures with 
modeling techniques, MCP -Mod, will be used to analyze the dose-response data over the 
JNJ-[ADDRESS_1241444] describes the observed data and use it to estimate adequate doses with associated 
precision. The study will be considered positive if a dose-response signal for the prim ary 
endpoint is detected. In addition to the dose -response analysis, pairw ise com parisons of the 
JNJ-64304500 treatment groups versus the placebo group will be performed for the change
from baseline in the CDAI score at Week 12; these comparisons will not be adjusted for 
multiplicity.
Section 2.1.2,
Endpoints ; Section 
[IP_ADDRESS], Other 
Efficacy Endpoint 
AnalysesThree effica cy endpoints were updated :
Clinical remission based on CDAI at Week 24 among subjec ts in clinical response at 
Week 12.
Clinical remission based on CDAI at Week [ADDRESS_1241445] s in clinical remission at 
Week 12.
Clinical remission based on CDAI at Week 12by [CONTACT_887082]. Subjects who are 
positive in at least 1 of 2 SNPs (NKG2D or MICB) will be considered to be 
SNP-positive.
Section 3.1,Overview 
of Study DesignFigure [ADDRESS_1241446] is not enrolling in the Part II LTE.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 22
Approved , Date: 4 June 2021Section 3.2.2, 
Efficacy AssessmentsThis section was revised to :
The efficacy evaluations selected for both parts of the study (eg, CDAI, CRP, fecal 
biomarkers; Section 9.2) are well-established measures that areaccepted by [CONTACT_887083]’s 
disease studies.
The primary endpoint for Part I is change from baseline in CDAI at Week 8. The primary 
endpoint for Part II is change fr om baseline in CDAI at Week 12.
Change in the CDAI is being used as the primary endpoint because this measure is more 
sensitive than remission (ie, the change in CDAI provides greater pow er than rem ission for 
the same sample size). Therefore, the study canbe more efficient for Phase 2 using the 
change in CDAI.
To evaluate the level of efficacy after prolonged discontinuation of study drug, CDAI will 
be assessed at the final efficacy and safety visit in Part I and Part II for those subjects who 
do not enter the Part II LTE. The Crohn’s Disease Activity Index will be not assessed 
during the Part II LTE.
It is anticipated that endoscopic improvement will occur by [CONTACT_10585] 12. In order to have an 
appropriate comparison of JNJ-[ADDRESS_1241447] paragraph w as revised to:
In Part I, the visit window  should be ±4 days for each visit. In Part II, the visit window 
should be ±4days, from the Week 0 visit up to and including the Week 12visit, and 
±7days from Week 16until the end of the study.
Section [IP_ADDRESS], 
Primary Endpo int 
Analysis ; Section 
[IP_ADDRESS], Major 
Secondary Endpoint 
AnalysesAll references to Week 8 w ere changed to Week 12.
Rationale: The Part II Week 24 optional endoscopy was removed. The optional Week 24 endoscopy in Part II was 
intended to obtain additional biom arker data . Similar to Part I, mandatory baseline and Week 12 endoscopi[INVESTIGATOR_887054], which will be used to assess efficacy in conjunction with the prim ary efficac y 
endpoin t (change in CDAI from baseline at Week 12).Elimination of the optional Week [ADDRESS_1241448] the primary Part II endpoint and is expected to reduce the burden upon the patients, sites, 
and i nvestigators at the Week 24 visit.
Table 2, Time and 
Events Schedule: Part 
IIVideo ileocolonoscopy and ileocolonoscopy biopsy sample collection for RNA and 
histology were removed from the Week 24 visit.
Footnote t w as rem oved ; the Week 24 video ileocolonoscopy and related endoscopic 
assessments are optional.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 23
Approved , Date: [ADDRESS_1241449] paragraph was revised :
Endoscopic improvement will be assessed during endoscopy (ileocolonoscopy). A video 
ileocolonoscopic examination will be performed to determine the presence or absence of 
mucosal inflammation and ulcera tion at screening and Week 12, and Week 24 (optional in 
Part I), according to the Study Reference Manual provided to each site; if the video 
ileocolonoscopic examination is not performed on the day of the visit, it must be 
performed at least 8 days before the Week 0 visit and no more than 8 days before the Week 
12 visit. The Week 24 video ileocolonoscopy in Part Iis suggested but not required; if 
performed, it should occur not more than 8 days before the Week 24 visit. The video 
ileocolonoscopy will not beperform ed at Week 24 in Part II.Video endoscopi[INVESTIGATOR_887055] a central facility that will be blinded to treatment group and study visit. A 
complete video endoscopic examination does not require assessment of the terminal ileum 
if it cannot be vi sualized. 
Rationale: Guidelines for administration of parenteral nutrition and enteral nutrition were updated. As a safet y 
mitigation measure, exclusion of total parenteral nutrition has now been broadened to exclusion of both total and 
partial parenteral nutrition administer ed through any indwelling catheter. The exclusion of subjects recently 
initiating enteral therapy is added because initiation of enteral therapy may confound the efficacy endpoint 
evaluation in this study.
Section 4.2, 
Exclusion CriteriaFootnote 5i w as added:
Initiation of total (com plete) or partial (supplemental) parenteral nutrition administered 
through any indwelling catheter <3 weeks before baseline or anticipated to require 
parenteral nutrition administered through an indwelling catheter during enrollment in the 
study.
Footnote 5j w as added:
Initiation of enteral therapy for Crohn’s disease (defined as liquid nutritional formula 
comprising ≥80% of total caloric intake administered through the gastrointestinal tract) <[ADDRESS_1241450] s who are ona stable regimen of enteral feeds ≥3 weeks 
before baseline may be considered for enrollment if they plan to continue enteral feeds as 
treatment for Crohn’s disease through the duration of the study (Week 24, Part I or Part II).
Section 8.1, 
Concomitant 
MedicationsThe first paragraph was revised to add enteral therapy:
Subjects who are receiving oral 5-ASA compounds, oral corticosteroids, conventional 
immunomodulators (ie, AZA, 6-MP, or MTX), enteral therapy ,and/or antibiotics for the 
treatm ent of Crohn’s disease at baseline should maintain a stable dose for a specified 
period before baseline, as defined in the Inclusion Criteria (Section 4.1).
The 3rdparagraph, 5thbullet point was revised to:
Total (complete) or partial (supplemental) parenteral nutrition administered through 
an indwelling catheter as a treatment for Crohn’s disease.
A 6thbullet point was added to the 3rdparagraph:
Enteral therapy (liquid nutritional formula comprising ≥80% of total caloric intake) 
as treatment for Crohn’s disease.
Rationale: Discontinuation of study treatment guidelines were updated for clarification. 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 24
Approved , Date: 4 June 2021Section 10.2, 
Discontinuation of 
Study Treatm entThe 5thbullet point w as revised :
Adverse events of NCI-CTCAE grade ≥3 potentially related to worsening of Crohn’s disease
will be evaluated by [CONTACT_887084] a determination 
on discontinuation of study agent. Discontinuation of study agent should be considered in 
subjects with worsening Crohn’s disease where continuation of the study drug is not in the 
best interest of the subject.
The follow ing was added as the 7thbullet point:
Total (complete) or partial (supplemental) parenteral nutrition is initiated through an 
indwelling catheter at any time during the study.
The 2ndparagraph w as revised from:
Discontinuation of study agent adm inistration must be considered for subjects who develop a 
severe injection -site or infusion reaction or who develop a serious infection.
To:
In the event of any serious infection, severe injection -site or infusion reaction, the study drug 
must be held and dosing may not be resumed until the investigator has discussed the case 
with the study medical monitor.
Rationale: Attachment 2: Definitions of Inadequate Response to or Intolerance of Corticosteroids or 
AZA/6 -MP/MTX and Corticosteroid Dependence was updated to include Methotrexate (MTX). There is no change 
to the originally intended protocol criteria. The specified criteria for MTX were erroneously omitted in the original 
protocol.
Attachment 2:
Definitions of 
Inadequate 
Response to or 
Intolerance of 
Corticosteroids or 
AZA/6 -MP/MTX 
and Corticosteroid 
DependenceThe content in this attachment w as revised:
CORTICOSTEROIDS
Subjects have failed to respond to corticosteroids ifthey have had evidence of an initial 
inadequate response, recurrent disease, or a relapse despi[INVESTIGATOR_837614] 0.75 mg/kg/day 
or >40mg/day of prednisone (or corticosteroid equivalent, given orally or intravenously) for 
2 weeks; or ≥9 mg/day of budesonide or ≥5 mg/day of beclom ethasone dipropi[INVESTIGATOR_887056] 4 w eeks.
Subjects are intolerant of corticosteroids if:
They have developed clinically significant adverse events (eg, osteonecrosis or 
osteoporosis, psychosis, uncontrolled diabetes) unresponsive to dose reduction that, in 
the judgment of the investigator, precluded the use of corticosteroids to treat Crohn’s 
disease.
OR
They have a medical condition that precludes the use of corticosteroids as a treatment 
for Crohn’s disease.
Subjects are corticosteroid dependent ifthey have failed to successfully taper their 
corticosteroid (ie, had a flare of disease) within 3 months of starting therapy, or if a relapse 
occurs within 3 months after stoppi[INVESTIGATOR_887057] 3 months after starting them.
6-MERCAPTOPURINE (6 -MP), AZ ATHIOPRINE (AZA), OR METHOTREXATE
(MTX):
Subjects have failed to respond to 6-MP, AZA, or MTXifthey have had evidence of an 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 25
Approved , Date: 4 June 2021initial inadequate response, recurrent disease, or a relapse despi[INVESTIGATOR_338466]:
At least 3 months of therapy with 1 mg/kg/day of 6-MP, 2 mg/kg/day of AZA, or 
25 mg/we ek (intramuscular or subcutaneous) of MTX.
OR
A lower dosage of 6-MP, AZA, or MTX when country or local guidelines specify a 
different treatment regimen. (In such an event, the country or local guidelines needs to 
be included in the source document).
OR
The dosage of 6-MP, AZA, or MTX confirmed to be therapeutic for the subject with 
whole blood thioguanine nucleotide levels >200 pmole/8 x108red blood cells.
OR
The highest tolerated dosage due to leukopenia, elevated liver enzymes, or nausea.
Subjects are intolerant of 6 -MP, AZ A, or MTX if:
They have developed clinically significant adverse events (eg, pancreatitis, arthritis 
accompanied by [CONTACT_676508]/or rash, leukopenia, or persistently elevated liver 
enzymes) unresponsive to dose reduction that, in the judgment of the investigator, 
precluded the use of 6-MP, AZA, or MTX to treat Crohn’s disease within the past 
5 years.
OR
They have a medical condition that precludes the use of 6 -MP, AZA, or MTX.
Rationale: Attachment 3: QuantiFERON -TB Gold Testing was removed since most of this information is included 
in the Site Laboratory Manual and is not necessary to be included in the protocol. QuantiFERON -TB Gold test has 
been updated to QuantiFERON -TB test since there may be regional or country -specific varia bility in the type of 
QuantiFER ON-TB test used based on change sin performance of the test by [CONTACT_6626] .
Table 1, Time and 
Events Schedule: Part 
I; Table 2, Time and 
Events Schedule: Part 
II; Section 4.1, 
Inclusion Criteria 
#11.d.1; Section 
9.1.2, Screening 
Period; Section 9.7, 
Safety Evaluations ; 
Section 10.2, 
Discontinuation of 
Study TreatmentQuantiFERON -TB Gold test revised to QuantiFERON -TB test.
Attachment 3: 
QuantiFERON -TB 
Gold TestingRemoved from protocol.
Rationale: Minor errors w ere noted.
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 26
Approved , Date: 4 June 2021Amendment 4 (24 April 2018 )
The overall reason for the amendment: To revise the study drug concentrations in Section 6.[ADDRESS_1241451] Preparation 
Instructions dilution regimen.
Applicable Section(s) Description of Change(s)
Rationale: To clarify the study drug concentrations of JNJ -64304500 in Part II of the study.
6.2 Part II The 3rdbullet is revised from:
JNJ-64304500 middle dose: 150 mg SC at Week 0 and 75 mg SC at Weeks 2, 4, 8, 12, 16, 
and 20. (Study drug concentration=100 mg/mL and 50 mg/mL at Week 0, 75 mg/mL for 
subsequent doses)
To:
JNJ-64304500 middle dose: 150 mg SC at Week 0and 75 mg SC a t Weeks 2, 4, 8, 12, 16, 
and 20 (study drug concentration=75 mg/mL) .
The 4thbullet is revised from:
JNJ-64304500 low  dose: 50 mg SC at Week 0 and 25 mg SC at Weeks 2, 4, 8, 12, 16, 
and20. (Study drug concent ration=50 mg/mL at Week 0, 25 mg/mL for subsequent doses)
To:
JNJ-64304500 low  dose: 50 mg SC at Week 0 and 25 mg SC a t Weeks 2, 4, 8, 12, 16, 
and20(study drug concentration=25 mg/mL) .
Rationale: Minor errors w ere noted
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
Amendment 3 12December 2017
This amendment is considered to be substantial based on the criteria set forth in the Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union.
The overall reason for the amendment: To change the timing and subject population for the Interim Analysis in 
Part I; change the overall sample size of Part I; and change the subject population and sample size in Part II .
Clarification of specific study procedures is also included in this amendment as described below .
Applicable Section (s)Description of Change (s)
Rationale (To change the timing and subject population for the Interim  Analysis in Part I) :The original 
planned interim analysis was solely based on the Bio-IR population. It was projected that this study w ould enroll the 
Bio-IR population before the Bio -NF population. In actuality, both populations are enrolling at a similar rate. The 
change in the subject population reflects the current recruitment rate and will enable a decision based upon both 
populations. This is important considering the population in Part II w ill now also include Bio -NF subjects. In 
addition, a change from Week 8 to Week 12 for the int erim analysis allows endoscopic data to be incorporated into 
the decision on whether to initiate Part II.
Applicable Section(s) Description of Change(s)
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 27
Approved , Date: 4 June 2021Synopsis Under the Endpoints section, the following sentence was added:
The data from Study 1 and Study 2 in Part I w ill be pooled for analysis.
In the Overvie w of Study Design section, the fourth paragraph was revised to read:
An interim analysis is planned in Part I when 100 randomized Part I subjects ( Study 1: Bio-
IR and Study 2: Bio-NF) have completed their Week [ADDRESS_1241452] completed their 
Week 12 visit (or 
have terminated study participation prior to Week 12). If Part II is not initiated based on the 
interim anal ysis results, then the results through Week 12 for all subjects in Part I (ie, when 
all randomized subjects in Part I have either completed the Week 12 visit or terminated 
study participation prior to Week 12) w ill be examined to determine whether to start Part II. 
Under this scenario, a pause in enrollment between Part I and Part II w ill occur.
In the Dosage and Administration Part I section, the first paragraph was revised to read:
In Part I, a minimum of 120 subjects and a maximum of 170 subjects (Bio -IRand Bio -NF) 
will be randomly assigned to receive placebo or the JNJ -64304500 high dose in a 1:1 ratio 
using permuted block randomization, stratified by [CONTACT_393379] ( ≤300 or >300) and 
SNP-positive status (yes or no). The Bio -IR and Bio -NF populatio ns will be randomized 
separately.
2.1.2. Endpoints The follow ing sentence was added:
The data from Study 1 and Study 2 in Part I w ill be pooled for analysis.
3.1. Overview  of 
Study DesignThe fourth paragraph was revised to read:
The 2 studies in Part I serve to build on the original Phase 2a study findings by [CONTACT_887085] -IR and Bio -NF subjects. If acceptable safety and 
efficacy are established in the combined Bio -IR and Bio -NF populations, Part II of the 
protocol, w hich co nsists of a dose -ranging study (Study 3) in subjects who are Bio -IR or 
Bio-NF, will be initiated.
The follow ing sentence was removed from the tenth paragraph:
Each of the 3 studies will be analyzed separately.
3.1.1. Part I This section was revised to rea d:
In Part I, a minimum of 120 subjects and a maximum of 170 subjects (Bio-IR and Bio -NF) 
will be randomly assigned to receive placebo or the JNJ -64304500 high dose in a 1:1 ratio 
using permuted block randomization, stratified by [CONTACT_393379] ( ≤300 or >300) and 
SNP-positive status (yes or no). Separate randomizations will be used for the Bio -IR and 
Bio-NF populations.
The treatment groups for each study in Part I w ill be as follows:
Placebo SC at Weeks 0, 2, 4, 6, 8, and 10; from Week 12, these subjects will receive 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 28
Approved , Date: 4 June 2021additional doses as follows:
Placebo -treated subjects who arein clinical response at Week 12 (≥100 -point 
reduction from baseline in CDAI or CDAI <150) will continue to receive 
placebo SC injections q2w  from Week 12 through Week 22.
Placebo -treated subjects w ho are not in clinical response at Week 12 will receive 
JNJ-64304500 400 mg SC at Week 12 and then 200 mg SC q2w from Week14 
through Week 22. 
JNJ-64304500 400 mg SC at Week 0 then 200 mg SC q2w  through Week 22.
An interim analysis is planned in Part I when 100 randomized subjects (Bio -IR and Bio -
NF) have completed their Week [ADDRESS_1241453]. If Part II is not initiated based on the interim 
analysis results, then the r esults through Week 12 for all subjects in Part I (ie, when all 
randomized subjects in Part I have either completed the Week 12 visit or terminated study 
participation prior to Week 12) w ill be examined to determine whether to start Part II. 
Under this sce nario, a pause in enrollment between Part I and Part II w ill occur.
3.1.3. Interim 
AnalysisThe entire section was revised to read:
An interim analysis is planned in Part I when 100 randomized Part I subjects (Study 1: Bio-
IR and Study 2: Bio-NF) have completed their Week [ADDRESS_1241454] or completion of Part I it w ill be considered administrative and will not require 
multiplicity adjustment for the final Part I analysis.
A sponsor committee independent of the study team will be establi shed to review  the 
interim data and formulate recommended decisions/actions in accordance w ith predefined 
decision rules (to be defined in the Interim Analysis Plan).
An interim analysis is not planned for Part II .
Other planned DBLs are described in Secti on 5.[ADDRESS_1241455] paragraph was revised to read:
This protocol is comprised of 2 parts (Part I [Study 1 :Bio-IR subjects and Study 2 :Bio-NF 
subjects] and Part II [Bio -IR and Bio -NF subjects]) that are designed to evaluate the safety 
and efficacy of JNJ -64304500 in subjects w ith moderately to severely active Crohn’s 
disease. Study 1 and Study 2 constitute Part I of the protocol. In this part, the safety and 
efficacy of a single dosing regimen of JNJ -64304500 in Bio -IR and Bio -NFsubjects with 
moderately to severely active Crohn’s disease is evaluated. If acceptable efficacy is 
established in Part I (for the combined Bio -IR and Bio -NF subjects), Part II (a dose -ranging 
study in Bio -IR and Bio -NF subjects) w ill be initiated.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 29
Approved , Date: 4 June [ZIP_CODE].2.1 . Study 
PopulationThe entire section was removed:
The target population for each of the 3 studies consists of men or w omen ≥18 y ears of age 
at the time of informed consent w ith moderately to severely active Crohn’s disease (of at 
least 3 months’ duration) , defined as a CDAI score ≥220 and ≤450, with elevated CRP 
>0.3 mg/dL (>3.0 mg/L) and/or calprotectin >250 mg/kg.
Additionally, subjects in these studies must have previously failed or been intolerant to 1 or 
more approved biologic agents (ie, TNFα -antagon ists or vedolizumab) orhave 
demonstrated an inadequate response to or failed to tolerate corticosteroids or 
immunomodulators (ie, 6 -mercaptopurine [6 -MP], azathioprine [AZA], and MTX) but not 
a biologic agent.
The Bio -IR population, comprising subjects wh o have failed to respond, lost response, or 
have been intolerant to one or more biologic therapi[INVESTIGATOR_014], is the primary population of interest 
for this protocol because it has the highest unmet need with current therapi[INVESTIGATOR_014]. Responses to 
therapi[INVESTIGATOR_887058] l ower in the Bio -IR population than in the Bio -NF population.
The cohort of Bio -NF subjects is included in Part I (Study 2) to obtain additional 
information about the effect of JNJ -[ADDRESS_1241456] paragraph w as removed:
The clinical remission endpoint is being used for the interim analysis, however, as it is a 
more stringent endpoint and provides a more conservative decision rule to determine 
whether to start Part II early.
11.10 Interim 
AnalysisThe e ntire section was revised to read:
An interim ana lysis is planned in Part I when 100 randomized subjects (Study 1: Bio-IR 
and Study 2 :Bio-NF) have completed their Week [ADDRESS_1241457] to the change in CDAI from baseline (in the combined Bio -IR and Bio -NF 
subjects). Other selected efficacy analyses (eg, clinical remission, clinical response, and 
change in SES -CD) will also been performed; details will be provided in the Interim 
Analysis Plan.
A sponsor committee independent of the study team will be established to review  the 
interim data and formulate recommended decisions/actions in accordance w ith predefined 
decision rules that will be defined in the Interim Analysis Pl an.
Rationale (change the overall sample size of Part I) : The Part I analysis is now focused on all subjects (Bio-IR vs. 
Bio-NF) due to the faster than anticipated enrollment of the Bio -NF population. This analysis may be more 
reflective of the patient po pulation in need of therapy. The overall sample size of Part I w as changed to a minimum 
of 120subjects and a maximum of 170 subjects (Bio-IR and Bio -NF). 
Applicable Section(s) Description of Change(s)
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 30
Approved , Date: 4 June 2021Synop sis The Overv iew of Study Design section was revised to read:
This protocol is comprised of 2 parts (Part I [Study 1: Bio -IR subjects and Study 2: Bio-NF 
subjects] and Part II [Bio -IR and Bio -NF subjects]). Each study is a randomized, double -
blind, placebo -controlled, parallel -group, multicente r study of JNJ -64304500 in subjects 
with moderately to severely active Crohn’s disease. A minimum of 120 subjects and a 
maximum of 170 subjects (Bio-IR and Bio -NF) will be randomize d in Part I. An additional 
[ADDRESS_1241458] failed biologic 
or conventional therapy (Bio -IR or Bio -NF subjects, respectively). Part II will study the 
safety and efficacy of multipl e-dose regimens of JNJ -64304500 compared with placebo, 
with ustekinumab (STELARA®) as a reference arm, in Bio -IR and Bio -NF subjects.
The duration of the study will be [ADDRESS_1241459] 
who completes all scheduled vis its, including study agent administration visits and a final 
efficacy and safety follow -up visit. Eligible subjects will only participate in Part I orPart II 
of the study.
The Time and Events Schedules summarize the frequency and timing of assessments for
efficacy, PK, biomarkers, immunogenicity, PD, and safety in Part I and Part II of the study.
An interim analysis is planned in Part I when 100 randomized Part I subjects ( Study 1: Bio-
IR and Study 2: Bio-NF) have completed their Week [ADDRESS_1241460] completed their 
Week 12 visit (or have terminated study participation prior to Week 12). If Part II is not 
initiated based on the interim analysis results, then the results through Week 12 for all 
subjects in Part I (ie, when all randomized subjects in Part I have either completed the 
Week 12 visit or terminated study participation prior to Week 12) w ill be examined to 
determine whether to start Part II. Under this scenario, a pause in enrollmen t between Part I 
and Part II w ill occur.
An external Data Monitoring Committee (DMC) will review unblinded safety data from all 
subjects periodically to monitor subject safety.
The end of the 64304500CRD2001 study is defined as the date on which the lastsubject 
completes the last efficacy and safety follow -up visit.
In the Sample Size Determination section, the first and second paragraphs w ere revised to 
read:
Sample size calculations for Part I (Bio -IR subjects and Bio -NF subjects combined) w ere 
determi ned by [CONTACT_887086] a significant difference in the change from baseline in 
the CDAI score at Week [ADDRESS_1241461]. 
Sample size calculation for Part II (Bio -IR and Bio -NF subjects) w as determined by [CONTACT_887081] a dose -response signal in the change from baseline in the CDAI score at 
Week 8 (primary endpoint in Part II ) using the Multiple Comparison Procedures w ith 
modeling techniques (MCP -Mod) m ethod.
For Part I, assuming the mean CDAI change from bas eline at Week 8 is -98 in the JNJ -
64304500 group and -46 in the placebo group w ith a common SD of 96, 60 subjects per 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 31
Approved , Date: 4 June 2021treatment group will provide 84% pow er to detect a treatment difference between JNJ -
[ADDRESS_1241462] 3paragraphs were revised to read:
This protocol is comprised of 2 separate parts (Part I [Study 1: Bio -IR subjects and Study 2: 
Bio-NF subjects] and Part II [Bio -IR and Bio -NF subjects]). Part I and Part II w ill be 
analyzed separately with separate Type I error control for the primary endpoint (at the 0.05 
level of significance). The other endpoints within each part will not be controlled for 
multiplicity.
For each part, the analysis set is all randomized subj ects who received study agent. Efficacy 
analyses will be based on a modified intent -to-treat principle. Therefore, the efficacy data 
for each subject who received study agent will be analyzed according to the assigned 
treatment regardless of the actual tre atment received.
For Part I , the primary endpoint of change from baseline in the CDAI score at Week 8 will 
be compared betw een the JNJ -64304500 treatment group and the placebo treatment group 
by [CONTACT_887087] a f ixed factor and baseline CDAI score, SNP -positive status (yes or no), and Bio -IR 
status (yes or no) as covariates. Part I will be considered to be positive if a significant 
improvement is detected in the change from baseline in the CDAI score at Week 8 in the 
JNJ-64304500 group compared w ith the placebo group at the 0.05 level of significance.
3.1. Overview  of 
Study DesignThe seventh paragraph was revised to read:
It is a nticipated that approximately 395-445 subjects will be randomized overall across Part
I and Part II :
Part Iwill study the safety and efficacy of a high dose regimen of JNJ-64304500 
compared with placebo and will enroll a minimum of 120subjects and a maximum of 
170 subjects (Bio-IR and Bio -NF).
3.1.1. Part I The first paragraph was revis ed to read:
In Part I, a minimum of 120subjects and a maximum of 170 subjects (Bio-IR and Bio -NF)
will be randomly assigned to receive placebo or the JNJ -64304500 high dose in a 1:1 ratio 
using permuted block randomization, stratified by [CONTACT_393379] ( ≤300 or >300) and 
SNP-positive status (yes or no). Separate randomizations will be used for the Bio -IR and 
Bio-NF populations. 
11.1. Sample Size 
Determinatio nThe first paragraph was revised to read:
Sample size calculations for Part I and Part II were determined by [CONTACT_676464] a 
significant difference in the change from baseline in the CDAI score at Week 8 (primary 
endpoint in each part) betw een JNJ -[ADDRESS_1241463]. 
11.1.1. Sample Size 
in Part I (Study 1 and 
Study 2)The s ection header was updated to Sample Size in Part I.
Subheaders [IP_ADDRESS]. Bio -IR Subjects (Study 1), [IP_ADDRESS].1. All Bio -IR Subjects, [IP_ADDRESS].2 
Bio-IR Subjects Who Are SNP -Positive (Bio -IR/SNP+), [IP_ADDRESS]. Bio -NF Subjects 
(Study 2), [IP_ADDRESS].1. All Bio -NF Subjects, and [IP_ADDRESS].2. Bio -NF Subjects Who Are SNP -
Positive (Bio -NF/SNP+) w ere removed.
The entire section was revised to read:
Part I is pow ered based on the combined data from Study [ADDRESS_1241464] differences between JNJ -64304500 and placebo.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 32
Approved , Date: 4 June 2021The assumptions for the sample size calculations in Part I w ere based on data from 
CNTO1275CRD300 1 (a study conducted by [CONTACT_887088] w ith Crohn’s disease 
who had failed or w ere intolerant to TNF -antagonist therapy) and CNTO1275CRD3002 (a 
study conducted by [CONTACT_887089]’s disease who had failed or w ere 
intolerant to co rticosteroids or immunomodulators but who had not failed TNF -antagonist 
therapy). In CNTO1275CRD3001, the mean CDAI change from baseline at Week 8 was -
25.1 (SD=91.41) and -78.7 (SD=91.79) for the placebo and ustekinumab 6 mg/kg groups, 
respectively. These assum ptions incorporated the impact of 6% of subjects being 
noncompleters (in CNTO1275CRD3001). In CNTO1275CRD3002, the mean CDAI 
change from baseline at Week 8 w as -66.3 (SD=97.81) and -116.3 (SD=102.88) for the 
placebo and ustekinumab 6 mg/kg groups, re spectively. These assumptions incorporated 
the impact of 4% of subjects being noncompleters (in CNTO1275CRD3002).
For Part I, assuming the mean CDAI change from baseline at Week 8 is -98 in the JNJ -
64304500 group and -46 in the placebo group w ith a common SD of 96 (these values are 
derived assuming 1:1 ratio of Bio -IR and Bio -NF subjects) 60 subjects per treatment group 
(a total of 120 subjects) will provide 84% pow er to detect a treatment difference between 
JNJ-64304500 and placebo at an overal l Type 1 error of 0.05 (2 -sided ).
Table 4 w as updated.
Section 11.2. 
Efficacy AnalysesThis section was revised to read:
This protocol is comprised of 2separate parts (Part I [Study 1: Bio -IR subjects and Study 2: 
Bio-NF subjects] and Part II [Bio -IR and Bio -NFsubjects]) .Part I and Part II w ill be 
analyzed separately with separate Type I error control for the primary endpoint (at the 0.05 
level of significance). The other endpoints within each part will not be controlled for 
multiplicity.
For each part, the an alysis set is all randomized subjects who received study agent. Efficacy 
analyses will be based on a modified intent -to-treat principle. Therefore, the efficacy data 
for each subject w ho received study agent will be analyzed according to the assigned 
treatment regardless of the actual treatment received.
11.2.1. Part I (Study 1 
and Study 2)Subheader title updated to Part I
[IP_ADDRESS] Primary 
Endpoint AnalysisEntire section revised to read:
The primary endpoint for Part I is the change from baseline in the CDAI score at Week 8.
The change from baseline in the CDAI score will be compared betw een the JNJ -64304500 
treatment group and the placebo treatment group for all subjects in Part I. For the 
comparison, an ANCOVA model on the van der Waerden normal scores will be used with 
treatment as a fixed factor and baseline CDAI score, SNP -positive status (yes or no), and 
Bio-IRstatus (yes or no) as covariates. For this analysis, treatment fail ure rules and missing 
data rules as specified in Section [IP_ADDRESS] will be applied.
Part I w ill be considered to be positive if a significant improvement is detected in the 
change from baseline in the CDAI score at Week 8 in the JNJ -64304500 group compared 
with the placebo group at the 0.05 level of significance.
[IP_ADDRESS] Other 
Efficacy Endpoint 
AnalysesFirst sentence revised to read:
The following endpoints will be com pared between the JNJ-64304500 treatment group and 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 33
Approved , Date: 4 June 2021the placebo treatment group for all s ubjects in Part I a nd by [CONTACT_44313] -IR status (yes or no): 
11.2.2. Study 2 (Part I 
Bio-NF Subjects)This section was removed.
Rationale (change the subject population in Part II) :To evaluate the efficacy and safety of JNJ -[ADDRESS_1241465] population in Part II w as changed to include both Bio -IR and Bio -NF subjects .
Applicable Section(s) Description of Change(s)
Synopsis In the first section, the bullet regarding Part II, Study 3 was revised to read:
Study 3: A dose -ranging study in subjects who are Bio -IR or Bio -NF
In the Dosage and Administration Part II section, the first paragraph was revised to read:
In Part II of the study, subjects (Bio -IR and Bio -NF) will be randomly assigned in equal 
proportions to receive placebo, 1 of 3dose regimens of JNJ -64304500, or ustekinumab, 
using permuted block randomization, stratified by [CONTACT_393379] ( ≤300 or >300), 
SNP-positive status (yes or no), and Bio -IR status (yes or no). The treatment groups are as 
follows:
In the Efficacy Ana lyses section, the fourth and fifth paragraphs were revised to read:
The primary endpoint for Part II is also the change from baseline in the CDAI score at 
Week 8. A unified strategy that combines Multiple Comparison Procedures with modeling 
techniques, MC P-Mod, w ill be used to analyze the dose -response data over the JNJ -
[ADDRESS_1241466] 
describes the observed data and use it to estimate adequate doses with associated precision. 
The study will be considered positive if a dose -response signal for the prima ry endpoint is 
detected. In addition to the dose -response analysis, pairwise comparisons of the JNJ -
64304500 treatment groups versus the placebo group w ill be performed for the change from 
baseline in the CDAI score at Week 8; these comparisons will not be adjusted for 
multiplicity.
The major secondary endpoints are only specified in Part II. The major secondary endpoints 
that are dichotomous endpoints will be analyzed by [CONTACT_25549] -Mantel -Haenszel chi -
square test (2 -sided) stratified by [CONTACT_887090] e (≤300 or >300), SNP -positive status 
(yes or no), and Bio -IR status (yes or no); the major secondary endpoints that are 
continuous endpoints will be analyzed by [CONTACT_887091] a fixed factor and appropriate baseline level of 
the variable, SNP -positive status (yes or no), and Bio -IR status (yes or no) as covariates. 
The major secondary endpoints will not be controlled for multiplicity.
1.2.2. Crohn’s 
DiseaseThe eighth paragraph was revised to read:
In Part II, the follow ing study will be conducted:
Study 3: A dose-ranging study in subjects who are biologic intolerant or refractory 
(Bio-IR) or Biologic non failure (Bio-NF)
The follow ing paragraph was removed from this section:
In order to provide an efficient means of rapi[INVESTIGATOR_887059] 2 dose -ranging, 
this protocol is designed to be a comprehensive Phase 2 program in which the sponsor will 
evaluate safety and efficacy in subjects who are biologi c intolerant or refra ctory (ie, Bio-IR 
population or Bio -NF). 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 34
Approved , Date: 4 June 2021The ninth paragraph was revised to read:
In Study 1, a higher dose regimen than was used in the Phase 2a study will be employed 
supported by [CONTACT_887092] 1 (the Novo Nordisk 
Phase 1 single ascending/multiple ascending dose study NN8555 -3618), and the high 
exposure margins relative to NOAEL exposure in cynomolgus monkeys. This higher dose 
will be used to provide additional information on safety and efficacy for the Bio -IR 
population, as proof of concept w as not established in this population in the Novo Nordis k 
Phase 2a study (NN8555 -3797). In addition, this higher dose w illalso be evaluated in Bio -
NF subjects to determine if a more robust efficacy outcome than was shown in the Phase 2a 
study can be achieved while maintaining an acceptable safety profile. Comb ined with data 
from Phase 2a in Bio -NF subjects, Part I and Part II would provide valuable information for 
the assessment of dose/exposure -response and thus the selection of the optimal dose in Bio -
NF population for the Phase 3 program. Study 1 and Study 2 comprise Part I of the protocol 
and these 2 components will be initiated in parallel. The decision to initiate the dose -
ranging portion of the protocol (Part II, Bio -IR and Bio -NF) is dependent on demonstration 
of acceptable safety and efficacy in Part I (combined Bio -IR subjects and Bio -NF subjects). 
A ustekinumab reference arm will be included in Part II to provide context in the 
interpretation of results from the JNJ -[ADDRESS_1241467] in the 
overall selection of dose(s) to carry forw ard into the Phase [ADDRESS_1241468] paragraph was revised to read:
Study 3: A dose -ranging study in subjects who are Bio -IR or Bio -NF
Figure 1 w as revised to include Bio -IRand Bio -NF subjects in Part II.
The 2ndbullet in the sixth paragraph was revised to read:
Biologic nonfailure (Bio-NF) subjects are defined as those who have demonstrated 
an inadequate response to or have failed to tolerate corticosteroids or the 
immunomodulators 6-MP, AZA, or MTX (Attachment 2). Subjects who have 
demonstrated corticosteroid dependence (ie, an inability to successfully taper 
corticosteroids without a return of the symptoms of Crohn’s disease) are also eligible. 
Bio-NF subjects may also have received biologic therapy but only if it was 
discontinued for reasons other than lack of efficacy or intolerance (eg, drug holiday).
The second bullet in the seventh paragraph was revised to read:
Part II will study the safety and efficacy of multiple-dose regimens of JNJ-64304500 
compared with placebo, with ustekinumab (STELARA®) as a reference arm. Part II 
will enroll approximately 275 subjects (Bio-NF subjects will be no more than 50% 
and Bio -IR subjects w ill be no more than 60%).
3.1.2. Part II The first paragraph was revised to read:
In Part II, 275additional Bio -IR or Bio -NF subjects will be randomly assigned to receive 
placebo or 1 of 3 dose levels of JNJ -64304500 or ustekinumab in a ratio of 1:1:1:1:1 using 
permuted block randomization, stratified by [CONTACT_393379] ( ≤300 or >300), SNP -
positi ve status (yes or no), and BIO -IR status (yes or no). Bio -NF subjects w ill be no more 
than 50% and Bio -IR subjects will be no more than 60%.
4.1. Inclusion Criteria Inclusion Criterion 6 w as revised to read:
6. In Part II,meet the following requirement for prior or current medications for 
Crohn’s disease:
a. Has previously demonstrated inadequate response, loss of response, or 
intolerance to 1 or more approved biologic therapi[INVESTIGATOR_014] (eg, infliximab, 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 35
Approved , Date: 4 June 2021adalimumab, certolizumab pegol, or vedolizumab) as outlined in Attachment 1.
OR
b. Has failed conventional therapy:
1) Is currently receiving corticosteroids and/or immunomodulators (ie, AZA, 
6-MP, or MTX) at adequate therapeutic doses ( Attachment 2 ).
OR
2) Has a history of failure to respond to or tolerate an adequate cours e of 
corticosteroids and/or immunomodulators (ie, AZA, 6-MP, or MTX) 
(Attachment 2).
OR
3) Is corticosteroid dependent or has had a history of corticosteroid 
dependency ( Attachment 2 ).
5.1. Treatment 
AllocationThe first paragraph was revised to read:
Central randomization will be implemented in this study. Subjects will be randomly 
assigned to 1 of 2 treatment groups (1:1 ratio) in Part I and to 1 of 5 treatment groups 
(1:1:1:1:1 ratio) in Part II, based on a computer -generated randomization schedule p repared 
before the study by [CONTACT_43754]. Each of the [ADDRESS_1241469] 
separate randomizations. Each randomization will be balanced by [CONTACT_887093] ( ≤300 or >300) and SNP -positive 
status (yes or no; Part II will also be stratified by [CONTACT_44313] -IR status [yes or no]). The interactive 
web response system (IWRS) will assign a unique treatment code, which will dictate the 
treatment assignment and matching study drug kit for the subject. The requestor must use 
his or her own user identification and personal identi fication number when contact[CONTACT_111127], and will then give the relevant subject details to uniquely identify the subject.
11.2.2.Study 3 (Part 
II)Subheader title revised to Part II.
Rationale (change the sample size in Part II) :The sample size in Part II was increased to 275subjects in order to 
have sufficient pow er based on the amended Part II population.
Applicable Section(s) Description of Change(s)
Synopsis In the Sample Size Determination section, the entire section was revised to read:
Sample size calculations for Part I (Bio -IR subjects and Bio -NF subjects combined) w ere 
determined by [CONTACT_887086] a significant difference in the change from baseline in the 
CDAI score at Week [ADDRESS_1241470]. Sample 
size calculation for Part II (Bio -IR and Bio -NF subjects) was determined by [CONTACT_887094] a dose -response signal in the change from baseline in the CDAI score at Week 8 
(primary endpoint in Part II ) using the Multiple Comparison Procedur es with modeling 
techniques (MCP -Mod) m ethod.
For Part I, assuming the mean CDAI change from baseline at Week 8 is -98 in the JNJ -
64304500 group and -46 in the placebo group w ith a common SD of 96, 60 subjects per 
treatment group will provide 84% pow er to detect a treatment difference between JNJ -
64304500 and placebo at an overall Type 1 error of 0.05.
For Part II, assuming the mean CDAI change from baseline at Week 8 is -98 in the JNJ -
64304500 group and -46 in the placebo group w ith a common SD of 96, 55 s ubjects per 
treatment group will provide a mean power of 83% to detect a dose -response signal based on 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 36
Approved , Date: [ADDRESS_1241471] paragraph was revised to read:
In Part II, 275 additional Bio-IR or Bio -NF subjects will be randomly assigned to receive 
placebo or 1 of 3 dose levels of JNJ -64304500 or ustekinumab in a ratio of 1:1:1:1:1 using 
permuted block randomization, stratified by [CONTACT_393379] ( ≤300 or >300), SNP -
positive status (y es or no), and BIO -IR status (yes or no). Bio -NF subjects w ill be no more 
than 50% and Bio -IR subjects will be no more than 60%.
11.1.2. Sample Size 
in Part II (Study 3)Subheader title changed to Sample Size in Part II
[IP_ADDRESS] All Bio -IR 
SubjectsThis subheader title was removed. The content for this section is now included in section 
11.1.2. Sample Size in Part II.
[IP_ADDRESS]. Bio -IR 
Subjects Who Are 
SNP-Positive(Bio -
IR/SNP+)This section was removed.
Rationale: Contents for blinding and planned database locks w ere updated based on the changes to the study design.
Applicable Section(s) Description of Change(s)
5.2. Blinding The second and third paragraphs were revised to read:
Interim analysis lock for Part I:Occurs when 100 randomized subjects (Bio-IR and 
Bio-NF) in Part I have completed their Week 12visit or have terminated their study 
participation before Week 12 .
Week 12 DBL for Part I: Occurs when all subjects in Part I have completed their Week 
12visit or have terminated their study participation before Week 12 .
Week 12 DBL for Part II (final DBL for Part I occurs at the same time): Occurs 
when all Part II subjects have completed their Week [ADDRESS_1241472] terminated their 
study participation be fore Week 12.
Week 24 DBL for Part II:Occurs when all Part II subjects have completed their 
Week [ADDRESS_1241473] terminated their study participation before Week 24.
Final DBL for Part II:Occurs when all Part II subjects have completed their final 
efficacy and safety visit or have terminated their study participation before the final 
efficacy and safety visit.
At the time of the interim analysis lock for Part I, a limited number of sponsor personnel will 
become unblinded to treatment assignment. At the t ime of the Week 12 DBL for Part I and the 
Week 12 DBL for Part II, the sponsor, except for site monitors (w ho have interactions with 
the investigative sites), w ill become unblinded to treatment assignment. Identification of 
sponsor personnel who will have access to subject -level data for the interim analysis lock for 
Part I w ill be documented before the unblinding. The study blind w ill be maintained for 
investigators, site personnel, subjects, and sponsor site monitors until the final analyses have 
been com pleted for all subjects in Part I and Part II. This measure will mitigate the potential 
bias in the remaining investigator and subject assessments.
Rationale: Minor w ording changes to the numerical rating scale ( NRS )content based on feedback from a Health
Authority .
Applicable Section(s) Description of Change(s)
9.2.3. Abdominal This section was updated to read:
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 37
Approved , Date: 4 June 2021Pain Numerical 
Rating ScaleThe NRS for pain is a unidimensional measure of pain intensity in adults.5An 11 -point (0 -10) 
NRS will be used to evaluate abdominal pain. The score of 0 represents “no abdominal pain” 
and the score of 10 represents the “w orst possible abdominal pain”, with greater scores 
indicating greater pain severity and intensity. Subjects will select only one number that best 
reflects their pain at its w orst in the past 24 hours. The abdominal pain NRS will be assessed 
daily. Subjects will complete the NRS at approximately the same time each day before going 
to bed and bring the diary to ea ch visit.
Rationale: Minor w ording changes to Patient’s Global Impression of Severity ( PGIS )content based on feedback 
from a Health Authority .
Applicable Section(s) Description of Change(s)
9.2.4. Patient’s 
Global Impression of 
Severity of Crohn’s 
DiseaseThis section was updated to read:
The PGIS of Crohn’s disease is a 5 -point scale (“None”, “Mild”, “Moderate”, “Severe” and 
“Very Severe”) to rate Crohn’s disease intensity. Subjects will rate their PGIS of Crohn’s 
disease at Weeks 0, 4, 8, 12, and 24.
Rationale: Minor edits w ere noted.
Applicable Section(s) Description of Change(s)
Throughout the 
protocolMinor grammatical, formatting, or spelling changes were made.
Amendment 2 (09November 2016 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union. 
The overall reason for the amendment: The overall reason for the ame ndment was to address health authority 
requests.
Clarification of specific study procedures is also included in this amendment ,as described below . 
Applicable Sections Description of Changes
Rationale: The [ADDRESS_1241474] study agent administration in both Part I and 
Part II of the study, the study duration was increased by 4 weeks in both Part I and Part II.
Synopsis In the Overvie w of Study Design section, the second paragraph w as revised to read:
The duration of the study will be [ADDRESS_1241475] 
who completes all scheduled visits, including study agent administration visits and a final 
efficacy and safety follow -up visit. Eligible subjects will only particip ate in Part I or Part II 
of the study.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 38
Approved , Date: 4 June 2021Time and Events 
Schedule: Part IFootnote c w as revised to read:
c. Subjects who terminate study participation should complete an early termination visit. If 
a subject completed assessments at Week 24 and terminated after Week 24, the only 
assessments that should be performed at the early termination visit are those planned for 
the final efficacy and safety follow -up. Subjects who discontinue study agent 
administration before Week 8 (but have not terminated study participation) should 
complete the Week [ADDRESS_1241476] study agent administration. Subjects 
who discontinue study agent administration after Week 8 (but have not terminated study 
participation) should complete the Week [ADDRESS_1241477] study agent 
administration. 
Footnote d w as revised to read:
d. Subjects should complete a final efficacy and safety follow -up visit approximately 
16weeks after their last study agent administration . For subjects who complete all vis its, 
this will occur at Week 38 .
Time and Events 
Schedule: Part I IFootnote d w as revised to read:
d. Subjects should complete a final efficacy and safety follow -up visit approximately 
16weeks after their last study agent administration. For subjects who complete all visits, 
this will occur at Week 36.
3.1 Overview  of 
Study DesignFigure 2 w as updated to indicate Week 38 as the final efficacy and safety visit in Part I, 
and Figure 3 w as updated to indicate Week 36 as the f inal efficacy and safety visit in 
Part II. 
[IP_ADDRESS]. JNJ -
64304500The follow ing paragraph was added after the second paragraph:
A [ADDRESS_1241478] administration of study agent has been 
employed based on the observed safety profi le and PK profile of JNJ -64304500 in the 
completed clinical studies in RA and Crohn’s disease subjects. The average s erum 
concentration of JNJ -[ADDRESS_1241479] administration of study agent is 
predicted to be approximately 0.01 μg /mL, which is consider ed unlikely to produce drug -
related effect sor safety concern s.
4.1 Inclusion Criteria Inclusion Criterion 13.b.2 w as revised to read:
Agrees to remain on a highly effective method of contraception throughout the study and 
for at least [ADDRESS_1241480] administration of study agent.
Inclusion Criterion 14 w as revised to read:
A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted 
reproduction during the study and for a period of [ADDRESS_1241481] part Inclusion Criterion 15 w as revised to read:
During the study and for at least [ADDRESS_1241482] administration of study agent, a 
man
4.2 Exclusion Criteria Exclusion Criterion 28 w as revised to read:
Is a w oman who is pregnant, or breast -feeding, or planning to become pregnant or is a man 
who plans to father a child while enrolled in this study or within [ADDRESS_1241483] 
administration of study agent.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 39
Approved , Date: [ADDRESS_1241484] ion 3 w as revised to read:
Subjects must agree not to receive a live virus or live bacterial vaccination, including a 
BCG vaccination, during the study and for [ADDRESS_1241485] dose of study 
agent for BCG vaccination or 16 w eeks for other live vaccines.
9.1.2 Screening 
PeriodThe fourth paragraph was revised to read:
Wom en of childbearing potential must have a negative serum β -hCG pregnancy test result 
at screening. Subjects must be reminded that they are required to use a highly effectiv e 
method of contraception during the study (as described in Inclusion Criterion 13) and must 
continue taking such precautions for [ADDRESS_1241486] administration of 
study agent. The method(s) of contraception used by [CONTACT_887095] d ocumented.
9.1.4. Final Efficacy 
and Safety Follow -up 
VisitThis section was revised to read:
Subjects in Part I and Part II should complete the final efficacy and safety follow -up visit 
approximately [ADDRESS_1241487] study agent administration (Table 1, Table 2). 
10.1. Completion The first paragraph was revised to read:
A subject w ill be considered to have completed the study if he or she has completed 
assessments through the final efficacy and safety visit (ie, Week 38 in Part I and Week 36 
in Part II), as specified in the Time and Events Schedules for Part I or Part II.
The third paragraph w as revised to read:
The final efficacy and safety follow -up visit for subjects who discontinue study agent is 
approximately [ADDRESS_1241488] admin istration of study agent in both Part I and 
Part II.
10.2. Discontinuation 
of Study TreatmentThe second bullet of the second paragraph w as revised to read:
The subject becomes pregnant or plans a pregnancy within the study period or w ithin 
16weeks after the last study agent administration.
12.3.1. All Adverse 
EventsThe first paragraph was revised to read:
All AEs and special reporting situations, whether serious or nonserious, will be reported 
from the time a signed and dated ICF is obtained until completion of the subject's last 
study -related procedure, which may include contact [CONTACT_20687] -up of safety. Serious 
adverse events, including those spontaneously reported to the investigator w ithin [ADDRESS_1241489] be repor ted using the Serious Adverse Event Form. 
The sponsor w ill evaluate any safety information that is spontaneously reported by [CONTACT_887096].
Rationale: In response to a Health Authority request, the Patie nt’s Global Impression of Severity (PGIS) of Crohn’s 
disease and the Patient’s Global Impression of Change (PGIC) of severity of Crohn’s disease were added as efficacy 
assessments in Part II of the study .
Synopsis Inthe Efficacy Evaluations section, the following were added:
Patient’s Global Impression of Severity ( PGIS) of Crohn’s disease
Patient’s Global Impression of Change (PGIC) of severity of Crohn’s disease
Time and Events 
Schedule: Part IIThe follow ing efficacy assessments were added:
PGIS of Crohn’s disease assessment at Weeks 0, 4, 8, 12, 24, and Early termination.
PGIC of severity of Crohn’s disease assessment at Weeks 4, 8, 12, 24, and Early 
termination.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 40
Approved , Date: [ADDRESS_1241490] paragraph w as revised to read :
The follow ing efficacy endpoints will be evaluated in each of the 3 studies (except for the 
Patient’s Glob al Impression of Severity [PGIS] of Crohn’s disease and the Patient’s Gl obal 
Impression of Change [PGIC] of severity of Crohn’s disease , which will only be evaluate d 
inStudy 3 ):
The follow ing were added to the list of efficacy endpoints:
Change in PGIS of Crohn’s disease from baseline atWeeks 4, 8, 12, and 24.
A ≥1-point improvement in PGIS of Crohn’s disease from baseline atWeeks 4, 8, 12 ,
and 24.
Improvement in PGIC of severity of Crohn’s disease at Weeks 4, 8, 12, and 24.
9.2. Efficacy 
EvaluationsThis section was revised to read:
The CDAI will be the primary tool for assessing disease activity response to JNJ -
64304500, along w ith PRO -2, PRO -3, Bristol stool form scale, abdominal pain based on 
NRS 0 -10 scale, PGIS of Crohn’s disease , and PGIC of severity of Crohn’s disease . The 
degree of inflammation will be assessed by [CONTACT_887097]. Stool 
samples will be collected and analyzed to evaluate changes in markers that may reflect 
JNJ-64304500 or ustekinumab treatment. The w ell-being of subjects will be measured 
using the IBDQ and the SF -36. Mucosal healing will be assessed by [CONTACT_218758]. For 
subjects with fistulizing disease, fistula closure will also be assessed.
9.2.4 Patient’s Global 
Impression of 
Severity of Crohn’s 
DiseaseIn Section 9.2 Efficacy Evaluations, a new section 9.2.4 Patient’s Global Impression of 
Severity of Crohn’s D isease was added:
The PGIS of Crohn’s d isease is a 5 -point scale (“Absent“, “Mild”, “Moderate”, “Severe” 
and “Very Severe”) to rate Crohn’s disease intensity. Subjects w ill rate their PGIS of 
Crohn’s d isease atWeeks 0, 4, 8, 12, and 24.
9.2.5 Patient’s Global 
Impression of Change
of Severity of Crohn’s 
DiseaseIn Section 9.2 Efficacy Evaluations, a new section 9.2.5 Patient’s Global Impression of 
Change of Severity of Crohn’s D isease was added:
The PGIC of severity of Crohn’s d isease is a 7 -point scale ranging from “a lot better now” 
to “a lot w orse now” with a neutral center point (“neither better nor w orse”) to measure 
perceived change (improvement or deterioration) i n severity of Crohn’s disease . Subjects 
will assess their PGIC of severity of Crohn’s d isease at Week s4, 8, 12 ,and 24.
[IP_ADDRESS]. Other 
Efficacy Endpoint 
AnalysesThis section was revised to read:
Com parisons between each of the JNJ -64304500 treatment groups and the placebo 
treatment group will also be made for each of the endpoints specified in Section [IP_ADDRESS] 
andforthe following endpoints.
Change in PGIS of Crohn’s d isease from baseline atWeeks 4, 8, 12, and 24.
A ≥1-point improvement in PGIS of Crohn’s d isease from baseline atWeeks 4, 8, 12, 
and 24.
Improvement in PGIC of severity of Crohn’s d isease at Weeks 4, 8, 12, and 24.
Pairwise comparisons of the ustekinumab treatment group with the JNJ -[ADDRESS_1241491] of supplies provided to the investigator:
Worksheets for data collection 
Rationale: In response to a Health Authority request, further clarification of the study design and protocol structure 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 41
Approved , Date: 4 June 2021wasadded. 
1.2.2. Crohn’s 
DiseaseThe second paragraph w as revised to read:
Subjects w ere evaluated for the primary endpoint of change from baseline in the CDAI 
score at Week 4. Safety and efficacy evaluations were performed t hrough Week 24. The 
observed 16 -point greater reduction in CDAI in the JNJ -64304500 group at Week 4 
compared with the placebo group w as not significant (p=0.403). Based on a predefined 
significance level of 0.10, however, the reduction in CDAI score w as significantly higher 
in the JNJ -64304500 group compared with the placebo group at Week 12 ([ADDRESS_1241492] ion in CDAI was observed in JNJ -64304500 compared w ith placebo, p=0.056). 
Based on the same predefined significance level of 0.10, reductions in CDAI scores were 
significantly higher in the predefined subgroup of “no prior failure to biologics” (Bio-NF, 
71% of the study population) in the JNJ -[ADDRESS_1241493] baseline visits through Week 12 (Week 1, p=0.068; Week 2, p=0.048; Week 4, 
p=0.095; Week 8, p=0.015; and Week 12, p=0.025). The biologic intolerant or refrac tory 
population (Bio -IR)in the Novo Nordisk Phase 2a study constituted 29% of the study 
population (N=12 in the active treatment arm and N=11 in the placebo arm). In this 
subpopulation, a 45-point greater reduction in CDAI was observed at Wee k [ADDRESS_1241494] paragraph w as replaced w ith the following 3paragraphs at the end of the section:
In order to provide an efficient means of rapi[INVESTIGATOR_887059] 2 dose-ranging , 
this protocol is designed to be a comprehensive Phase 2 program in which the sponsor will 
evaluate safety and efficacy in subjects who are biologic intolerant or refractory (the Bio -
IR population, Study 1).
In Study 1, a higher dose regimen than was used in the Phase 2a study will be employed 
supported by [CONTACT_887092] 1 (the Novo Nordisk 
Phase 1 single ascending/multiple ascending dose study NN8555 -3618), andthe high 
exposure margins relative to NOAEL exposure in cy nomolgus monkeys. This higher dose 
will be used to establish safety and efficacy (Proof of Concept) for the Bio -IR population, 
as this was not satisfactorily established in this population in the Novo Nordisk Phase 2a 
study (NN8555 -3797). In addition, this higher dose w ill also be evaluated in subjects who 
have not previously failed a biologic therapy (Study 2 , Bio -NF) to determine if amore 
robust efficacy outcome than was shown in the Phase 2a study can be achieved while 
maintaining an acceptable safety p rofile. Combined with data from Phase 2a in Bio -NF 
subjects, Study 2 w ould provide valuable information for the assessment of dose/exposure -
response and thus the selection of the optimal dose in Bio -NF population for the Phase 3 
program. Study 1 and Study 2 com prise Part I of the protocol and these 2 components will 
be initiated in parallel. It is anticipated that Bio -NF subjects will enroll slower than Bio -IR 
subjects. Therefore, initiation of Study 2 in parallel with Study 1 will facilitate the 
completion of Study 2 in a timely fashion to be able to inform Phase 3 study planning for 
the Bio -NF population. The decision to initiate the dose-ranging portion of the protocol 
(Study 3, Bio -IR) is dependent on demonstration of acceptable safety and efficacy in th e 
Bio-IR subjects in Study 1. A ustekinumab reference arm will be included in Study [ADDRESS_1241495] in the overall selection of dose(s) to carry forw ard into the P hase [ADDRESS_1241496] and program decision -making based on planned interim DBLs as described in 
Section 3.1.1, Section 3.1.3, and Section 5.2.
Rationale: Inclusion criteria related to prior or current medications for Crohn’s disease were updated to clarify the 
requirements for Part I (Study 1 and Study 2 ) and Part II ( Study 3 ).
4.1. Inclusion Criteria Inclusion Criterion 5 w as revised to read:
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 42
Approved , Date: 4 June [ZIP_CODE]. Criterion modified per Amendment 2:
5.1 In Study 1 , meet the following requirements for prior or current m edications for 
Crohn’s disease:
a.Has previously demonstrated inadequate response, loss of response, or intolerance 
to 1 or more approved biologic thera pi[INVESTIGATOR_014] (eg, infliximab, adalimumab, certolizumab 
pegol, or vedolizumab) as outlined in Attachment 1.
InStudy 2 , meet the following requirements for prior or current medications for 
Crohn’s disease:
b.Has failed conventional therapy as follows :
1)Is currently receiving corticosteroi ds and/or immunomodulators (ie , AZA, 
6-MP, or MTX) at adequate therapeutic doses (Attachment 2).
OR
2)Has a history of failure to respond to or tolerate an adequate course of 
corticosteroi ds and/or immunomodulators (ie , AZA, 6 -MP, or M TX) 
(Attachment 2).
OR
3)Is corticosteroid dependent or has had a history of corticosteroid dependency 
(Attachment 2).
Inclusion Criterion 6 w as revised to read:
6.InStudy 3 , meet the following requirement for prior or current medications for 
Crohn’s disease: has previously demonstrated inadequate response, loss of response, or 
intolerance to 1 or more approved biologic therapi[INVESTIGATOR_014] (eg, infliximab, adalimumab, 
certolizumab pegol, or vedolizumab) as outlined in Attachment 1.
Rationale: To accurately assess potential injection -site reactions, additional instructions regarding injection -site 
location were added.
Time and Events 
Schedule: Part IUnder Study Procedures, Administer study agent was revised to read:
Administer study agent e(SC study agent at a different location at each visit [Section 6])
Time and Events 
Schedule: Part I IUnder Study Procedures, Administer study agent was revised to read:
Administer study agent e(SC study agent at a different location at each visit [Section 6])
6.Dosage a nd 
AdministrationThe follow ing was added at the beginning of the section:
Subcutaneous injections of study agent should be administered at different locations at 
each visit at which study agent is administered to allow  for as sessment of potential 
injection -site reactions.
Rationale: Theinclusion criterion related to contraception was revised to be consistent with the core safety 
information for JNJ -64304500. 
4.1. Inclusion Criteria The follow ing was added as the last sentence of Inclusion Criterion 13.b.1:
If using a hormone birth control method ,a second method of birth control, such as a 
condom or diaphragm ,must be used.
Rationale: The footnote for video ileocolonoscopy in the T ime and Events Schedule Part II was updated to be 
consistent with the footnote for video ileocolonoscopy in the Tim e and Events Schedule Part I. 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 43
Approved , Date: 4 June 2021Time and Events 
Schedule Part IIFootnote r was revised to read:
r. Because these procedures must not interfere with the collection of CDAI data, if 
performed on the day of these visits, the [ADDRESS_1241497] 8 days before the Week 0 visit and no more than 8 days before the 
Week 12 visit.
Rationale: Thenumbers of subjects exposed to JNJ-64304500 in clinical studies were updated to be consistent with 
the Investigator’s Brochure .
1.2. Clinical Studies This section was revised to read:
As of 11 Nov ember 2015, a total of 128 s ubjects had been exposed to JNJ -64304500 in 
3clinical studies: 88 subjects in 2 studies in rheumatoid arthritis (RA) and 40 subjects in a 
Phase 2a study in Crohn’s disease.
1.2.1. Rheumatoid 
ArthritisThis section was revised to read:
Two studies with JNJ -[ADDRESS_1241498] -in-humans , Phase 1, singl e ascending dose/multiple ascending 
dose study that included single -dose (0.0002 to 7.5 mg/kg) and multiple -dose (0.02 to 4 
mg/kg every 2 w eeks for 4 administrations) parts, 13 dose levels were evaluated in 24 
subjects exposed to JNJ -64304500 in the single ascending dose portion and 23 subjects 
exposed to JNJ -64304500 in the multiple ascending dose portion. Sub cutaneous 
administration of JNJ -64304500 w as well tolerated at the dose ranges investigated and no 
safety signals were associated with either the sin gle-or multiple -dose regimens.
In NN8555 -3796 , a Phase 2a, randomized, single -dose, double -blind, placebo -controlled, 
parallel -group study, clinical efficacy was assessed in subjects with active RA 
concomitantly treated w ith methotrexate (MTX). In this study, a single SC injection of 
4mg/kg JNJ -[ADDRESS_1241499] version of the IB.
Rationale: The timing for the collection of the random population pharmacokinetic (PK) sample s was clarified. 
Time and Events 
Schedule: Part IFootnote x was revised to read:
x.Each random population PK sample should be collected at any time between Weeks 0 
and 2 (after the Week 0 study agent administration) and between Weeks 22 and 24 (after 
the Week 22 study ag ent administration). The date for the random population PK sample 
collection will be at the subject’s discretion. However ,samples should not be draw n on or 
within 1 day of a schedu led visit (ie, the Week0, 2, 22, or 24 visit) in this time period.
Time and Events 
Schedule: Part I IFootnote x was revised to read:
x.Each random population PK sample should be collected at any time between Weeks 0 
and 2 (after the Week 0 study agent administration) and between Weeks 20 and 24 (after 
the Week 20 study agent administration). The date for the random population PK sample 
collection will be at the subject’s discretion. However, samples should not be draw n on or 
within 1 day of a scheduled visit (ie, the Week 0, 2, 20, or 24 visit) in this time period.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 44
Approved , Date: [ADDRESS_1241500] paragraph was revised to read:
Serum samples used to evaluate the PK and immunogenicity of JNJ -64304500 and 
ustekinumab (antibodies to JNJ -64304500 and antibodies to ustekinumab) will be 
collected according to the Time and Events Schedule s. Samples collected for analyses of 
serum concentration of JNJ -[ADDRESS_1241501] be recorded on the laboratory requisition form.
Rationale: The instructions regarding the components of the CDAI were clarified. 
Time and Events 
Schedule: Part IFootnote e w as revised to read:
e.All assessments are to be completed before study agent administration, unless 
otherwise specified. It is recommended that PRO assessments be completed first, starting 
with the PRO components of the CDAI. 
Footnote nwas revised to read:
n.The hematocrit value obtained during screening will be used to calculate CDAI at 
Week 0. For other visits, the most recent hematocrit value obtained before a visit will be 
used to calculate the CDAI for that visit. 
Time and Events 
Schedule: Part I IFootnote e w as revised to read:
e.All assessments are to be completed before study agent administration, unless 
otherwise specified. It is recommended that PRO assessments be completed first, starting 
with the PRO components of the CDAI. 
Footnote nwas revised to read:
n.The hematocrit value obtained during screening will be used to calculate CDAI at 
Week 0. For other visits, the most recent hematocrit value obtained before a visit will be 
used to calculate the CDAI for that visit. 
Rationale: The instructions regarding the procedures/assessments to be completed at early termination were 
clarified. 
Time and Events 
Schedule: Part IFootnote c w as revised to read:
c. Subjects who terminate study participation should complete an early termination visit. If 
a subject completed assessments at Week 24 and terminated after Week 24, the only 
assessments that should be performed at the early termination visit are those planned for 
the final efficacy and safety follow -up. Subjects who discontinue study agent 
administration before Week 8 (but have not terminated study participation) should 
complete the Week [ADDRESS_1241502] study agent administration. 
Subjects who discontinue study agent administration after Week 8 (but have not 
terminated study participation) should complete the Week [ADDRESS_1241503] study agent administration.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 45
Approved , Date: 4 June 2021Time and Events 
Schedule: Part I I Footnote c w as revised to read:
c.Subjects who terminate study participation should complete an early termination visit. 
If a subject completed as sessments at Week 24 and terminated after Week 24, the only 
assessments that should be performed at the early termination visit are those planned for 
the final efficacy and safety follow -up. Subjects who discontinue study agent 
administration before Week 8 (but have not terminated study participation) should 
complete the Week [ADDRESS_1241504] study agent administration. Subjects 
who discontinue study agent administration after Week 8 (but have not terminated study 
participation) should complete the Week [ADDRESS_1241505] study agent 
administratio n.
Rationale: Exploratory histologic assessments were added.
Synopsis In the Efficacy Evaluations section, the following was added:
Histologic assessment
2.1.2 Endpoints The follow ing was added:
Endpoint(s) for histologic assessment based on the Global Histology Activity Score 
(GHAS; to be detailed in the Statistical Analysis Plan [SAP]). 
9.2.12 Histologic
Assessment In Section 9.2 Efficacy Evaluations, a new section 9.2.12 Histologic Assessment was 
added:
Histologic assessment will be performed using biopsy samples collected during 
endoscopy. Biopsy samples will be collected at screening, Week 12, and Week 24 from 
each of 3 predefined anatomic locations: the terminal ileum, splenic flexure, and rectum. 
The biopsy samples collected at Week 12 and Week 24 w ill be obtained near w here the 
biopsy samples at screening were collected from each of the 3 predefined locations. 
Histologic assessment will be conducted by a central reader who is blinded to treatment 
groups. The GHAS will be used to evaluate histologic improvement. Additional details 
will be provided in the Study Reference Manual.
[IP_ADDRESS] Other 
Efficacy Endpoint 
AnalysesThe follow ing was added:
Endpoint(s) for histologic assessment based on the GHAS (to be detailed in the 
SAP).
11.5. Biomarker 
AnalysesThe last sentence was revised to read:
Results of serum, whole blood analyses, stool, and mucosal biopsy analyses will be 
reported in separate technical reports.
Rationale: The requirement for a nileocolon oscopy biopsy sample collection at early termination was added as it 
was erroneously omitted from the protocol. 
Time and Events 
Schedule: Part IIIn the Pharmacodynamics/Biomarkers Assessments section, an X was added in the Early 
Term ination co lumn of the Ileocolonoscopy biopsy sample collections for RNA and 
histology row.
Rationale: To clarify the efficacy assessment calculations for c hange in abdominal pain score and c hange in stool 
frequency score , mean daily average was revised to daily average. 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 46
Approved , Date: 4 June [ZIP_CODE].1.2 Endpoints The follow ing were revised to read:
Change in abdominal pain score (daily average based on the CDAI assessment) from 
baseline at all postbaseline visits.
Change in stool frequency score (daily average based on the CDAI assessment) from 
baseline at all postbaseline visits.
[IP_ADDRESS]. Other 
Efficacy Endpoint 
AnalysesThe follow ing were revised to read:
Change in abdominal pain score (daily average based on the CDAI assessment) from 
baseline at all postbaseline visits.
Change in stool frequency score (daily average based on the CDAI assessment) from 
baseline at all postbaseline visits.
Rationale: The rationale for an interim analysis was clarified. 
Synopsis , Overview 
of Study DesignThe fourth paragraph was revised to read:
An interim analysis is planned in Study [ADDRESS_1241506] 80% of the randomized 
Bio-IR subjects in Study 1 of Part I (at least [ADDRESS_1241507] 30 Bio -
IR/SNP -positive subjects per treatment group) have completed their Week [ADDRESS_1241508] 
terminated their study participation before Week 8. This interim analysis will allow  for an 
earlier start of Part II (ie, Study 3 , the dose-ranging part) if a sufficient effect is observed . 
Part II w ill be initiated if results from Study 1 of Part I demonstrates acceptable safety and 
efficacy, either at the interim analysis or w hen 100% of the Bio -IR subjects have 
completed their Week 12 visit (or have terminated study participation prior to this time).
3.1.3. Interim 
AnalysisThe second paragraph w as revised to read:
This interim analysis will allow for an earlier start of Part II (ie , Study 3, the dose -ranging 
part) if a sufficient effect is observed (see Section 11.10). As this interim analysis does not 
affect the conduct or completion of Study 1, it will be considered administrative and will 
not require multiplicity adjustment for the final Study [ADDRESS_1241509] paragraph was revised to read:
An interim analysis is planned in Study [ADDRESS_1241510] 80% of the randomized Part I Bio -
IR subjects (at least [ADDRESS_1241511] 30 Bio -IR/SNP -positive subjects per 
treatment group) have completed their Week [ADDRESS_1241512] terminated their study 
participation before Week 8. This interim analysis will allow for an earlier start of Part II 
(ie, Study 3 , the dose -ranging part) if a sufficient effect is observed . As this interim 
analysis does not affect the conduct or completion of Study 1, it w ill be considered 
administrative and will not require multiplicity adjustment for the final Study 1 analysis.
Rationale: Safety data for dose selection were clarified. 
[IP_ADDRESS]. JNJ-
64304500The first paragraph was revised to read:
The results of PK, PD and efficacy analyses and safety data from previous clinical studies 
of JNJ -64304500 in subjects with RA and Crohn’s disease were used to guide the dose 
selection for the [ADDRESS_1241513] single SC 
dose investig ated w as 7.5 mg/kg and the highest multiple SC dose regimen investigated 
was 4 mg/kg q2w  for a total of 4 doses in RA subjects. JNJ -64304500 w as well tolerated 
and no safety concerns were identified in subjects w ith RA or Crohn’s disease from the 
previous clinical studies. In addition, a [ADDRESS_1241514] level (NOAEL) of 100 mg/kg SC once weekly 
in cynomolgus monkeys. The exposures achieved in the last dosage interval (100 mg/kg) 
of the 52 -week study were 10,900 and 8,480 μg/mL for maximum concentration (Cmax),
and 1,520,000 and 1,250,000 hr·μg/mL for AUC 0-168hr ,for male and female monkeys, 
respectively. Based on these safety and toxicology findings, it is expected that the 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 47
Approved , Date: [ADDRESS_1241515] paragraph w as revised to read:
The selection of the [ADDRESS_1241516] characterization of the exposure -response relationship of 
JNJ-64304500 in the treatment of Crohn’ s disease.
Rationale: The definitions of inadequate initial response, loss of response, or intolerance to TNF -antagonist 
therapi[INVESTIGATOR_887060] . 
Attachment 1 Attachment 1 w as replaced w ith the updated definitions . 
Rationale: Minor errors w ere noted .
Throughout the 
protoco lMinor grammatical, formatting, or spelling changes were made.
Amendment 1 (14 June 2016 )
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) of Directive 
2001/20/EC of the European Parliament and the Council of the European Union . 
The overall reason for the amendment: The overall reason for the amendment wasto address health authority 
requests.
Clarificat ion of specific study procedures is also included in this amendment as described below . 
Applicable S ections Description of Changes
Rationale: At the request of a health authority, collection of stool cons istency data using the Bristol stool form 
scale and assessment of abdominal pain based on the Numerical Rating Scale (NRS) were added, as wellas
exploratory analys esof these data.
Synopsis In the Efficacy Evaluations section, the following bullets on Bristol stool form scale and 
assessment of abdominal pain were added:
Bristol stool form scale
Abdominal pain Numerical Rating Scale (NRS)
Time and Events
Schedule: Part Iand 
Part IIIn the Efficacy Assessments section, the Bristol stool form scale w as added as an 
assessment with data collection at Weeks 0, 2, 4, 6, 8, 10, and 12. Also, a new  footnote o 
was added and subsequent footnotes were renumbered:
o. Subject w ill com plete the Br istol stool form scale as a daily diary entry and bring the 
diary to each visit. Daily diary information should be collected for every day prior to each 
visit.
In the Efficacy Assessments section, abdominal pain NRS was added as an assessment 
with diary da ta collection at all visits. Also, a new footnote p was added and subsequent 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 48
Approved , Date: 4 June 2021Applicable S ections Description of Changes
footnotes were renumbered:
p. Subject w ill com plete the abdominal pain NRS assessment as a daily diary entry and 
bring the diary to each visit. For all visits up to Week 24, daily diary information should be 
collected for every day prior to the visits. For the final efficacy and safety visit, daily diary 
information should be collected for 14 days prior to the visit .
2.1.2 Endpoints The follow ing efficacy endpoints bullets were ad ded to each of the 3 studies:
Change in abdominal pain score (mean daily average based on the CDAI assessment) 
from baseline at all postbaseline visits.
Change in stool frequency score (mean daily average based on the CDAI assessment) 
from baseline at all postbaseline visits.
Endpoint(s) based on Bristol stool form scale (to be detailed in the Statistical Analysis 
Plan).
Change in abdominal pain from baseline at all postbaseline visits based on a 0 -10 
Numerical Rating Scale (NRS).
9.2 Efficacy 
EvaluationsThe section w as revised to read:
The CDAI will be the primary tool for assessing disease activity response to JNJ -
64304500, along w ith PRO -2, PRO -3, Bristol stool form scale, and abdominal pain based 
on NRS [ADDRESS_1241517] JNJ -64304500 or ustekinumab treatment. The w ell-being of 
subjects will be measured using the IBDQ and the SF -36. Muco sal healing will be assessed 
by [CONTACT_218758]. For subjects with fistulizing disease, fistula closure will also be 
assessed.
9.2.2 Bristol Stool 
Form  ScaleIn Section 9.2 Efficacy Evaluations, a new Section 9.2.2 Bristol Stool Form Scale was 
added:
The Bristol stool form scale is a m edical aid to classify the form (or consistency) of human 
feces into 7 categories.8It has been used as a research tool to evaluate the effectiveness of 
treatments for various diseases of the bowel ( eg, irritable bowel syndro me).4 Subjects will 
complete the Bristol stool form scale as a daily diary entry and bring the diary to each visit 
up to Week 12.
9.2.3 Abdominal Pain 
Numerical Rating 
ScaleIn Section 9.2 Efficacy Evaluations, a new Section 9.2.3 Abdominal Pain Numerical
Rating Scale was added:
The NRS for pain is a unidimensional measure of pain intensity in adults.5An 11 -point (0 -
10) NRS w ill be used to evaluate abdominal pain. The score of 0 represents “no pain” and 
the score of 10 represents the “pain as bad as you c an imagine”, with greater scores 
indicating greater pain severity and intensity. Subjects will select only one number that 
best reflects their pain at its worst in the past 24 hours. The abdominal pain NRS will be 
assessed daily. Subjects are to complete a daily diary entry and bring the diary to each 
visit.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 49
Approved , Date: 4 June 2021Applicable S ections Description of Changes
[IP_ADDRESS] Other 
Efficacy Endpoint 
AnalysesThe follow ing new bullets were added:
Change in abdominal pain score (mean daily average based on the CDAI assessment) 
from baseline at all postbaseline visits.
Change in stool frequency score (mean daily average based on the CDAI assessment) 
from baseline at all postbaseline visits.
Endpoint(s) based on Bristol stool form scale (to be detailed in the SAP).
Change in abdominal pain from baseline at all pos tbaseline visits based on a 0 -10 NRS.
15 Study -Specific 
MaterialsStudy -specific materials pertaining to the Bristol stool form scale and assessment of 
abdominal pain were added:
Bristol stool form scale diary
Abdominal pain NRS diary
References Two references for the Bristol stool form scale (Dove et al 2013 and Lew is/Heaton 1997) 
were added to the References and other references were renumbered accordingly.
One reference for the abdominal pain NRS assessment (Hawker et al 2011) w as added to 
the Refe rences and other references were renumbered accordingly.
Rationale: Text w as revised to clarify that the sample size for Study [ADDRESS_1241518] a dose -
response signal and the sample size/pow er considerations for the pairw ise com parisons of the JNJ -64304500 groups 
with placebo w ere based on the comparison of the high dose group with placebo.
Synopsis Inthe Statistical Methods section, the text under Sample Size Determination was revised 
to read:
Sample size calculations for Study 1 (Part I Bio -IR subjects) and Study 2 (Part I Bio -NF 
subjects) w ere determined by [CONTACT_887086] a significant difference in the change 
from baseline in the CDAI score at Week 8 (primary endpoint in each study) between 
JNJ-[ADDRESS_1241519]. Sample size calculation for Study 3 
(Bio-IR subjects) w as determined by [CONTACT_676464] a dose -response signal in the 
change from baseline in the CDAI score at Week 8 (primary endpoint in Study 3) using the 
Multiple Comparison Procedur es with modeling techniques (MCP -Mod) method.
For Study 1, assuming the mean CDAI change from baseline at Week 8 is -79 in the 
JNJ-64304500 group and -25 in the placebo group with a common SD of 92, 50 subjects 
per treatment group w ill provide approximatel y 80% pow er to detect a treatment 
difference between JNJ -64304500 and placebo at an overall Type 1 error of 0.05.
For Study 2, assuming the mean CDAI change from baseline at Week 8 is -152 in the 
JNJ-64304500 group and -66 in the placebo group with a commo n SD of 100, 50 subjects 
per treatment group w ill provide approximately 99% pow er to detect a treatment 
difference between JNJ -64304500 and placebo at an overall Type 1 error of 0.05.
For Study 3, assuming the m ean CDAI change from baseline at Week 8 is -79 in the 
JNJ-64304500 group and -25 in the placebo group with a common SD of 92, 50 subjects 
per treatment group w ill provide a mean pow er of 85% to detect a dose -response signal 
based on 7 candidate dose -response models at an overall Type 1 error of 0.05.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 50
Approved , Date: 4 June 2021Applicable S ections Description of Changes
[IP_ADDRESS] All Bio -IR 
SubjectsThe section w as revised to read:
Using the same assumptions as w ere used for the Bio -IR population in Study 1, 50 subjects 
per treatment group w ill provide a mean pow er of 85% to detect a dose -response signal for 
change from baseline in CDAI at Week 8 based on 7 candidate dose -response models (to 
be detailed in the SAP) at an overall Type 1 error of 0.05 (2 -sided). Fifty subjects per 
treatment group will also provide approximately 80% pow er to detect a treatment 
difference between the JNJ -[ADDRESS_1241520] dose and the 
placebo treatment group for change from baseline in CDAI at Week 8 at a Type I error of 
0.05 (2 -sided; Table 4). This will result in a total sample size of 250 subjects in Part II 
(incorpo rating an additional 50 subjects for the ustekinumab treatment group).
Fifty Bio -IR subjects per treatment group in Part II w ill also provide 90% pow er to detect 
a difference betw een the JNJ -[ADDRESS_1241521] dose and the 
placebo tr eatment group in the proportion of subjects in clinical remission at Week 8 (the 
first major secondary endpoint) at a Type 1 error of 0.05 (2 -sided; Table 4), assuming 
JNJ-64304500 has a remission rate of 31%, which is 10% greater than the ustekinumab 
remission rate in CNTO1275CRD3001.
[IP_ADDRESS] Bio -IR 
Subjects Who Are 
SNP-Positive (Bio -
IR/SNP+)The section w as revised to read:
Based on the assumption that 75% of the Crohn’s disease population will be SNP -positive, 
50Bio-IR subjects w ill provide approximately 38 Bio -IR/SNP+ subjects. Thirty -eight 
Bio-IR/SNP+ subjects per group will provide 80% pow er to detect a difference between 
the JNJ -[ADDRESS_1241522] dose and the placebo treatment group
in the proportion of subjects in clinical remission at Week 8 at a Type 1 error of 0.05 
(2-sided; Table 4), assuming JNJ -64304500 has a remission rate of 31%, w hich is 10% 
greater than the ustekinumab remission rate in CNTO1275CRD3001.
Rationale: In order to clarify the Efficacy Assessments (CDAI assessments, Fistula exam, and Collect and revie w 
diary cards) and the Clinical Laboratory Assessments (Hematology) in the Time and Events Schedules, the 
frequency of completing the seevents was increased to all visits of the Main Study phase (and to the Final efficacy 
and safety follow -up visit for the Fistula Exam) .
Time and Events 
Schedule: Part I In the Efficacy Assessments section (CDAI assessments, Fistula exam, and Collect and 
review diary cards) and the Clinical Laboratory Assessments section (Hematology) , an X 
was added at Weeks 14, 18, and 22 for completion of the se events .An X was also added at 
the Final Efficacy and Safety Follow -Up Visit for completion of the Fistula Exam. A new 
footnote m w as added for the collection and review of diary cards, and subsequent 
footnotes were renumbered:
m. For all visits up to Week 24, daily diary information should be collected for every day 
prior to each visit. For the final efficacy and safety visit, daily diary information should be 
collected for 14 days prior to the visit.
Time and Events 
Schedule: Part IIIn the Efficacy Assessments section (CDAI assessments, Fistula exam, and Collect and 
review diary cards) and the Clinical Laboratory Assessments sectio n (Hematology) , an X 
was added at Week 14 for completion of the se events. An X w as also added at the Final 
Efficacy and Safety Follow -Up Visit for completion of the Fistula Exam. A new footnote 
m was added for the collection and review of diary cards, and subsequent footnotes were 
renumbered:
m. For all visits up to Week 24, daily diary information should be collected for every day 
prior to each visit. For the final efficacy and safety visit, daily diary information should be 
collected for 14 days prior to the visit.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 51
Approved , Date: 4 June 2021Applicable S ections Description of Changes
Rationale: At the request of a health authority to identify early immunogenic responses, an additional sample for 
anti-drug antibody analysis was added at Week 2 in Part I (Studies 1 and 2) and Part II ( Study 3).
Time and Events
Schedule: Part Iand 
Part IIAdded an X for Week 2 collection of samples to measure antibodies to JNJ -64304500 in 
Part I, and Assessment for antibody to study agent in Part II.
Rationale: In order to clarify instructions on sample handling for site investigators, additional footnotes were added 
to the Time and Events Schedules, and new text was added to Section 9.3.1 Evaluations.
Time and Events
Schedule: Part Iand 
Part IITo the events of ‘JNJ -64304500 serum concentration’, ‘JNJ -64304500 random population 
PK sample’ and ‘Antibodies to JNJ -64304500’ in Part I, and ‘Study agent serum 
concentration’, ‘JNJ -64304500 random population PK sample’ and ‘Assessment for 
antibody to study agent’ in Part II, a new  footnote w was added:
w. At visits where only serum concentration of study agent will be evaluated ( ie, no 
antibodies to study agent will be evaluated), 1 venous blood sample of sufficient volume 
should be collected, and each serum sample should be divided into 2 aliquots (1 for serum 
concentration o f study agent, and a back -up). At visits where serum concentration of study 
agent and antibodies to study agent will be evaluated, 1 venous blood sample of sufficient 
volume should be collected. Each serum sample will be divided into 3 aliquots (1 each for
serum concentration of study agent, antibodies to study agent, and a back -up).
9.3.1 Evaluations New  text was added to the second paragraph in order to clarify instructions on sample 
handling for site investigators, as follows:
At visits where only serum concentration of study agent will be evaluated ( ie, no 
antibodies to study agent will be evaluated), 1 venous blood sample of sufficient volume 
should be collected, and each serum sample should be divided into 2 aliquots (1 for serum 
concentration of stud y agent, and a back -up).
Rationale: The requirement for a video ileocolonoscopy at early termination was added as it was erroneously 
omitted from the protocol. 
Time and Events
Schedule: Part IIIn the Efficacy Assessments section, an X was added in the Early Termination column of 
the Video ileocolonoscopy row. 
Rationale: In order to specify the type of procedures that will not be included in the category of Crohn’s disease -
related hospi[INVESTIGATOR_887061], a new footnote was added to the Time and Events Schedules.
Time and Events 
Schedule: Part I and 
Part IITo the event of ‘Crohn’s disease -related hospi[INVESTIGATOR_887061]’, a new footnote aa 
was added:
aa. Hospi[INVESTIGATOR_887062].
Rationale: In countries where tuberculin is not available for the skin test, this meth od of testing will not be
required. QuantiFERON -TB Gold and chest radiograph must still be done if tuberculosis (TB) is suspected, along 
with referral to a TB specialist if possible.
Time and Events
Schedule: Part I and 
Part IIFootnote g was revised to read:
g. All subjects w ill undergo QuantiFERON -TB Gold testing. In countries where the 
QuantiFERON -TB Gold test is not registered/approved, TB skin testing will also be 
required (recommended but not required for study centers in countries where tuberculin is 
not available). The QuantiFERON -TB Gold test is not required at screening for subjects 
with a history of latent TB and appropriate treatment (as described in Inclusion 
Criterion 11a).
Time and Events 
Schedule: Part I and 
Part IIFootnote l w as revised to read:
l. If TB is suspected at any time during the study , a chest radiograph and QuantiFERON -
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 52
Approved , Date: [ADDRESS_1241523] is 
not registered/approved, TB skin testing should also be performed (recommen ded but not 
required for study centers in countries where tuberculin is not available). 
4.[ADDRESS_1241524] is recommended 
but not required for study centers in countries where tuberculin is not available, as follows:
Within [ADDRESS_1241525] (Attachment 3), or have a newly identified positive 
QuantiFERON -TB Gold test in which active TB has been ruled out, and for which 
appropriate treatment for latent TB has been initiated either before or simultaneously with 
the first administration of study agent (except in countries with high multidrug -resistant 
TB burden [ eg, Brazil, China, India, the Russia n Federation, and South Africa]), where 
subjects with a newly identified positive QuantiFERON -TB Gold test result are excluded). 
Indeterminate results should be handled as outlined in Section 9.1.2. A negative tuberculin 
skin test (Attachment 4) is additio nally required if the QuantiFERON -TB gold test is not 
approved/registered in that country. A tuberculin skin test is recommended but not 
required for study centers in countries where tuberculin is not available. The 
QuantiFERON -TB Gold In -Tube test is not required at screening for subjects with a 
history of latent TB and appropriate treatment as described above in Inclusion 
Criterion 11a.
9.1.2 Screening 
PeriodThe sixth paragraph was revised as follows:
Subjects with a negative QuantiFERON -TB Gold test result (and a negative tuberculin 
skin test result in countries in which the QuantiFERON -TB Gold test is not 
approved/registered or the tuberculin skin is mandated by [CONTACT_72952]) are 
eligible to continue with prerandomization procedures. A tuberculin skin test is 
recommended but not required for study centers in countries where tuberculin is not 
available. Subjects with a newly identified positive QuantiFERON -TB Gold (or tuberculin 
skin) test result must undergo an evaluation to rule out activ e TB and initiate appropriate 
treatment for latent TB. Appropriate treatment for latent TB is defined according to local 
country guidelines for immunocompromised patients. If no local country guidelines for 
immunocompromised patients exist, US guidelines m ust be follow ed, or the subject w ill be 
excluded from the study. Note: Subjects in countries with high multidrug -resistant TB 
burden ( eg, Brazil, China, India, the Russian Federation, and South Africa) identified with 
latent TB at screening will be exclude d from participating in the study.
9.[ADDRESS_1241526] paragraph was 
revised as follows:
Subjects who experience close contact [CONTACT_40976] a repeat chest radiograph, a repeat QuantiFERON®-TB 
Gold test, a repeat tuberculin skin test in countries in which the QuantiFERON -TB Gold 
test is not approved/registered and, if possible, referral to a physician specializing in TB to 
determine the subject’s risk of developi[INVESTIGATOR_887063]. A tuberculin skin test is recommended but not required for study centers in 
countries where tuberculin is not available. A positive QuantiFERON -TB Gold ( or 
tuberculin skin) test result should be considered detection of latent TB. If the 
QuantiFERON -TB Gold test result is indeterminate, the test should be repeated as outlined 
in Section 9.1.2. If recommended, treatment for latent TB must be initiated before or 
simultaneously with the administration of further study agent. Subjects who discontinue 
treatment for latent TB prematurely or who are noncompliant w ith therapy must 
immediately discontinue further administration of study agent and be encouraged to ret urn 
for all subsequent scheduled study visits.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 53
Approved , Date: [ADDRESS_1241527] ineligibility was revised to read:
A subject undergoing continued evaluation has a chest radiograph with evidence 
of current active TB and/or a positive QuantiFERON -TB Gold test result and/or 
a positive tuberculin skin test result in countries in which the QuantiFERON -TB 
Gold is not approved/registered (recommended but not required for study 
centers in countries where tu berculin is not available) unless active TB can be 
ruled out and appropriate treatment for latent TB can be initiated either prior to 
or simultaneously with the next administration of study agent and continued to 
completion. (Note: Study agent must be disc ontinued for all subjects diagnosed 
with latent TB in countries with high multidrug -resistant TB burden [ eg, Brazil, 
China, India, the Russian Federation, and South Africa]).
Attachment 3 
QuantiFERON -TB 
Gold TestingUnder the subheading Adherence to Loca l Guidelines, t he follow ing sentence was added to 
the second (and final) paragraph:
In countries where the QuantiFERON -TB Gold test is not approved/registered, the 
tuberculin skin test is recommended but not required if tuberculin is not available.
Attachment [ADDRESS_1241528] sentence:
NOTE: The tuberculin skin test is recommended but not required in countries where 
tuberculin is not available.
Rationale: Language was added to clarify that an indeterminate result for SNP w ould not meet inclusion criteria for 
the study, and that the deoxyribonucleic acid (DNA) samples can be used for both the required and optional DNA 
research.
4.1 Inclusion Criteria Inclusion Criterion 18 w as revised to read:
DNA sample collection for SNP testing is required for all subjects in this study. Each 
subject must have a SNP status of either positive or negative. Each subject must sign a 
separate informed consent form ( ICF)if he or she agrees to consent to additional optional 
DNA research where local regulations permit. Refusal to give consent for the optional 
DNA research does not exclude a subject from participation in the study.
Rationale: Additional details were added for maintaining the study blind during prepar ation of JNJ -[ADDRESS_1241529] paragraph was updated to add the w ords ‘or syringe number’, and was revised to 
read:
To maintain the study blind, the study agent container w ill have a label containing the 
study name [CONTACT_887140]. The label w ill not identify the 
study agent in the container. The medication number or syringe number will be entered in 
the case report form (CRF) when the drug is dispensed. The study agents will be identical 
in appea rance and packaging.
Rationale: The text in the Prestudy and Concomitant Therapy section was updated for clarity.
8 Prestudy and 
Concomitant TherapyThe follow ing (first) sentence was deleted for clarity:
Prestudy therapi[INVESTIGATOR_43710] [ADDRESS_1241530] be 
recorded at screening.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 54
Approved , Date: 4 June 2021Applicable S ections Description of Changes
Rationale: The text pertaining to concomitant medications was updated to specify that medications are required to 
remain stable through the final study visit.
8.1 Concomitant 
MedicationsThe second paragraph w as revised to specify that concomitant medications are required to 
remain stable through the final study visit as opposed to Week 24, as follows:
With the exception of oral corticosteroids, subjects who are receiving these medications for
Crohn’s disease at baseline should maintain a stable dose through the final efficacy and 
safety visit. Corticosteroids must be maintained at baseline doses through Week 12 (see 
Section 8.1.1 ).
Rationale: The third paragraph of Section 8.1.[ADDRESS_1241531] paragraph of S ection 8.1.1 Corticosteroid Tapering w as moved to Section 8.1 
Concomitant Medications. In addition, the text was revised to indicate that subjects may 
transiently use increased doses of corticosteroids for reasons other than worsening of 
Crohn’s disease, but not for loss of response to treatment for Crohn’s disease, as follows:
After Week 12, subjects may transiently use ( ie, for <4 weeks) increased doses of 
corticosteroids for reasons other than worsening of Crohn’s disease ( eg, stress doses of 
corticosteroids for surgery, asthma, adrenocortical insufficiency).
Rationale: In Section 9.2.1 Crohn’s Disease Activity Index, the text was updated to clarify that subjects w ill 
complete CDAI as a daily diary entry and will bring the diary to each study visit.
9.2.1 Crohn’s Disease 
Activity IndexThe section w as revised to read:
The CDAI will be assessed by [CONTACT_393396] 8 different Crohn’s disease -
related variables (Attachment 5):1extra -intestinal manifestations, abdominal mass, weight, 
hematocrit, total number of liquid stools, abdominal pain/crampi[INVESTIGATOR_007], use of antidiarrheal 
drug(s) and/or opi[INVESTIGATOR_858], and general well -being. The last [ADDRESS_1241532]. The PRO -2 score is based on the CDAI components of the 
total number of liquid stools and abdominal pain/crampi[INVESTIGATOR_007]. The PRO -3 score, which is 
also based on the CDAI, comprises the PRO -2 com ponents plus general well -being. 
Subjects are to complete a daily diary entry and bring the diary to each visit.
Rationale: At the request of a health authority, the National Cancer Institute Comm on Terminology Criteria for 
Adverse Events definitions of adverse events and hepatotoxicity guidelines were incorporated. 
9.[ADDRESS_1241533] paragraph was revised as 
follows:
Blood samples for serum chemistry and hematology will be collected. The investigator 
must revie w the laboratory results, document this revie w, and record any clinically 
relevant changes occurrin g during the study in the Adverse Event section of the CRF. 
Clinical hematology and chemistry laboratory test results will be graded by [CONTACT_4681] (NCI -CTCAE) 
toxicity criteria. The laborato ry reports must be filed with the source documents. 
10.2 Discontinuation 
of Study TreatmentThe fourth bullet was revised as follows:
A serious adverse reaction occurs that is related to an injection or an infusion, 
including an injection -site or infusio n reaction, resulting in bronchospasm with 
wheezing and/or dyspnea that requires ventilatory support ORthat results in 
symptomatic hypotension with a decrease in systolic blood pressure >40 mm Hg or 
blood pressure <90/60 mm Hg. This may include events of NCI -CTCAE toxicity 
grade ≥3.
A new fifth bullet was added:
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 55
Approved , Date: 4 June 2021Applicable S ections Description of Changes
Adverse events of NCI -CTCAE grade ≥3 potentially related to w orsening of Crohn’s 
disease will be evaluated by [CONTACT_887084] a 
determination on discontinuation of study agent. Discontinuation of study agent 
should be considered in subjects with w orsenin g Crohn’s disease where continuation 
of the study drug is not in the best interest of the subject.
11.9 Safety Analyses Under the subheading Clinical Laboratory Tests, the second bullet was revised to specify 
that the summary of maximum NCI -CTCAE toxicity grade for postbaseline hematology 
and chemistry laboratory values will be used to assess the safety of subjects, as follows:
Summary of maximum NCI -CTCAE toxicity grade for postbaseline laboratory 
values (hematology and chemistry).
12.1.[ADDRESS_1241534] sentence was revised as follows:
An assessment of severity grade w ill be made using the follow ing general categorical 
descriptors as outlined in Section [IP_ADDRESS] and by [CONTACT_12134] -CTCAE toxicity grade outlined in 
Section [IP_ADDRESS]. 
12.1.3 .1Severity 
Criteria : General 
Categorical 
DescriptorsThe follow ing text was moved from Section 12.1.3 Severity Criteria to newly added 
Section [IP_ADDRESS] Severity Criteria: General Categorical Descriptors :
Mild: Awareness of symptoms that are easily tolerated, causing minimal discomfort and 
not interfering with everyday activities.
Moderate: Sufficient discomfort is present to cause interference with normal activity.
Severe: Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal everyday activities.
The investigator should use clinical judgment in assessing the severity of events not 
directly experienced by [CONTACT_423] ( eg, laboratory abnormalities).
Note: Seriousness an d severity should not be confused. A subject could experience a 
severe heada che that would not qualify as a serious adverse event ( SAE ), while another 
might experience a mild stroke that, while not severe, w ould be considered serious.
[IP_ADDRESS] Severity 
Criteria Based o n 
National Cancer 
Institute Common 
Term inology Criteria 
for Adverse Events
Toxicity GradeThe follow ing text was added to newly added Section [IP_ADDRESS] Severity Criteria Based on 
National Cancer Institute Common Terminology Criteria for Adver se Events Toxicity 
Grade:
An assessment of severity grade w ill also be made using the following NCI -CTCAE 
categorical descriptors. The NCI -CTCAE Grade refers to the severity of the AE. The NCI -
CTCAE displays Grades 1 through 5 w ith unique clinical descript ions of severity for each 
AE based on this general guideline:
Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.
Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limit ing age -
appropriate instrumental Activities of Daily Living (ADL)*.
Grade 3: Severe or medically significant but not immediately life -threatening; 
hospi[INVESTIGATOR_3111]; disabling; limiting self -care 
ADL**.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 56
Approved , Date: 4 June 2021Applicable S ections Description of Changes
Grade 4: Life-threatening consequences; urgent intervention indicated.
Grade 5: Death related to AE.
*Instrumental ADL refer to preparing meals, shoppi[INVESTIGATOR_3112], using the 
telephone, managing money, etc.
**Self -care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, 
taking medications, and not bedridden.
Rationale: At the request of a health authority, additional guidelines on the evaluation of abnormal liver function 
tests were added. 
9.7 Safety 
EvaluationsUnder subheading Clinical Laboratory Tests, the following new bullet was added:
Abnormal liver function tests: If laboratory testing for a subject enrolled in the 
study and receiving study drug reveals an increase of serum aminotransferases (ALT 
or AST) to >3x t he upper limit of normal ( ULN )and an increase of bilirubin to >2x 
ULN, study agent should be suspended immediately. In addition, laboratory tests for 
ALT, AST, alkaline phosphatase, and total bilirubin should be confirmed by a retest 
within [ADDRESS_1241535] 
results. See Attachment 6 (Liver Safety Monitoring and Assessment) for additional 
information on monitoring and assessment of abnormal liver function tests.
10.2 Discontinuation 
of Study TreatmentThe follow ingnew bullet was added:
Severe hepatic function abnormalities as described in Section 9.7.
Rationale: An attachment was added to provide clarification regarding the definitions of inadequate response to or 
intolerance of corticosteroids or AZA/6 -MP and corticosteroid dependence.
Attachment 2: 
Definitions of 
Inadequate Response 
to or Intolerance of 
Corticosteroids or 
AZA/6 -MP and 
Corticosteroid 
Dependence The definitions of an inadequate response to or intolerance of corticosteroids or AZA/6 -
MP and corticosteroid dependence were added to the protocol as Attachment 2.
Rationale: At the request of a health authority, additional guidance on the evaluation of subjects who have evidence 
of hepatotoxicity is provided. 
Attachment 6 :Liver 
Safety Monitoring 
and AssessmentLiver Safety Monitoring and Assessment was added to the protocol as Attachment 6. 
Rationale: Minor errors w ere noted .
Throughout the 
protoco lMinor grammatical, formatting, or spelling changes were made.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 57
Approved , Date: 4 June 2021SYNOPSIS
A Phase 2b, Randomized, Double -blind, Placebo -controlled, Parallel -group, Multicenter Protocol to 
Evaluate the Safety and Efficacy of JNJ-64304500 in Subjects with Moderately to Severely Active 
Crohn’s Disease
Protocol Number: 64304500CRD2001
EudraCT Number: 2016 -000634 -21
JNJ-64304500 (formerly known as NNC0142 -002) is a human immunoglobulin G4 isotype monoclonal 
antibody that binds specifically to the natural killer group 2 member D (NKG2D) receptor, and blocks 
NKG2D ligand binding, thereby [CONTACT_887098] -signaling events that otherwise lead to cell 
proliferation and release of proinflammatory cytokines and cytotoxic mediators. Several lines of evidence 
from patients with Crohn’s disease support the hypothesis that NKG2D receptor activation plays a role in 
disease pathogenesis by[CONTACT_887099], activation of an immune response, 
and direct cytotoxicity of target intestinal cells. Collectively, preclinical and clinical data on the 
expression of NKG2D ligands or proinflammatory cytokines in the target tissue and abnormal expression 
and activation of the NKG2D receptor on CD8+ and CD4+ T cells provide a rationale for the clinical 
development of inhibitors of the NKG2D receptor.
Results from a Phase 2a study (conducted by [CONTACT_3454]) provided initial evidence for the efficacy of 
JNJ-64304500 in the treatment of Crohn’s disease, particularly in subjects who had not previously failed 
conventional therapy.
This Phase 2b protocol will further evaluate JNJ-64304500 in subjects with moderately to severely activ e
Crohn’s disease who have failed bio logic or conventional therapy.
The protocol is divided into 2 parts.
In Part I, the following 2 studies will be conducted:
Study 1: A study in subjects who are biologic intolerant or refractory (Bio -IR);
Study 2: A study in subjects who have not previously failed a biologic therapy (Biologic 
nonfailure [Bio -NF]).
In Part II, the following study will be conducted:
Study 3: A dose -ranging study in subjects who are Bio-IRor Bio -NF
A long-term extension (LTE) for Part II of the study was added to the protocol as part of Protocol 
Amendment 5. After Protocol Amendment [ADDRESS_1241536] completed 
Week 24assessments prior to the implementation of Protocol Amendment 5 will not be eligible to enroll 
in the Part II LTE.
OBJECTIVES, ENDPOINTS, AND HYPOTHESIS
Objectives
The objectives are the same in each of the 2 parts .
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 58
Approved , Date: 4 June 2021Primary Objectives
To evaluate the efficacy of JNJ-64304500 to reduce the Crohn’s Disease Activity Index (CDAI )
score from baseline.
To evaluate the safety of JNJ -64304500.
Secondary Objectives
To evaluate the efficacy of JNJ-64304500 to induce clinical remission, clinical response, and 
endoscopic healing of the mucosa, and to maintain remission .
To evaluate the relationship between efficacy and the presence of the NKG2D and/or MICB single 
nucleotide polymorphism ( SNP)biomarkers.
To evaluate the efficacy of JNJ-64304500 to improve general and disease -specific health -related 
quality of life and to reduce Crohn’s disease -related hospi[INVESTIGATOR_137655].
To evaluate the pharmacokinetics (PK) , immunogenicity, pharmacodynamics (PD) , and biomarkers 
(eg, reductions inC-reactive protein [CRP ], fecal calprotectin, and fecal lactoferrin) of 
JNJ-64304500 therapy.
Endpoints
The data from Study 1 and Study 2 in Part I will be pooled for analysis.
Primary Endpoint s
The primary endpoint for Part I is: Change from baseline in the CDAI score at Week 8.
The primary endpoint for Part II is: Change from baseline in the CDAI score at Week 12.
Major Secondary Endpoints
The following endpoints will be evaluated as major secondary endpoints only inPart II(the dose -ranging 
portion of the study); these endpoints will be evaluated inPart Ibut are not specified as major secondary 
endpoints.
Clinical remission at Week 12as measured by C DAI (CDAI <150).
Clinical response at Week 12as measured by [CONTACT_82274] ( ≥100 -point reduction from baseline in CDAI or 
CDAI <150).
Change in PRO -2 (the sum of the abdominal pain and stool frequency subscores of the CDAI score) 
from baseline at Week 12.
Clinical remission at Week 12as measured by [CONTACT_96553] -2 (PRO -2 <75).
Clinical response at Week 12as measured by [CONTACT_96553] -2 (≥50-point reduction from baseline in PRO -2 or 
PRO -2 <75).
Change in Simple Endoscopic Score for Crohn's Disease (SES -CD) from baseline at Week 12.
Hypothesis
The hypothesis for Part I and Part II is that JNJ-64304500 is superior to placebo in inducing a reduction 
from baseline in CDAI in subjects with moderately to se verely active Crohn’s disease.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 59
Approved , Date: 4 June 2021OVERVIEW OF STUDY DESIGN
This protocol is comprised of 2parts (Part I [Study 1: Bio-IR subjects and Study 2: Bio-NF subjects] and 
Part II [Bio-IR and Bio-NF subjects]) .Each study is a randomized, double -blind, placebo -controlled, 
parallel -group, multicenter study of JN J-64304500 in subjects with moderately toseverely active Crohn’s 
disease. A minimum of 120 subjects and a maxi mum of 170 subjects (Bio-IR and Bio-NF) will be
randomized in Part I.An additional 250subjects will be randomized inPart II. Part I  will study the safety 
and efficacy of a high dose regimen of JN J-[ADDRESS_1241537] failed 
biologic or conventional therapy (Bio-IR or Bio-NF subjects, respectively). PartII will study the safety 
and efficacy of multiple -dose regimens of JNJ-64304500 compared with placebo , with ustekinumab 
(STELARA ®) as a reference arm, in Bio-IR and Bio -NFsubjects .
The duration of the study will be 3 8weeks in Part I  and 3 6weeks in Part II for subjects who do not enter 
thePart IILTE. The study duration includes study agent administrat ion visits and a final efficacy and 
safety follow -up visit. Eligible subjects will only participate in Part I orPart II of the study.
After Protocol Amendment 5 is implemented, subjects who complete Part II of the study through 
Week 24and who may benefit from continued treatment in the opi[INVESTIGATOR_871], will be eligible 
to enter the Part II LTE to receive up to 52 weeks of additional treatment.
The Time and Events Schedules summarize the frequency and timing of assessments for efficacy, PK, 
biomarkers, immunogenicity, PD, and safety in Part I and Part II of the study.
An interim analysis is planned in PartI when 100 randomized Part I subjects (Study 1: Bio-IR and 
Study 2: Bio-NF) have completed their Week [ADDRESS_1241538] completed their Week 12 visit (or have terminated study  
participation prior to Week  12). If Part II is not initiated based on the interim analysis results, then the 
results through Week 12 for all subjects in Part I (ie, when all randomized subjects in Part I have either 
completed the Week 12 visit or terminated study participation prior to Week 12) will be examined to 
determine whether to start Part II. Under this scenario, a pause in enrollmen t between Part I and Part II 
will occur.
An external Data Monitoring Committee (DMC) will review unblinded safety data from all subjects
periodically to monitor subject safety.
The end of the 64304500CRD2001 study is defined as the date on which the last subject completes the 
last efficacy and safety follow -up visit.
SUBJECT POPULATION
The subject population consists of men or women ≥18 years of age with moderately to severely active 
Crohn’s disease (of at least 3 months’ duration), defined as a CDAI score ≥220 and ≤450, with elevated 
CRP >0.3 mg/dL (>3.0 mg/L) and/or calprotectin >250 mg/kg. Subjects must have colitis, ileitis, or 
ileocolitis previously confirmed at any time in the past by [CONTACT_485622], histology, and/or endoscopy. 
Subjects also must have previously failed or been intolerant to 1 or more approved biologic agents (ie, 
tumor necrosis factor alpha antagonists or vedolizumab; Bio-IR subjects) or have demonstrated an 
inadequate response to or failed to tolerate corticosteroids or immunomodulators (ie, 6-mercaptopurine, 
azathioprine, and methotrexate) but not a biologic (Bio -NF subjects).
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 60
Approved , Date: 4 June 2021DOSAGE AND ADMINISTRATION
Part I
In Part I,a minimum of 120 subjects and a maximum of 170 subjects (Bio-IR and Bio-NF) will be 
randomly assigne d to receive placeb o or the JNJ-64304500 high dose in a 1:1 ratio using permuted block 
randomization, stratified by [CONTACT_393379] ( ≤300 or >300) and SNP -positive status (yes or no ). The 
Bio-IR and Bio -NFpopulations will be randomized separately .
The treatment groups in Part I will be as follows:
Placebo subcutaneously (SC)at Weeks 0, 2, 4, 6, 8, and 10; from Week 12, these subjects will 
receive additional doses as follows:
Placebo -treated subjects who arein clinical response at Week 12 (≥100 -point reduction from 
baseline in CDAI or CDAI <150) will continue to receive placebo SC injections every 2weeks 
(q2w) from Week 12through Week 22.
Placebo -treated subjects who are not in clinical response at Week 12 will receive JNJ -64304500 
400mg SC at Week 12,and then JNJ -64304500 200 mg SC from Week 14through Week 22.
JNJ-64304500 400 mg SC at Week 0 then 200 mg SC q2 wthrough Week 22.
Part II
In Part II of the study, subjects (Bio-IR and Bio-NF) will be randomly assigned in equal proportions to 
receive placebo, 1of 3dose regimens of JNJ-64304500, or ustekinumab, using permuted block 
randomization, stratified by [CONTACT_393379] (≤300 or >300) ,SNP-positive status (yes or no), and 
Bio-IR status (yes or no) . The treatment groups are as follows:
Placebo SC at Weeks 0, 2, 4, 8; from Week12, these subjects will receive additional doses as 
follows:
oPlacebo -treated subjects who arein clinical response at Week 12 (≥100 -point reduction 
from baseline in CDAI or CDAI <150) will continue to receive placebo SC injections at 
Weeks 12, 14, 16 and 20.
oPlacebo -treated subjects who are notin clinical response at Week 12 will receive 
JNJ-64304500 150mg SC at Week 12 and JNJ-64304500 75 mg SC at Weeks 14, 16, 
and 20.
JNJ-64304500 high dose: 400 mg SC at W eek 0 and 200 mg SC at Week 2 and Week 4, then 200 mg 
every 4 weeks ( q4w) through Week 20.
JNJ-64304500 middle dose: 150 mg SC at Week 0 and 75 mg SC at Week 2 and Week 4, then 75 mg 
q4w through Week 20.
JNJ-64304500 low dose: 50 mg SC at Week 0 and 25 mg SC at Week 2 and Week 4, then 25mg 
q4w through Week 20.
Ustekinumab: tiered doses approximating 6mg/kg intravenously (IV)at Week [ADDRESS_1241539] will be eligible to receive up to 52 weeks of additional study drug 
(for a total of up to 72 we eks of stud y drug in Part II). The first dose of study drug within the Part II LTE 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 61
Approved , Date: [ADDRESS_1241540] been completed .The dose may be administered 
on the same day as the Week 24 assessments, or may be administered on a later date, as long as the dose 
is administered within the Week 24 visit window.
Subjects will continue to receive the same treatment regimen during the Part II LTE that they were 
recei ving between Week 12 and Week 20in the main study phase of Part II (placebo, high, middle, low 
dose JNJ -64304500 or ustekinumab). To maintain the study blind, all patients, investigators, and sites will 
remain blinded to treatment allocation during the Part II LTE until the last subject in the Part II main 
study phase has completed the Week [ADDRESS_1241541]’s unblinding during the Part II LTE will depend upon his/her Part II 
enrollment date. Therefore, a portion of subjects will complete the entire Part II LTE in a blinded fashion 
before study unblinding, while other subjects could be unblinded to treatment allocation during their 
participation in the Part II LTE.
On [ADDRESS_1241542] dose of study drug. For subjects that remain in the Part II LTE at 
the time of study unblinding, continuation of study drug during the Part II LTE will be dependent upon 
treatment allocation as follows:
JNJ-64304500: Subject s receiving JNJ-[ADDRESS_1241543] dose of study drug.
Placebo : Subjects receiving placebo who remain in the Part II LTE at the time of study unblindin g 
will have their final safety follow -up visit subsequent to unblinding and will be discontinued from the 
study. No further follow -up visits will be performed.
Ustekinumab : Subjects receiving ustekinumab will continue to receive it during the Part II LTE u ntil 
unblinding occurs. Afte r unblinding, based on the trea ting physician’s clinical judg ment , subjects may 
receive ustekinumab in a manner dependent on the country in which they are located:
oIf a subject is not continuing on ustekinumab after unblinding, the subject will need to return 
for a final safety follow -up visit that will be performed [ADDRESS_1241544] continues on ustekinumab in a country where commercial ustekinumab is 
available and approved for the treatment ofadult Crohn’s disease, the treating physician is 
responsible for providing the subject with commercial ustekinumab, which should be 
administered according to the approved dosing regimen in each country. The final safety 
follow -up visit should be performed after unblinding but before receiving the first dose of 
commercial ustekinumab.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 62
Approved , Date: [ADDRESS_1241545] continues on ustekinumab in countries where commercial ustekinumab is not 
available or approved for adult Crohn’s disease, ustekinumab will continue to be provided to 
subjects through Week 72 .
For eligible Part II subjects, participation in the Part II LTE is entirely voluntary. Eligible subjects who do 
not wish to enter the Part II LTE will complete the Part II Week 24 safety and efficacy assessments, 
followed by [CONTACT_887100] 36.
During the Part II LTE, all concomitant medications, including Crohn’s disease -specific medications 
(except for the prohibited medications listed in Section 8.2) may be administered at the discretion of the 
investigator.
All subjects in the Part II LTE (before unblinding for JNJ -64304500, ustekinumab, and placebo and after 
unblinding for JNJ 64304500) will be assessed according to the Time & Events Schedule (Table 3), 
which includes assessments, adverse events (AEs), laboratory analyses, and PK and immunogenicity 
samples. Ustekinumab subjects in the Part II LTE (after unblinding for ustekinumab subjects in countries 
where ustekinumab is not commercially available) will be assessed according to the Time & Events 
Schedule ( Table 4), which includes assessments and adverse events (AEs).
EFFICACY EVALUATIONS
The following e fficacy evaluations will be performed in Part I and Part II of the main study phase.
Crohn’s Disease Activity Index (CDAI)
C-reactive protein (CRP)
Fecal lactoferrin and fecal calprotectin
Inflammatory Bowel Disease Questionnaire (IBDQ)
36-Item Short Form Health Survey (SF -36)
Fistula assessment
Bristol stool form s cale
Abdominal pa in Numerical Rating Scale (NRS )
Patient’s Global Impression of Severity (PGIS) of Crohn’s disease
Patient’s Global Impression of Change (PGIC) of severity of Crohn’s disease
Ileocolonoscopy
Histologic assessment
Efficacy evaluations will not be performed during the Part II LTE.
PHARMACOKINETIC, PHARMACODYNAMIC, AND IMMUNOGENICITY EVALUATIONS
Serum samples will beused to evaluate the PK, PD, and immunogenicity of JNJ-64304500 (and 
ustekinumab in Part II) and will be collected from each subject at the timep oints indicated in the Time and 
Events Schedules.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 63
Approved , Date: 4 June 2021DNA AND BIOMARKER EVALUATIONS
Biomarker assessments will be made to examine the biologic response to treatment and to identify 
biomarkers that are relevant to JNJ-64304500 treatment and/or Crohn’s disease. Blood samples for 
serum -based biomarker analyses will be collected from all subjects to assess proteins related to the 
NKG2D pathway or the pathogenesis of Crohn’s disease. Whole blood samples will be collected from all 
subjects for the analysis of RNA expression and T-cell receptor repertoire. Mucosal biopsy samples will 
be collected during ileocolonoscopy for the analysis of gene and/or protein expression and the histologic 
assessment of disease and/or healing. Receptor occupancy assessments for NKG2D and
immunophenotypi[INVESTIGATOR_580505] (including natural killer [NK]cells and CD8+ T cells) will also be 
performed.
Whole blood will be collected from all subjects for SNP analysis (the NKG2D SNP rs2255336 and the 
MICB [NKG2D ligand]); subjects who have signed an optional pharmacogenomics consent form will 
undergo complete genomic testing.
SAFETY EVALUATIONS
Safety evaluations will include AEs; clinical laboratory tests (chemistry and hematology); vital signs and 
physical examinations; a screening electrocardiogr am; allergic reactions, infusion reactions and 
injection -site reactions; infections; and early detection of active tuberculosis.
STATISTICAL METHODS
Sample Size Determination
Sample size calculations for Part I (Bio-IR subjects and Bio-NF subjects combine d) were determined by 
[CONTACT_676464] a significant difference in the change from baseline in the CDAI score at Week [ADDRESS_1241546]. Sample size calculation sfor Part II (Bio-IR
and Bio-NFsubjects) were determined by [CONTACT_676464] a dose-response signal forthechange from  
baseline in the CDAI score at Week 12(primary endpoint in Part II)using the Multiple Comparison 
Procedures with modeling techniques (MCP -Mod) method.
For Part I, assuming the mean CDAI change from baseline at Week [ADDRESS_1241547] deviation (SD)of 96, 60 subjects pertreatment 
group will provide 84% power to detect a treatment difference between JNJ-64304500 and placebo at an 
overall Type 1 error rate of 0.05.
For Part II, assuming the mean CDAI change from baseline at Week 12is-111 in the JNJ-64304500 
group and-51in the placebo group with a common SD of102, 50subjects per treatment group will 
provide a mean power of85% to detect a dose-response signal based on 7 candidate dose-response 
models at an overall Type 1 error rate of 0.05.
Efficacy Analyses
This protocol is comprised of 2separate parts (Part I [Study 1: Bio-IR subjects and Study 2: Bio-NF 
subjects] and Part II [Bio-IR and Bio-NF subjects]) . Part I and Part II will be analyzed separately with 
separate Type I error control for the primary endpoint (at the 0.05 level of significance). The other 
endpoints within each part will not be controlled for multiplicity.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 64
Approved , Date: [ADDRESS_1241548] who 
received study agent will be analyzed according to the assigned treatment regardless of the actual 
treatment received.
For Part I, the primary endpoint of change from baseline in the CDAI score at Week 8 will be compared 
between the JNJ -64304500 treatment group and the placebo treatmen t group by [CONTACT_887101] a fixed factor and baseline CDAI score, 
SNP-positive status (yes or no) , and Bio -IR status (yes or no) as covariates. Part I will be considered to be 
positive if a significant improvement is detected in the change from baseline in the CDAI score at Week [ADDRESS_1241549] describes the observed data and use it to estimate adequate doses with associated 
precision. The study will be considered positive if a dose-response signal for the primary endpoint is 
detected. In addition to the dose-response analysis, pairwise comparisons of the JNJ-64304500 treatment 
groups versus the placebo group will be performed for the change from baseline in the CDAI score at 
Week 12; these comparisons will not be adjusted for multiplicity.
The major secondary endpoints are only specified inPart II. The major secondary endpoints that are 
dichotomous endpoints will be analyzed by [CONTACT_25549] -Mantel -Haenszel chi-square test (2-sided) 
stratified by [CONTACT_393379] (≤300 or >300) ,SNP-positive status (yes or no), and Bio-IR status (yes 
or no); the major secondary endpoints that are continu ous endpoints will be analyzed by [CONTACT_887102] a fixed factor and appropriate 
baseline level of the variable , SNP -positive status (yes or no), and Bio -IR status (yes or no) as covari ates. 
The major secondary endpoints will not be controlled for multiplicity.
Safety Analyses
Safety will be assessed by [CONTACT_269279], serious AEs, AEs considered by [CONTACT_887103], AEs leading to discontinuation of study agent, 
infections, infusion reactions, and injection -site reactions. Safety assessments will also include analyses 
of change from baseline in laboratory parameters (hematology and chemistry) and summary of maximum 
Nationa l Cancer Institute Common Term inology Criteria for Adverse Events toxicity grade for 
postbaseline laboratory values.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 65
Approved , Date: 4 June 2021TIME A ND EVENTS SCHE DULE : PART I
Table 1: Time and Events Schedule, Part I
Period ScreeningwMain Study phasexEarly 
term inationc Final 
efficacy 
& safety 
follow -
upd
Week -5 weeks 0 2 4 6 8 10 12 14 16 18 20 22 24
Study Proceduresaa
Screening/Administrative
Informed consent X
Inclusion/exclusion criteria X X
Medical history and demographics X
Chest radiographbbX
QuantiFERON -TB TestccX
Stool studies to evaluate for enteric 
pathogens ddX
Training on diary card completion X
Study Agent Administration
Randomization X
Administer study agent aa(SC study 
agent at a different location at each 
visit [Section 6]) X X X XXe
eX X X X X X X
Safety Assessments
Physical examination X X X
Weight X X X X X X X X X X X X X X X X
Height X
Vital signs ffX X X X X X X X X X X X X X X X
Baseline [ADDRESS_1241550] ggX X X X X X X X X X X X X X X
TB evaluation hh/other infection 
assessment X X X X X X X X X X X X X X X
Injection -site evaluation X X X X X X X X X X X X X X
Efficacy Assessments
Collect and review diary cardsiiX X X X X X X X X X X X X X X
CDAI assessments jjX X X X X X X X X X X X X X X
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 66
Approved , Date: 4 June 2021Table 1: Time and Events Schedule, Part I
Period ScreeningwMain Study phasexEarly 
term inationc Final 
efficacy 
& safety 
follow -
upd
Week -5 weeks 0 2 4 6 8 10 12 14 16 18 20 22 24
Study Proceduresaa
Fistula exam X X X X X X X X X X X X X X X
Bristol stool f orm scalekkX X X X X X X
Abdominal pain NRS assessmentllX X X X X X X X X X X X X X X
Stool sample (fecal lactoferrin and 
calprotectin) and microbiome XmmX XX
mmX
mmX
CRP X X X X X X X X X X X X
Video ileocolonoscopy nnX X XooX
IBDQ ppX X X X X
SF-[ADDRESS_1241551] X
Pharm acokinetics/ Immunogenicity
JNJ-64304500 serum concentration rr, 
ssX X X X X X X X X X X X
JNJ-64304500 random population PK 
sample tt, ss
---- X---- ---- X----
Antibodies to JNJ -64304500 rr, ssX X X X X X X X
Receptor occupancy X X X X X X X X
Immunophenotypi[INVESTIGATOR_007] (NK cells and 
CD8+ T cells) X X X X X X X X
Pharm acodynamics/Biom arkers
Blood sample collection (T -cell 
receptor repertoire) X X X X X X
Whole blood sample collection for 
RNA analysisuuX X X X X X
Serum proteins X X X X X X
Ileocolonoscopy biopsy sample X X XooX
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 67
Approved , Date: 4 June 2021Table 1: Time and Events Schedule, Part I
Period ScreeningwMain Study phasexEarly 
term inationc Final 
efficacy 
& safety 
follow -
upd
Week -5 weeks 0 2 4 6 8 10 12 14 16 18 20 22 24
Study Proceduresaa
collection sfor RNA and histology
Pharm acogenomics (DNA)
Whole blood sample collection for 
SNPs and DNA analysis vvX
Ongoing Subject Review
Concomitant therapy X X X X X X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X X X X
Crohn’s disease -related 
hospi[INVESTIGATOR_887064] X X X X X X X X X X X X X X X
Abbreviations: CDAI=Crohn’s Disease Activity Index; CRP=C -reactive protein; ECG=electrocardiogram; HBV=hepatitis B virus; HCV=hepatitis C virus; HIV=human 
immunodeficiency virus; IBDQ=Inflammatory Bowel Disease Questionnaire; NK=natural killer; NKG2D=natural killer group 2 member D; PK=pharmacokinetics; 
PRO=patient -reported outcome; SF -36=36 -Item Short Form  Health Survey ; SNP=single nucleotide polymorphism ; TB=tuberculosis .
w. Screening period should be a minimum of [ADDRESS_1241552] enough data to support CDAI calculation.
x. Visit windows should be ± [ADDRESS_1241553] completed assessments at Week 24 and terminated after 
Week 24, the only assessments that should be performed at the early termination visit are those planned for the final efficac y and safety follow -up. Subjects 
who discontinue study agent administration before Week 8 (but have not terminated study participation) should complete the Week [ADDRESS_1241554] study agent administration. Subjects who 
discontinue study agent administration after Week 8 (but have not terminated study participation) should complete the Week [ADDRESS_1241555] radiograph (posterior -anterior and lateral views) may be obtained w ithin [ADDRESS_1241556] is not registered/approved, TB skin testing will also be 
required (recommended but not required for study centers in countries where tuberculin is not available). The QuantiFERON -TB test is not required at 
screening for subjects with a history of latent TB and appropriate treatment (as described in Inclusion Criterion 11a).
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 68
Approved , Date: [ADDRESS_1241557] been performed within 4 months before Week 0. Additional testing, such as ova and parasites or Escherichia coli O157:H7 
assessment, may be performed at the investigator’s clinical discretion.
ee. Administration of study agent at the Week [ADDRESS_1241558] been completed.
ff. Temperature, pulse/heart rate, respi[INVESTIGATOR_697], and blood pressure.
gg. Must be performed before every study agent administr ation in female subjects of childbearing potential.
hh. If TB is suspected at any time during the study, a chest ra diograph and QuantiFERON -TB test should be performed. In countries where the QuantiFERON -TB 
test is not registered/approved, TB skin testing shou ld also be performed (recommended but not required for study centers in countries where tuberculin is not 
available).
ii. For al l visits up to Week 24, daily d iary information should be collected for every day prior to each visit. For the final efficacy and sa fety visit, daily d iary 
information should be collected for [ADDRESS_1241559] the actual times of PK sample col lections.
ss. At visits where only serum concentration o f study agent will be evaluated (ie, no antibodies to study agent will be evaluated), 1 venous blood sample of 
sufficient volume should be collected, and each serum sample should be divided into 2 aliquot s(1 for serum concentration of study agent, and a back -up). At 
visits where serum concentration of study agent and antibodies to study agent will be evaluated, 1 venous blood sample of suf ficient volume should be 
collected. Each serum sample will be divid ed into 3 aliquots (1 each for serum concentration of study agent, antibodies to study agent, and a back -up).
tt. Each random population PK sam ple should be collected at any time between Week s0 and 2 (after the Week 0 study agent administration) and betw een 
Weeks 22 and 24 (after the Week 22 study agent administration) .The date for the random population PK sample collection will be at the subject’s discretion. 
How ever,samples should not be drawn on or w ithin 1 day of a scheduled visit (ie, the Week 0, 2, 22 , or 24 visit) in this time period.
uu. Whole blood for RNA analysis will be collected from all subjects in the study.
vv. Whole blood for SNP analysis w ill be collected from all subjects .All subjects w ill be tested for the NKG2D SNP rs2255336 and the MICB (NKG2D ligand) 
SNP rs2239705 at screening. For subjects who have signed a separate informed consent form, DNA testing will be done to search for links of specific genes to 
disease or response.
ww. Hospi[INVESTIGATOR_887062]. 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 69
Approved , Date: 4 June 2021TIME A ND EVENTS SCHE DULE: PA RT II MAIN STUDY PHA SE
Table 2: Time and Events Schedule, Part II
Period ScreeningaMain study phasebEarly 
term inationcFinal 
efficacy & 
safety 
follow -upd,f
Week -5 weeks 0 2 4 6 8 10 12 14 16 20 24
Study Procedurese
Screening/Administrative
Informed consent X
Inclusion/exclusion criteria X X
Medical history and demographics X
Chest radiograph gX
QuantiFERON -TB Test hX
Stool studies to evaluate for enteric 
pathogen iX
Training on diary card completion X
Study Drug Administration
Randomization X
Administer study agente(SC study agent 
at a different location at each visit 
[Section 6]) X X X X X X X X
Safety Assessments
Physical examination X X X
Weight X X X X X X X X X X X X X X
Height X
Vital signs jX XkX X X X X X X X X X
Baseline [ADDRESS_1241560] lX X X X X X X X X X
TB evaluation m/other infection 
assessment X X X X X X X X X X X X X
Injection -site evaluation X X X X X X X X X X X
Efficacy Assessments
Collect and review diary cardsnX X X X X X X X X X X X X
CDAI assessments oX X X X X X X X X X X X X
Fistula exam X X X X X X X X X X X X X
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 70
Approved , Date: 4 June 2021Table 2: Time and Events Schedule, Part II
Period ScreeningaMain study phasebEarly 
term inationcFinal 
efficacy & 
safety 
follow -upd,f
Week -5 weeks 0 2 4 6 8 10 12 14 16 20 24
Study Procedurese
Bristol stool f orm scalepX X X X X X X
Abdominal pain NRS assessmentqX X X X X X X X X X X X X
PGIS of Crohn’s disease assessment X X X X X X
PGIC of severity of Crohn’s disease 
assessment X X X X X
Stool sample (fecal lactoferrin and 
calprotectin) and microbiome X rX X X rX rX
CRP X X X X X X X X X X X X
Video il eocolonoscopysX X X
IBDQ tX X X X X
SF-[ADDRESS_1241561] X
Pharm acokinetics/ Immunogenicity
Study agent serum concentrationv, wX X X X X X X X X X X X
JNJ-64304500 random population PK 
samplex, w---- X---- ---- X----
Assessment for antibody to study agent v, 
wX X X X X X X X
Receptor occupancy X X X X X X X X
Immunophenotypi[INVESTIGATOR_007] (NK cells and 
CD8+ T cells) X X X X X X X X
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 71
Approved , Date: 4 June 2021Table 2: Time and Events Schedule, Part II
Period ScreeningaMain study phasebEarly 
term inationcFinal 
efficacy & 
safety 
follow -upd,f
Week -5 weeks 0 2 4 6 8 10 12 14 16 20 24
Study Procedurese
Pharm acodynamics/Biom arkers
Blood sample collection (T -cell receptor 
repertoire) X X X X X X
Whole blood sample collection for RNA 
analysis yX X X X X X
Serum proteins X X X X X X
Ileocolonoscopy biopsy sample 
collections for RNA and histology X X X
Pharm acogenomics (DNA)
Whole blood sample collection for SNPs 
and DNA analysis zX
Ongoing Subject Review
Concomitant therapy X X X X X X X X X X X X X X
Adverse events X X X X X X X X X X X X X X
Crohn’s disease -related hospi[INVESTIGATOR_887065] X X X X X X X X X X X X X
Abbreviations: CDAI=Crohn’s Disease Activity Index; CRP=C -reactive protein; ECG=electrocardiogram; HBV=hepatitis B virus; HCV=hepatitis C virus; HIV=human 
immunodeficiency virus; IBDQ=Inflammatory Bowel Disease Questionnaire; NK=natural killer; NKG2D=natur al killer group 2 member D; PGIC=Patient’s Global 
Impression of Change; PGIS=Patient’s Global Impression of Severity; PK=pharmacokinetics; PRO=patient -reported outcome; SF -36=36 -Item Short Form  Health 
Survey; SNP=single nucleotide polymorphism; TB=tubercul osis.
a. Screening period should be a minimum of [ADDRESS_1241562] enough data to support CDAI calculation.
b. Visit windows should be ±4days for each visit up to and including Week 12 ;from Week 16 to end of study, visit window should be ± [ADDRESS_1241563] completed assessments at Week 24 and terminated after 
Week 24, the only assessments that should be performed at the early termination visit are those planned for the final efficac y and safety follow -upvisit. 
Subjects who discontinue study agent administration before Week 12(but have not terminated study participation) should complete the Week [ADDRESS_1241564] study agent administration. Subjects who discontinue study 
agent administration after Week 12(but have not terminated study participation) should complete the Week [ADDRESS_1241565] study agent administration . For subjects who 
complete all visits and are not enrolling in the Part II LTE, this will occur at Week 3 6.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 72
Approved , Date: [ADDRESS_1241566] radiograph (posterior -anterior and lateral views) may be obtained w ithin [ADDRESS_1241567] is not registered/approved, T B skin testing will also be 
required (recommended but not required for study centers in countries where tuberculin is not available). The QuantiFERON -TB test is not required at 
screening for subjects with a history of latent TB and appropriate treatment (a s described in Inclusion Criterion 11a).
i. Stool studies for enteric pathogens may be performed at either the central or a local laboratory and must include a stool culture and Clostridium difficile toxin 
assay. These must have been performed within 4 months before Week 0. Additional testing, such as ova and parasites or Escherichia coli O157:H7 
assessment, may be performed at the investigator’s clinical discretion.
j. Temperature, pulse/heart rate, respi[INVESTIGATOR_697], and blood pressure.
k. At Week 0, vital signs must be obtained before the IV infusion, approximately every 30 minutes during the infusion, and tw ice (at approximately 30 -minute 
intervals) after completion of the infusion.
l. Must be performed before every study agent administration in female subjects of childbearing potential.
m. If TB is suspected at any time during the study, a chest ra diograph and QuantiFERON -TB test should be performed. In countries where the QuantiFERON -TB 
test is not registered/approved, TB skin testing should also be performed (recommended but not required for study centers in countries where tuberculin is not 
avail able).
n. For al l visits up to Week 24, daily d iary information should be collected for every day prior to each visit. For the final efficacy and safety visit, daily d iary 
information should be collected for [ADDRESS_1241568] 8 days before the Week 0 visit and no more than 8 days before the Week 12 visit and Week 24 visit .
t. The IBDQ and SF -36 survey should be administered before any clinical procedures or tests are performed.
u. Laboratory tests at Week 0 are not required if screening laboratory tests were performed wi thin 2 w eeks before the Week 0 visit.
v. At all visits when study intervention will be administered, 1 blood sample should be collected prior to study intervention administration for ev aluation of 
serum concentrations and/or antibodies to the study interventi ons. FortheIV infusion related visit (W eek 0), the SC study intervention should be administered 
first, follow ed by  [CONTACT_16228]; another blood draw  should be taken approximately 60 minutes after completion of the infusion for serum concentration 
measureme nt.
w. At visits where only serum concentration of study agent will be evaluated ( ie, no antibodies to study agent will be evaluated), 1 venous blood sample of 
sufficient volume should be collected, and each serum sample should be divided into 2 aliquots (1 for serum concentration of study agent, and a back -up). At 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 73
Approved , Date: 4 June 2021visits where serum concentration of study agent and antibodies to study agent will be evaluated, 1 venous blood sample of suf ficient volume should be 
collected. Each serum sample will be divide d into 3 aliquots (1 each for serum concentration of study agent, antibodies to study agent, and a back -up).
x. Each random population PK sam ple should be collected at any time between Weeks 0 and 2 (after the Week 0 study agent administration) and betw een 
Weeks20 and 24 (after the Week 20 study agent administration) .The date for the random population PK sample collection will be at the subject’s discretion. 
How ever, samples should not be drawn on or w ithin 1 day of a schedu led visit (ie, the Week 0, 2, 20 , or 24 visit) in this time period.
y. Whole blood for RNA analysis will be collected from all subjects in the study.
z. Whole blood for SNP analysis w ill be collected from all subjects. All subjects w ill be tested for the NKG2D SNP rs2255336 and the MICB (NKG2D l igand) 
SNP rs2239705 at screening. For subjects who have signed a separate informed consent form, DNA testing will be done to search for links of specific genes to 
disease or response.
aa. Hospi[INVESTIGATOR_887062].
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 74
Approved , Date: 4 June 2021TIME A ND EVENTS SCHE DULE: PART II LONG -TERM EXTENSION
Table 3: Time and Events Schedule, Long -term  Extension Before Unblinding for JNJ -64304500, Ustekinumab, and Placebo and After Unblinding for 
JNJ-64304500j
Period Long -term  Extension
Week 24a,oEvery 4 
weeksa,lEvery 3 
monthsa,mEvery 6 
monthsa,nWeek 72aFinal safety 
follow -upa,dEarly 
term inationa
Study Procedures
Study Drug Administration
Administer study agent (SC study agent at a 
different location at each visit [Section 6])b,cX Xi
Safety Assessments
Symptom -driven physical examination X X X X X
Vital signseX X X X X
Urine pregnancy testfX X X X X
TB evaluation /other infection assessmentgX X X X
Injection -site evaluation X X X X X
Clinical Laboratory Assessments
Hem atology X X X X
Chemistry X X X X
Pharm acokinetics/ Immunogenicityk
Study agent serum concentrationhX X X
Assessment for antibody to study agent X X X
Ongoing Subject Review
Concomitant therapy X X X X
Adverse events X X X X X
Crohn’s disease -related hospi[INVESTIGATOR_817346] X X X X
a. Visit window is ±7days for each visit.
b. All assessments are to be completed before study agent administration unless otherwise specified . 
c. The first study agent administration in the Part II LTE will occur at Week 24. After the main study is unblinded to the investigative sites, subjects in the Part II LTE receiving placebo 
will be terminated from study participation, and subjects receiving ustekinumab will receive ustekinumab until commercial ustekinumab becomes available to them. Subjects 
receiving JNJ-[ADDRESS_1241569]’s last administration of study agent (for subjects who have not terminated study participation). If a subject’s 
treatment allocation is unblinded while the LTE is ongoing and the subject was receiving placebo, the site may schedule the final safety visit to occur earlier than [ADDRESS_1241570]’s last administration of study drug.
e. Temperature, pulse/heart rate, respi[INVESTIGATOR_697], and blood pressure. At a study agent admi nistration visit, vital signs should be obtained before and approximately 30 minutes after SC 
injection.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 75
Approved , Date: [ADDRESS_1241571] should be performed. In countries where the QuantiFERON is not registered/approved, TB skin testing 
should also be performed (recommended but not required for study centers in Ukraine if tuberculin is not av ailable) .
h. Serum concentration of study agent and antibodies to study agent will be evaluated. One venous blood sample of sufficient volume should be collected (at visits where study 
intervention will be administered, blood samples should be collected prior to study intervention administration) . Each serum sample will be divided into 3 aliquots (1 each for serum 
concentration of study agent, antibod ies to study agent and a back -up).
i. JNJ-64304500 dosing only after unblinding .
j. This Time & Events Schedule outlines the tasks that need to be completed during thePart IILTE prior to unblinding for all study subjects and after unblinding for study subjects 
receiving JNJ-64304500. Table 4outlines the tasks that need to be completed during the Part II LTE after study unblinding for study subjects receiving ustekinumab in countries 
where it is not commercially available.
k. Pharma cokinetic and immunogenicity samples will be obtained only at the specified timepoints and when SAEs are reported by [CONTACT_4866].
l. Visits every [ADDRESS_1241572] LTE 
does of study drug within the 7 -day visit window.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 76
Approved , Date: 4 June 2021TIME A ND EVENTS SCHE DULE: PART II LONG -TERM EXTENSIO N
Table 4: Time and Events Schedule, Long -term  Extension Phase After Unblinding for Ustekinumab Subjects in Countries Where Ustekinum ab Is Not 
Commercially Available
Period Long -term  Extension
Every 8 Weeksa,hEarly term inationa
Study Procedures
Study Drug Administration
Administer study agentb,c X
Safety Assessments
Symptom -driven physical examination X X
Vital signseX X
Urine pregnancy testfX X
TB evaluation /other infection 
assessmentgX X
Injection -site evaluation X X
Ongoing Subject Review
Concomitant therapy X X
Adverse events X X
Crohn’s disease -related hospi[INVESTIGATOR_887066] X X
a. Visit window is ±[ADDRESS_1241573] dose of commercial ustekinumab.
e. Temperature, pulse/heart rate, respi[INVESTIGATOR_697], and blood pressure. At a study agent administration visit, vital signs should be obtained before and approximately [ADDRESS_1241574] should be performed. In countries where the QuantiFERON is not registered/approved, TB skin testing 
should also be performed (recommended but not required for study c enters in Ukraine if tuberculin is not available) .
h. Visits every 8 weeks may include scheduled visits at Weeks 32, 40, 48, 56, 64, and 72. The final safety assessment should be performed at the final dosing visit.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 77
Approved , Date: [ADDRESS_1241575] aspartate aminotransferase
AUC area under the serum concentration –time curve
AZA azathioprine
BCG Bacille Calmette -Guérin
-hCG -human chorionic gonadotropin
Bio-IR biologic intolerant or refractory 
Bio-NF biologic nonfailure, ie, inadequate response to or failed to tolerate corticosteroids or 
immunomodulators, but not a biologic
CDAI Crohn’s Disease Activity Index
Cmax maximum concentration
CRF case report form (paper or electronic, as appropriate for this study)
CRP C-reactive protein
DBL database lock
DMC Data Monitoring Committee
DNA deoxyribonucleic acid
ECG electrocardiogram
eDC electronic data capture
FDA Food and Drug Administration
GCP Good Clinical Practice
GHAS Global Histology Activity Score
HBsAg hepatitis B surface antigen
HBV hepatitis B virus 
HCV hepatitis C virus 
HIV human immunodeficiency virus
IB Investigator’s Brochure
IBD inflammatory bow el disease
IBDQ Inflammatory Bow el Disease Questionnaire
ICF informed consent form
ICH International Conference on Harm onisation
IEC Independent Ethics Committee
IL interleukin
IRB Institutional Review Board
IUD intrauterine device
IUS intrauterine hormone -releasing system
IV intravenous
IWRS interactive web response system
JAK Janus kinase
LTE long-term extension
MCP -Mod Multiple Comparison Procedures w ith modeling
MCS Mental Component Summary
MICA major histocompatibility class I chain -related protein A
MICB major histocompatibility class I chain -related protein B
MTX methotrexate
NCI-CTCAE National Cancer Institute Common Terminology Criteria for Adverse Events
NK natural killer
NKG2D natural killer group 2 D 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 78
Approved , Date: 4 June 2021NRS numerical rating scale
PCS Physical Component Summary
PD pharmacodynamic
PFS prefilled syringe
PGIC Patient’s Global Impression of Change 
PGIS Patient’s Global Impression of Severity 
PK pharmacokinetic(s)
PQC Product Quality Complaint
PRO patient -reported outcome(s)
q2w every [ADDRESS_1241576] deviation
SES-CD Simple Endoscopic Score for Crohn's Disease
SF-[ADDRESS_1241577] upper limit of normal
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 79
Approved , Date: 4 June [ZIP_CODE]. INTRODUCTION
The natural killer group 2 member D (NKG2D) is an activating receptor expressed on the surface 
of natural killer (NK) cells, CD8+ Tcells, and subsets of CD4+ Tcells, invariant NKTcells, 
and gamma/delta (γδ) Tcells. It signals via the noncovalentl y associated DNAX -activating 
protein of 10 kDa and a phosphoinositide 3-kinase. The receptor recognizes an extensive 
repertoire of self-ligands (ie, ligands encoded by [CONTACT_40689]'s own genome as opposed to foreign 
antigens) , encoded by  [CONTACT_2669] 8 genes including th e major histocompatibility class I chain -related 
proteins A and B (MICA and MICB), and proteins from the ULPB/RAET1 family  (ULBP1 -6), 
some of which have extensive allelic polymorphism s. Expression of NKG2D ligands is tightly  
regulated. All NKG2D ligands are expressed at very  low levels in healthy  adul t tissues; however,
cellular stress, cancer, or virus infection can upregulate the expression of these self-encoded 
NKG2D ligands . Recognition of these self-encoded NKG2D ligands on unhealthy  cells by [CONTACT_887104]2D receptor (“induced self-recognition”) results in the proliferation and the subsequent 
release of proinflammatory  cytokines and cytotoxic mediators such as interferon gamma , Vav1 
guanine nucleotide exchange factor, interleukin (IL)-9, IL-10, vascular endothelial growth 
factor -A, IL-13, and tumor necrosis factor alpha (TNFα) by [CONTACT_887105]2D receptor -bearing NK 
and T cells leading to a deoxy ribonucleic acid ( DNA )damage response andinflammation.
Several lines of evidence from patients with Crohn’s disease support the hy pothesis that NKG2D 
receptor activation plays a role in disease pathogenesis by [CONTACT_887106] , activation of an immune response ,and direct cytotoxicity  oftarget intestinal cells. In 
Crohn’s disease, CD4+ and CD8+ T cells expressing the NKG2D receptor accumulate at sites of 
intestinal inflammation. The level of circulating NKG2D+CD4+ Tcells rapi[INVESTIGATOR_2478] y declines 
following surgical removal of inflamed intestinal tissue, and theirconcentration increases at the 
relapse of disease. Approximately  40% of patients with Crohn’s disease have circulatin g 
NKG2D+CD4+ Tcells, andthese cells were found in virtually  all samples of inflamed intestine. 
Expression of NKG2D ligands has been demonstrated to be upregulated in intestinal biopsies in 
patients with Crohn’s disease compared with healthy  subjects, further supporting arole for the 
involvement of the NKG2D receptor in inflammation. In addition, blockade of the NKG2D 
receptor is effective in preventing disease progression in preclinical animal models of human 
inflammatory  diseases. Collectively , preclini cal and clinical data onthe expression of 
NKG2D -ligands or proinflammatory  cytokines in the target tissue and abnormal expression and 
activation of the NKG2D receptor on CD8+ and CD4+ T cells provide a rationale for the clinical 
development of inhibitors of the NKG2D receptor .
JNJ-64304500 (formerl y known as NNC0142 -002) is a human immunoglobulin G4 isoty pe 
monoclonal antibody that binds specifically  to the NKG2D receptor, and blocks NKG2D ligand 
binding, thereb y preventing the downstream -signaling events that otherwise lead to cell 
proliferation and release of proinflammatory  cytokines and cytotoxic mediators . Results from a 
Phase 2a study  in subjects with moderatel y to severel y active Crohn’s disease who had failed or 
were intolerant to conventional thera py or TNFα antagonists for Crohn’s disease (conducted by 
[CONTACT_3454] )provide devidence for the efficacy  of JNJ-64304500 in the treatment of Crohn’s 
disease .
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 80
Approved , Date: [ADDRESS_1241578] version of the Investigator's Brochure (IB) for JNJ-64304500 . The term "sponsor" 
used throughout this document refers to the entities listed in the Contact [CONTACT_23774](s), 
which will be provided as a separate document.
1.1. Nonclinical Studi es
For the most comprehensive nonclinical information regarding JNJ-[ADDRESS_1241579] 
version of the I Bfor JNJ-64304500 .
1.2. Clinical Studies
As of 11 November 2015, a total of 128 subjects had been exposed to JNJ -64304500 in 3 clinical 
studies : 88 subjects in 2studies in rheumatoid arthritis (RA)and 40subjects in a Phase 2a study 
in Crohn’s disease.
1.2.1. Rheumatoid A rthritis
Two studies with JNJ -[ADDRESS_1241580]-in-human s, Phase 1,single ascending dose/multiple ascending dose
study thatincluded single -dose (0.0002 to 7.5 mg/kg) and multiple -dose (0.02 to 4 mg/kg every  2 
weeks [q2w] for 4 administrations ) parts , 13 dose level s were evaluated in 24 subjects exposed to 
JNJ-64304500 in the single ascending dose portion and 23 subjects exposed to JNJ-64304500 in 
the multiple ascending dose portion . Subcutaneous (SC) administration of JNJ-64304500 was 
well tolerated at the dose ranges investigated and no safety  signals were associated with either 
the single -or multiple -dose regimens.
InNN8555 -3796 , a Phase 2a, randomized, single -dose, double -blind, placebo -controlled, 
parallel -group study , clinical efficacy  was assessed in subjects with active RA concomitantly  
treated with methotrexat e (MTX ). In this study , asingle SC injection of 4mg/kg JNJ-[ADDRESS_1241581] version of the I B.
1.2.2. Crohn’s Disease
NN8555 -3797 was a Phase 2a, multicenter, randomized, double -blind, placebo -contr olled, 
parallel -group, single -dose study  in subjects with moderatel y to severel y active Crohn’s disease 
who had failed or were intolerant to conventional therapy  (corticosteroids or immunomodulators) 
or were intolerant or refractory  to [ADDRESS_1241582] therapy. Only subjects who had a Crohn’s 
Disease Activity  Index (CDAI) score ≥220 but ≤450 and inflammation confirmed by [CONTACT_319125] 
≥10mg/dL  or by [CONTACT_235127]  (endoscopic verification of active ulceration performed during 
screening and read by a blinded central imag ing reader) were included in the study . The study  
enrolled and randomized 78 subjects at 32investigational sites in North America, Europe, and 
Israel. All subjects were randoml y assigned in a 1:1 ratio at Week 0 to receive placebo SC 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 81
Approved , Date: 4 June 2021(n=38) or 2mg/kg JNJ-64304500 SC (n=40). Among the 78randomized subjects, the mean 
baseline CDAI  score was 330.5, and 29.5% were intolerant or refractory to a maximum of [ADDRESS_1241583] therap y.
Subjects were evaluated for the primary  endpoint of change from baseline in the CDAI  score at 
Week 4. Safety  and efficacy  evaluations were performed through Week 24. The observed 
16-point greater reduction in CDAI  in the JNJ-64304500 group at Week 4 compared with the 
placebo group was not significant (p=0.403). Based on a predefined significance level of 0.10, 
however, the reduction in CDAI  score was significantly  higher in the JNJ-64304500 group 
compared with the placebo group at Week 12 (55-point greater reduction in CDAI was observed 
in JNJ-64304500 compared with placebo, p=0.056) . Based on the same predefined significance 
level of 0.10, reductions in CDAI  scores were significantly  higher in the predefined subgroup of 
“no prior failure to biologics” (Bio -NF, 71% of the study  population) in the JNJ -[ADDRESS_1241584] baseline visits through Week 12 (Week 1, p=0.068; Week 2, 
p=0.048; Week 4, p=0.095; Week 8, p=0.015; and Week 12, p=0.025). The biologic intolerant or 
refractory  (Bio-IR) population in the Novo Nordisk Phase 2a study  constituted 29% of the study 
population (N=12 in the active treatment arm and N=11 in the placebo arm). In this 
subpopulation, a 45-point greater reduction in CDAI was observed at Week [ADDRESS_1241585] hoc analysis of efficacy  data demonstrated 
greater efficacy  in a subgroup of subjects with a specific single nucleotide polymorphism (SNP) 
in the NKG2D receptor and/or MICB ligand (SNP -positive cohort). The association between 
SNP-positive status and higher clinical efficacy will be tested prospectively  in this Phase 2b 
study .
The mean duration of study  participation was equivalent between the 2treatment groups. No 
deaths ormedical events of special interest were reported. Through Week 24, the proportions of 
subjects with 1 or more adverse events (AEs) were similar in the JNJ-[ADDRESS_1241586] commonly  reported AEs in both groups (17 and 
14subjects in the JNJ-64304500 and placebo groups, respectivel y). Serious AEs (SAEs) were 
uncommon and reported in 7 of 78 (9%) randomized subjects with 1 SAE each: 2 in the placebo 
group (1 Crohn's disease, 1 nephrolithiasis) compared with 5 in the JNJ-64304500 group 
(4Crohn's disease, 1 Clostridium difficile infection). All SAEs were evaluated as unlikely  related 
to treatment with study  agent.
Collectively , these data support the further development of JNJ-64304500 in subjects with 
moderatel y to severel y active Crohn’s disease.
This protocol (64304500CRD2001) is comprised of 2 randomized, double -blind, 
placebo -controlled, parallel -group, multicenter parts designed to evaluate the safet y and efficacy  
of JNJ-64304500 in subjects with moderatel y to severel y active Crohn’s disease who have 
previously  failed or who were intolerant to 1 or more approved biologic agents (Bio -IR) or those 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 82
Approved , Date: [ADDRESS_1241587] failed to tolerate corticosteroids or 
immunomodulators (B io-NF).
In Part I, the following 2 studies will be conducted:
Study  1: A study  in subjects who are biologic intolerant or refractory  (Bio -IR);
Study  2: A study  in subjects who have not previously  failed a biologic therap y (Biologic 
nonfailure [Bio -NF]).
InPart II, the following study  will be conducted:
Study  3: A dose-ranging study  in subjects who are biologic intolerant or refractory  (Bio-IR) 
or Biologic nonfailure (Bio -NF)
In Study  1, a higher dose regimen than was used in the Phase 2a study  will be empl oyed 
supported by [CONTACT_887107] y margins demonstrated in Phase 1 (the Novo Nordisk Phase 1 
single ascending/multiple ascending dose study  NN8555 -3618), and the high exposure margins 
relative to no-observed -adverse -effect level (NOAEL) exposure in cynomolgus monkey s. This 
higher dose will be used to provide additional information on safet y and efficacy  for the Bio-IR 
population, as proof of concept was not established in this population in the Novo Nordisk 
Phase 2a study  (NN8555 -3797). In addition, this higher dose will also be evaluated in Bio-NF 
subjects to determine if a more robust efficacy  outcome than was shown in the Phase 2a study  
can be achieved while maintaining an acceptable safet y profile. Combined with data from 
Phase 2a in Bio-NF subjects , Part I and Part II would provide valuable information for the 
assessment of dose/exposure -response and thus the selection of the optimal dose in Bio-NF 
population for the Phase 3 program. Study  1 and Study  2 comprise Part I of the protocol and 
these 2 components will be initiated in parallel. The decision to initiate the dose-ranging portion 
of the protocol (Part II, Bio-IR and Bio-NF) is dependent on demonstration of acceptable safet y 
and efficacy  in Part I (combined Bio -IR subjects and Bio-NF subjects). A ustekinumab reference 
arm will be included in Part II to provide context in the interpretation of results from the 
JNJ-[ADDRESS_1241588] in the overall selection of dose(s) to carry 
forward into the Phase 3 program.
A long-term extension (LTE) for Part II of the study  was added to the protocol as part of 
Protocol Amendment 5. After Protocol Amendment [ADDRESS_1241589] and program decision -making based on planned interim database locks 
(DBLs) as described in Section 3.1.1 , Section 3.1.2 , and Section 5.2.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 83
Approved , Date: 4 June [ZIP_CODE]. OBJECTIVES, ENDPOINT S, AND HYPOTHESIS
2.1. Objectives and Endpoints
2.1.1. Objectives
The objectives are the same in each of the 2 parts.
Primary Objectives
To evaluate the efficacy  of JNJ -64304500 to reduce the CDAI score from baseline.
To evaluate the safet y of JNJ -64304500.
Secondary Objectives
To evaluate the efficacy of JNJ-64304500 to induce clinical remission, clinical response, 
and endoscopic healing of the mucosa, and to maintain remission .
To evaluate the relationship between efficacy  and the presence of the NKG2D and/or MI CB 
SNP biomarkers.
To evaluate the efficacy  of JNJ-64304500 to improve general and disease -specific 
health -related quality  of life and to reduce Crohn’s disease -related hospi[INVESTIGATOR_817346].
To evaluate the pharmacokinetics (PK) , immunogenicity , pharmacod ynamics (PD) , and 
biomarkers (eg, reductions in CRP, fecal calprotectin, and fecal lactoferrin) of 
JNJ-64304500 therapy .
2.1.2. Endpoints
The data from Study  1 and Study  2 in Part I will be pooled for anal ysis.
The primary  endpoint for Part I  is: Change from baseline in the CDAI score at Week 8.
The primary  endpoint for Part II is: Change from baseline in the CDAI score at Week 12.
The following endpoints will be evaluated as major secondary  endpoints only  in Part II (the 
dose-ranging portion of the study ); these endpoints will be evaluated in Part I  but are not 
specified as major secondary  endpoints.
Clinical remission at Week 12 as measured b y CDAI (CDAI <150).
Clinical response at Week 12 as measured by [CONTACT_82274] (≥100 -point reduction from baseline in 
CDAI  or CDAI <150).
Change in PRO -2 (the sum of the abdominal pain and stool frequency subscores of the 
CDAI  score) from baseline at Week 12.
Clinical remission at Week 12 as measured b y PRO -2 (PRO -2 <75).
Clinical response at Week 12 as measured by [CONTACT_96553]-2 (≥50-point reduction from baseline in 
PRO -2 or PRO -2<75).
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 84
Approved , Date: 4 June 2021Change in Simple Endoscopic Score for Crohn's Disease (SES -CD) from baseline at 
Week 12.
The following efficacy  endpoints will be evaluated in Part I  and Part II (except for the Patient’s 
Global I mpression of Severity  [PGI S] of Crohn’s disease and t he Patient’s Global I mpression of 
Change [PGIC] of severity  of Crohn’s disease, which will only  be evaluated in Part II):
Change in CDAI from baseline at all postbaseline visits.
Clinical remission based on CDAI  at all postbaseline visits.
Clinical respons e based on CDAI  at all postbaseline visits.
Change in PRO -2 from baseline at all postbaseline visits.
Change in abdominal pain score (daily average based on the CDAI assessment) from 
baseline at all postbaseline visits.
Change in stool frequency  score (daily average based on the CDAI assessment) from 
baseline at all postbaseline visits.
Clinical remission based on PRO -2 at all postbaseline visits.
Clinical response based on PRO -2 at all postbaseline visits.
Change in PRO -3 (the sum of abdominal pain, stool frequency , and general well-being  
subscores of the CDAI score) from baseline at all postbaseline visits.
Clinical remission based on CDAI  at Week 24 among subjects in clinical response at 
Week 12.
Clinical remission based on CDAI  at Week 24 among subjects in clinical remission at 
Week 12.
Change in SES -CD score from baseline at Weeks 12 and 24.
Endoscopic improvement at Weeks 12 and 24 based on a reduction from baseline in 
SES-CD score ≥3. Endoscopy  will only  be performed during Part I.
Atleast 50% impro vement from baseline in SES -CD at Weeks 12 and 24.
Endoscopic healing (defined as the absence of mucosal ulcerations) at Weeks 12 and 24.
Endpoint (s) for histologic assessment based on the Global Histology  Activity  Score (GHAS; 
to be detailed in the Statis tical Analy sis Plan [SAP]).
Fistula response at all postbaseline visits, defined as a ≥50% reduction from baseline in the 
number of draining fistulas.
Endpoint(s) based on Bristol stool form scale (to be detailed in the SAP).
Change in abdominal pain from baseline at all postbaseline visits based on a 0 -10 Numerical 
Rating Scale (NRS).
Change in PGIS of Crohn’s disease from baseline at Weeks 4, 8, 12, and 24.
A ≥1-point improvement in PGIS of Crohn’s disease from baseline at Weeks 4, 8, 12, and 
24.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 85
Approved , Date: 4 June 2021Improvement in PGI C of severit y of Crohn’s disease at Weeks 4, 8, 12, and 24.
Change in Inflammatory  Bowel Disease Questionnaire (IBDQ) score from baseline at 
Weeks 8, 12, and 24.
Clinical remission based on IBDQ ( ≥170) at Weeks 8, 12, and 24.
A ≥16-point improvement in IBDQ from baseline at Weeks 8, 12, and 24.
Change from baseline in the Physical Component Summary  (PCS) and Mental Component 
Summary  (MCS) scores of the 36-item Short Form Health Survey  (SF-36) at Weeks 8, 12, 
and 24.
A ≥5-point improvement in PCS or MCS scores of the SF -36 at Weeks 8, 12, and 24.
Change in biomarkers (CRP, fecal calprotectin, fecal lactoferrin) from baseline at Weeks 8, 
12, and 24.
Clinical remission based on CDAI at Week [ADDRESS_1241590] 1 of 2 SNPs (NKG2D or MI CB) will be considered to be SNP -positive.
Other efficacy  endpoints may  be examined by  [CONTACT_887082] (to be detailed in the SAP).
Refer to Section 9, Study Evaluations, for evaluations related to endpoints.
2.2. Hypothesis
The hypothesis for Part I and Part II is that JNJ-64304500 is superior to placebo in inducing a 
reduction from baseline in CDAI  in subjects with moderatel y to sev erely active Crohn’s disease.
3. STUDY DESIGN A ND RA TIONA LE
3.1. Overview  of Study  Design
This protocol is comprised of 2parts (Part I [Bio-IR subjects and Bio-NF subjects] and Part II 
[Bio-IR and Bio-NF subjects]) (Figure 1) that are designed to evaluate the safet y and efficacy  of 
JNJ-64304500 in subjects with moderatel y to severely active Crohn’s disease .
In Part I, the following 2studies will be conducted:
Study  1: A study  in subjects who are biologic intolerant or refractory  (Bio -IR);
Study 2: A study  in subjects who have not previously  failed a biologic therap y (Biologic 
nonfailure [Bio -NF]) .
In Part II, the following study  will be conducted:
Study  3: A do se-ranging study  in subjects who are Bio-IRor Bio -NF
The 2 studies in Part Iserve to build on the original Phase 2a study  findings by [CONTACT_887108]-IR and Bio-NF subjects. If acceptable safet y and efficacy  are
established in thecombined Bio-IR and Bio-NF population s, Part II of the protocol ,which 
consists of a dose-ranging study (Study  3)in subjects who areBio-IR or Bio-NF,will be 
initiated .
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 86
Approved , Date: [ADDRESS_1241591] completed Week 24 prior to the implemen tation of Protocol Amendment 5 will not be 
eligible to enroll in the Part II LTE.
Figure 1: Schematic representation of 64304500CRD200 1
The target population for each of the studies consists of men or women ≥18years of age with
moderatel y to severel y active Crohn’s disease (of at least 3 months’ duration), defined as a CDAI 
score ≥220 but ≤450 at Week 0, with elevated CRP >0.3 mg/dL (>3.0 mg/L ) and/or calprotectin 
>250 mg/kg at screening. Subjects must have colitis, ileitis, or ileocolitis previously  confirmed at 
any time in the past by  [CONTACT_237450] y, histology , and/or endoscop y.
Additionally , subjects must have previously  failed or been intolerant to 1 or more approved 
biologic agents (ie, TNF α-antagonists or vedolizumab , hereafte r referred to as Bio-IR subjects ) 
orhave demonstrated an inadequate response to or failed to tolerate corticosteroids or 
immunomodulators (ie, 6-mercaptopurine [6-MP], azathioprine [AZA ], and MTX) but not a 
biologic agent (hereafter referred to asbiologic nonfailure subjects ). These 2populations are 
described below:
Biologic intolerant or refractory (Bio -IR) subjects are defined as those who have received 
infliximab (or a biosimilar for infliximab) , adalimumab (or a biosimilar for adalimumab) , 
certolizumab pegol, or vedolizumab at a dose approved for the treatment of Crohn’s disease, 
and either did not respond initially , responded initially  but then lost response, or were 
intolerant to the medication (Attachment 1).Bio-IR subjects must allow a ≥8-week washout 
for pri or TNFα antagonist use and a 16-week washout period for prior vedolizumab use.

JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 87
Approved , Date: 4 June 2021Biologic nonfailure (Bio-NF) subjects are defined as those who have demonstrated an 
inadequate response to or have failed totolerate corticosteroids or the immunomodulators 
6-MP, AZA, or MTX (Attachment 2). Subjects who have demonstrated corticosteroid 
dependence (ie, an inability  to successfull y taper corticosteroids without a return of the 
symptoms of Crohn’s disease) are also eligible . Bio-NF subjects may also have received 
biologic therapy  but only if it was discontinued for reasons other than lack of efficacy  or 
intolerance (eg, drug holiday ).
It is anticipated that approximately  370to 420 subjects will berandomized overall across Part I 
and Part II :
Part Iwill study  the safety  and efficacy  of a highdose regimen of JNJ-64304500 compared 
with placebo and will enroll a minimum of 120 subjects and a maxi mum of 170 subjects
(Bio-IR and Bio -NF).
Part IIwill study  the safet y and efficacy  of multiple -dose regimens of JNJ-64304500 
compared with placebo, with ustekinumab (STELARA®) as a reference arm. Part II will 
enroll approximately 250 subjects (the maximum proportion of either Bio-NF or Bio-IR 
subjects will be 60%).
Schematic representation sof Part I and Part II are shown in Figure 2and Figure 3, respectivel y.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 88
Approved , Date: 4 June 2021Figure 2: Schematic Overview of Part I of Study 64304500CRD2001
Throughout Part I and the main study  phase of Part II efficacy , PK, PD, immunogenicit y, 
biomarkers, and safet y will be assessed at timepoints indicated in the appropriate Time and 
Events Schedules (Table 1andTable 2). Efficacy evaluations will not be assessed in the Part II 
LTE.
Blood samples for pharmacogenomic analyses will be collected from subjects who consent 
separately  to this component of the protocol (where local regulations permit). Subject 
participation in pharmacogenomic research is optional.
The primary  endpoint for Part I is the change from baseline in the CDAI score at Week 8. The 
primary  endpoint for Part II is the chang e from base line in the CDAI score at Week 12 .
After Protocol Amendment 5 is implemented, all subjects who complete Part II of the study  
through Week 24,and who may benefit from continued treatment in the opi[INVESTIGATOR_1070] ,are eligible to enter thePart IILTE and continue to receive treatment forup to 

JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 89
Approved , Date: 4 June 202152weeks (Week 24 to Week 72), as described in Section 3.1.4 .A schematic representation of the 
Part II LTE is shown in Figure 3.
Figure 3: Schematic Overview of the 64304500CRD2001 Part II ( Including the Long -term  Extension)
An external Data Monitoring Committee (DMC) will review unblinded safet y data from all 
subjects periodicall y to monitor subject safety . The DMC will consist of at least one medical 
expert [INVESTIGATOR_524930]. The DMC responsibilities, 
authorities, and procedures will be documented in its charter. Refer to Section 11.11,Data 
Monitoring Committee , for details.

JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 90
Approved , Date: 4 June [ZIP_CODE].1.1. Part I
In Part I, a minimum of120subjects and a maximum of 170 subjects (Bio-IR and Bio-NF) will 
be random ly assigned to receive placebo or the JNJ-64304500 high dose in a 1:1 ratio using 
permuted block randomization, stratified by [CONTACT_887109] (≤300 or >300) and 
SNP-positive status (y es or no). Separate randomizations will be used for the Bio-IR and Bio -NF 
populations.
The treatment groups for each stud y in Part I will be as follows:
Placebo SC at Weeks 0, 2, 4, 6, 8, and 10; from Week 12, these subjects will receive 
additional doses as follows:
Placebo -treated subjects who arein clinical response at Week 12 (≥100 -point reduction 
from baseline in CDAI or CDAI  <150) will continue to receive placebo SC injections
q2w from Week 12 through Week 22.
Placebo -treated subjects who are notin clinical response at Week 12 will receive 
JNJ-64304500 400 mg SC at Week 12 and then 200 mg SC q2w from Week 14through 
Week 22.
JNJ-64304500 400 mg SC at Week 0 then 200 mg SC q2w through Week22.
An interim analy sis is planned in Part I when 100 randomized subjects (Bio-IR and Bio-NF)
have complet ed their Week [ADDRESS_1241592]. If Part II is not initiated based on the interim anal ysis results, 
then the results through Week 12 for all subjects in Part I (ie, when all randomized subjects in 
Part I have either completed the Week 12 visit or termin ated study participation prior to 
Week 12) will be examined to determine whether to start Part II. Under this scenario, a pause in 
enrollment between Part I and Part II will occur.
3.1.2. Part II
In Part II, 250 additional Bio-IR or Bio-NF subjects will be random ly assigned to receive 
placebo or 1 of 3dose levels of JNJ-64304500 or ustekinumab in a ratio of 1:1:1:1:1 using 
permuted block randomization, stratified by [CONTACT_887109] (≤300 or >300), SNP-positive 
status (yes or no), and Bio-IR status (yes or no). The maximum proportion of either Bio-NF or 
Bio-IR subjects will be 60%.
The treatment groups in Part II will be as follows:
Placebo SC at Weeks 0, 2, 4, and 8; from Week 12, these subjects will receive additional 
doses as follows:
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 91
Approved , Date: 4 June 2021Placebo -treated subjec ts who arein clinical response at Week 12 (≥100 -point reduction 
from baseline in CDAI or CDAI <150) will continue to receiv e placebo at Weeks 12, 
14, 16, and 20.
Placebo -treated subjects who are notin clinical response at Week 12 will receive 
JNJ-6430450 0 150 mg SC at Week 12 and then JNJ-64304500 75 mg SC at Weeks 14, 
16, and 20.
High dose: JNJ-64304500 400 mg SC at Week 0 and 200 mg SC at Weeks 2 and 4, then 
200mg SC every  4 weeks (q4w) through Week 20.
Middle dose: JNJ-64304500 150 mg SC at Week 0 and75 mg SC at Weeks 2 and 4, then 
75mg SC q4w through Week 20.
Low dose: JNJ -64304500 50 mg SC at Week 0 and 25 mg SC at Weeks 2 and 4, then 25 mg 
SC q4w through Week 20.
Ustekinumab (tiered doses approximating 6 mg/kg intravenousl y [IV]) at Week 0 (as 
indicated in the bullets below), followed b y 90 mg SC at Weeks 8 and 16.
Ustekinumab 260 mg (weight ≤55 kg).
Ustekinumab 390 mg (weight >55 kg and ≤85 kg).
Ustekinumab 520 mg (weight >85 kg);
As indicated in Figure 2, subjects will also receive placebo administrations, as necessary , to 
maintain the blind of Part II; see Section 6.2for details.
3.1.3. Interim A nalysis
An interim analy sis is planned in Part I when 100 randomized subjects (Bio-IR and Bio-NF)
have completed their Week [ADDRESS_1241593] or 
completion of Part I, it will be considered administrative and will not require multiplicity  
adjustment for the final Part I analy sis.
A sponsor committee independent of the study  team will be established to review the interim 
data and formulate recommended decisions/actions in accordance with predefined decision rules
(tobe defined in the Interim Analy sis Plan) .
An interim anal ysis is not planned for Part II .
Other planned DBLs are described in Section 5.2.
3.1.4. Part II Long -Term Extension
After Protocol Amendment [ADDRESS_1241594] will be eligible to receive up 
to 52 weeks of additional study  drug (for a total of up to 72 weeks of study  drug in Part II).The 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 92
Approved , Date: [ADDRESS_1241595] been completed .The dose may be administered on the same day as the Week 
24 assessments, or may be administered on a later date, as long as the dose is administered 
within the Week 24 visit window.
Subjects will continue to receive the same treatment regimen during the Part II LTE that they 
were recei ving between Week 12 and Week 20 in the main study  phase of Part II (placebo, high, 
middle, low dose JNJ-64304500 or ustekinumab). To maintain the study  blind, all patients, 
investigators, and sites will remain blinded to treatment allocation during the Part II LTE until 
the last subject in the Part II main study phase has completed the Week [ADDRESS_1241596] will receive his/her treatment allocation during the
Part II LTE will depend upon his/her Part II en rollment d ate. Therefore, a portion of subjects will 
complete the entire Part II LTE in a blinded fashion befor e study  unblinding, while other subjects
could be unblinded to treatment allocation during their participation in the Part II LTE.
On [ADDRESS_1241597] dose of study  drug. For subjects who remain in the 
Part II LTE at the time of study  unblinding, continuation of study  drug during the Part II LTE 
will be dependent upon treatment allocation ,as follows:
JNJ-64304500 : Subjects receiving JNJ-[ADDRESS_1241598] dose of study  drug.
Placebo : Subjects receiving placebo who remain in the Part II LTE at the time of study  
unblinding will have their final safety  follow -up visit subsequent to unblinding and will be 
discont inued from the study . No further follow -up visits will be performed.
Ustekinumab : Subjects receiving ustekinumab will continue to receive it during the Part II 
LTE until unblinding occurs. After unblinding, based on the treating physician’s clinical 
judgment, subjects may receive ustekinumab in a manner dependent on the country  in which 
they are located:
oIf a subject is not continuing on ustekinumab after unblinding, the subject will need to 
return for a final safety  follow -up visit that will be performed 16 weeks after the final 
dose of study  ustekinumab.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 93
Approved , Date: [ADDRESS_1241599] continues on ustekinumab in a country  where commercial ustekinumab is 
available and approved for adult Crohn’s disease, t he treating phy sician is responsible 
for providing the subject with commercial ustekinumab, which should be 
administered according to the approved dosing regimen in each country . The final 
safet y follow -up visit should be performed after unblinding but before receiving the 
first dose of commercial ustekinumab.
oIf a subject continues on ustekinumab in countries where commercial ustekinumab is 
not available or approved for adult Crohn’s disease, ustekinumab will continue to be 
provided to subjects through Week 72.
For eligible Part II subjects, participation in the Part II LTE is entirely  voluntary . Eligible 
subjects who do not wish to enter the Part II LTE will complete the Part II Week 24 safet y and 
efficacy  assessments, followed by  [CONTACT_887110] y assessments at Week 36.
During thePart IILTE, all concomitant medications, including Crohn’s disease -specific 
medications (except forthe prohibited medications listed in Section 8.2) may be administered at 
the discretion of the investigator.
All subjects in the Part II LTE (before unblinding for JNJ-64304500, ustekinumab, and placebo 
and after unblinding for JNJ 64304500 )will be assessed according to the Time & Events 
Schedule (Table 3), which include sassessments ,AEs, laboratory  analyses, and PK and 
immunogenicit y samples. Ustekinu mab subjects in the Part II LTE (after unblinding for 
ustekinumab subjects in countries where ustekinumab is not commercially  available) will be 
assessed according to the Time & Events Schedule (Table 4), which includes assessments and 
AEs.
3.2. Study Design Rationale
This protocol is comprised of 2 parts (Part I [Study  1: Bio-IR subjects andStudy  2: Bio-NF 
subjects] and Part II [Bio-IR and Bio-NF subjects]) that are designed to evaluate the safet y and 
efficacy  of JNJ-64304500 in subjects with moderatel y to severel y active Crohn’s disease. 
Study 1 and Study  2 constitute PartI of the protocol. In this part, the safet y and efficacy  of a 
single dosing regimen of JNJ-64304500 inBio-IR and Bio-NF subjects with moderatel y to 
severel y active Crohn’s disease is evaluated. Ifacceptable efficacy  is established in PartI(for the 
combined Bio-IR and Bio-NF subjects) , PartII (a dose-ranging study in Bio-IRand Bio-NF
subjects )will be initiated. After Protocol Amendment [ADDRESS_1241600] completed Week 24 prior to the implementation of Protocol 
Amendment 5 will not be eligible to enroll in the Part II LTE.
3.2.1. Choice of JNJ -64304500 Dose for Placebo Nonresponders
In Part I, the high dose of JNJ-64304500 (400 mg/200 mg) was chosen for placebo 
nonresponders because it is the only  dose regimen studied in this part.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 94
Approved , Date: 4 June 2021In Part II, the middle dose was chosen for placebo nonresponders as it is believed that this dose 
will be effective since it is higher than the dose studied in the prior Phase 2a study  (where 
efficacy  was shown). The middle dose also requires fewer injections compared with the high 
dose.
3.2.2. Efficacy  Assessments
The efficacy  evaluations selected for both parts of thestudy  (eg, CDAI, CRP, fecal biomarkers; 
Section 9.2) are well-established measures that are accepted by  [CONTACT_887111] y relevant effect of disease activity in Crohn’s disease studies.
The primary  endpoint for Part I is change from baseline in CDAI at Week 8. The primar y 
endpoint for Part II is change from baseline in CDAI at Week 12.
Change in the CDAI is being used as the primary  endpoint because this measure is more 
sensitive than remission (ie, the change in CDAI provides greater power than remission for the 
same sample size). Therefore, the study  can be more efficient for Phase [ADDRESS_1241601] an 
appropriate comparison of JNJ-64304500 to placebo, the placebo -controlled period will continue 
to Week 12.
Efficacy  evaluations will not be performed during the Part II LTE.
3.2.3. Pharmacokinetic A ssessments
Pharmacokinetic assessments will be used to further understand the disposition of JNJ -64304500 
in subjects with Crohn’s disease.
3.2.4. Immunogenicity  Assessments
Serum samples for the detection of antibodies to JNJ-64304500 will be collected to further 
evaluate the immunogenicity  of JNJ -64304500 in subjects with Crohn’s disease.
3.2.5. Pharmacody namic Assessments
Serum samples for the analysis of PD will be collected to further understand the response of 
subjects with Crohn’s disease to treatment with JNJ -64304500.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 95
Approved , Date: 4 June [ZIP_CODE].2.6. DNA  and Biomarker Collection
It is recognized that genetic variation can be an important contributory  factor to interindividual 
differences in drug distribution and response and can also serve as amarker for disease 
susceptibility  and prognosis. Pharmacogenomic research may help to explain interindividual 
variability  in clinical outcomes and may help to identify  population subgroups that respond 
differentl y to a drug.
Whole blood will be collected from all subjects for SNP analy sis (the NKG2D SNP rs2255336 
and the MICB [NKG2D ligand] SNP rs2239705) to understand the association of these SNPs 
with response to JNJ-64304500 (refer to the latest version of the IB for more information). In
addition, subjects who sign an optional pharmacogenomics consent form will undergo complete 
genomic testing.
The goal of thispharmacogenomic component is to collect DNA to allow the identification of 
genetic factors that may influence the PK, PD, efficacy , safet y, or tolerability  of JNJ-64304500
and to identify  genetic factors associated with Crohn’s disease.
Biomarker assessments will be made to examine the biologic response to treatment and to 
identify  biomarkers that are relevant to JNJ-64304500 treatment and/or Crohn’s disease. Blood 
samples for serum -based biomarker anal yses will be collected from all subjects to assess proteins 
related to the NKG2D pathway  or the pathogenesis of Crohn’s disease. Whole blood samples 
will be collected from all subjects for the analysis ofribonucleic acid (RNA )expression and 
T-cell receptor repertoire. Mucosal biopsy  samples will be collected during ileocolonoscopy  for 
the analysis of gene and/or protein expression and the histologic assessment of disease and/or 
healing.
Recepto r occupancy  (RO) assessments for NKG2D and immunophenoty pi[INVESTIGATOR_580505] 
(including NK cells and CD8+ Tcells) will also be performed. Immunophenoty pi[INVESTIGATOR_887067]4, CD8, and NK cells before versus 
after dose administration.
3.2.7. Control, Randomization, and Blinding
In both parts of the study , aplacebo control will be used to establish the frequency  and 
magnitude of changes in clinical endpoints that may occur in the absence of active treatment. In 
addition to placebo control, austekinumab reference arm will be used in Part IIto determine the 
sensitivity  of the clinical endpoints in this study .
Ustekinumab was chosen for use as a reference arm because the efficacy and safet y profile of 
ustekinumab are well described. It is also recognized that use of other therapeutics (eg, TNFα 
antagonists) could potentially  confound the population of Bio-IR subjects and introduce 
substantial patient burden to maintain blinding.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 96
Approved , Date: [ADDRESS_1241602] attributes (eg, demographic and 
baseline characteristics) are evenly  balanced across treatment groups, and to enhance the validity 
of statistical comparisons across treatment groups. Blinded treatment will be used to reduce 
potential bia s during data collection and evaluation of clinical endpoints.
3.2.8. Dose Selection
[IP_ADDRESS]. JNJ-64304500
The results of PK, PD and efficacy  analyses and safet y data from previous clinical studies of 
JNJ-64304500 in subjects with RA and Crohn’s disease were used to guide the dose selection for 
the [ADDRESS_1241603] single SC dose investigated 
was 7.5mg/kg and the highest multiple SC dose regimen investigated was 4mg/kg q2w for a 
total of 4doses in RA subjects. JNJ-64304500 was well tolerated and no safety  concerns were 
identified in subjects with RA or Crohn’s disease from the previous clinical studies. In addition, 
a 52-week repeat -dose toxicology  study has demonstrated a NOAEL of 100mg/kg SC once 
weekl y in cy nomolgus monkey s. The exposures achieved in the last dosage interval (100 mg/kg) 
of the 52-week study  were 10,900 and 8,480 μg/mL  formaximum concentration (Cmax), and 
1,520,000 and 1,250,000 hr·μg/mL for AUC 0-168hr , for male and female monkey s, respectivel y. 
Based on these safet y and toxicology  findings, it is expected that the proposed dose regimens of 
JNJ-[ADDRESS_1241604] acceptable safet y profiles.
Population PK/PD model ing and simulation was performed using JNJ-64304500 PK and 
NKG2D RO data from the previous clinical studies. The model -predicted JNJ-64304500 
concentrations and NKG2D RO in the intestines were used to help guide the selection of the dose 
regimens for the present study . NKG2D RO in the intestines is predicted by [CONTACT_887112]-64304500 in the intestines is approximately  10% of the concentration in the 
peripheral circulation because a 5%-15% antibody  distribution coefficient between the general 
circulation and the intestines has been reported .[ADDRESS_1241605] administration of study  agent has been employ ed 
based on the observed safet y profile and PK profile of JNJ-64304500 in the completed clinical 
studies in RA and Crohn’s disease subjects. The average serum concentration of JNJ-[ADDRESS_1241606] administration of study  agent is predicted to be approximately
0.01 μg/mL , which is considered unlikel y to produce drug -related effects or safet y concerns .
PART I
The selected JNJ-[ADDRESS_1241607]-in-human study (NN8555 -3618), the
highest multiple -dose regimen of 4mg/kg SC q2w (4 doses) provided a median (range) Cmax in 
serum of 79.3 (52.8 to 91.2) µg/mL . The predicted median JNJ-64304500 Cmax in serum 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 97
Approved , Date: 4 June 2021is64.64 μg/mL , median JNJ-64304500 concentration in serum at Week 8 is 38.94 μg/mL  and 
median steady state trough JNJ-64304500 serum concentration is 38.31 μg/mL  in subjects with 
Crohn’s disease ( Table 5).
Assuming the concentration of JNJ-64304500 in the intestines is approximately  10% of 
concentration of JNJ-64304500 in serum, the predicted median peak and trough concentrations 
of JNJ-64304500 in the intestines are 6.46 μg/mL and 3.83 μg/mL , respectively . Anal ysis of the 
ex vivo relatio nship between the NKG2D RO and the JNJ-64304500 serum concentration 
suggests that 90% RO is achieved when the JNJ-64304500 serum concentration is 3μg/mL. 
As a result , the PartIdose regimen is expected to result in approximately  99% NKG2D RO in 
the intestine (Table 5). Thus, the PartIdose regimen is expected to increase the probability  to 
achieve maximum clinical response while remaining within the acceptable safet y margins in 
subjects with Crohn’s disease.
Table 5: Predicted median serum JNJ -64304500 concentr ations and NKG2D receptor occupancy 
after administration of the selected dose regimens of JNJ -64304500
Dosing
Regimen 
(SC)JNJ-64304500 Serum Concentration 
(μg/m L)NKG2D Receptor Occupancy (%RO)
Parameter Value Week %RO in blood %RO in intestine
400 mg at 
Week 0 
then 200 
mg q2wCmax 64.64 - - -
Cmin (Week 8) 38.94 8 100 99
Ctrough
(steady state)38.31 24 100 99
400 mg 
(Wk0), 
200mg 
(Wks 2 &4) 
then 200 
mg q4wCmax 53.99 - - -
Cmin (Week 8) 18.95 8 100 97
Ctrough
(steady state)12.00 24 100 96
150 mg 
(Wk0), 
75mg 
(Wks 2 &4) 
then 75 mg 
q4wCmax 19.53 - - -
Cmin (Week 8) 6.34 8 100 91
Ctrough
(steady state)4.24 24 99 87
50 mg 
(Wk0),
25 mg 
(Wks 2 &4) 
then 25 mg 
q4wCmax 6.46 - - -
Cmin (Week 8) 1.77 8 97 76
Ctrough
(steady state)0.74 24 94 64
Cmax=maximum concentration; C min(Week 8)=concentration at Week 8 ; Ctrough (steady state)=steady state trough 
concentration ; NKG2D =natural killer group 2D; q2w=every 2 w eeks; q4w =every 4 weeks; %RO=percent 
receptor occupancy; SC=subcutaneous; Wk=Week
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 98
Approved , Date: 4 June 2021PART II
Three dose regimens of JNJ-64304500 (high, middle and low) have been selected for PartII 
which are expected to provide a wide range of systemic drug exposures in order to assess 
exposure -response relationship in subjects with Crohn’s disease. The loading doses at Week0, 2,
and 4 are intended to produce rapid onset of clinical response. Since the apparent terminal half-
life of JNJ-64304500 at the proposed dose regimens is about 2 to 3weeks, SC administration of 
JNJ-64304500 at 4 -week interval sfrom Week 4 through Week 20 is expected to produce median 
steady  state trough serum JNJ-64304500 concentrations that are likely to maintain clinical 
response in Crohn’s disease subjects. In addition, the PK/PD modeling results described below 
support the use of a4-week dosing interval in Part II.
The high dose regimen for PartII is 400mg at Week 0, 200 mg at Weeks 2 and 4, followed by 
200mg q4weeks through Week 20. This dose regimen is predicted to result in a median 
JNJ-64304500 Cmax in serum of 53.99 µg/mL, a median JNJ-64304500 serum concentration at 
Week 8 of 18.95 µg/mL , and a median trough serum JNJ -64304500 concentration at steady  state 
of 12.00µg/mL  in subjects with Crohn’s disease. Simulations results suggest that 89% of 
subjects on this high dose regimen are expected to maintain trough serum JNJ-64304500
concentrations >3µg/mL at stead y state, and the predicted median intestinal NKG2D RO is 
>96% ( Table 5).
The middle dose regimen for Part II is 150 mg SC at Week 0, 75 mg at Weeks 2 and 4, followed 
by 75 mg q4w through Week 20. This middle dose regimen is predicted to result in 
approximately  38% of the sy stemic exposure achieved with the high dose regimen. The predicted 
median intestinal NKG2D RO at stead y state is 87%.
The low dose regimen for Part II is 50mg SC at Week 0, 25mg at Weeks 2 and 4, followed by 
25mg q4weeks through Week 20. The low dose regimen is selected to explore the minimum 
effective dose of JNJ-64304500 in subjects with Crohn’s disease. The predicted median serum 
trough concentration of JNJ-64304500 at steady state is 0.74 μg/mL  which is predicted to result 
in a median NK G2D RO of 64% in the intestine. Furthermore, in the first -in-humans study  in RA 
subjects, a decrease in NKG2D expression on NK cells was not observed until the dose of 
JNJ-64304500 was 0.3mg/kg q2w, and decreases in NKG2D expression on both CD8+ T cells 
and NK cells were not observed until the dose was 1mg/kg q2w. These observations suggest 
that a dose regimen of at least 0.3mg/kg q2w may be required to produce pharmacological 
effects, and the selected low maintenance dose regimen of 25mg q4w would likely produce 
treatment effect at the lower part of the exposure -response curve.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 99
Approved , Date: [ADDRESS_1241608] characterization of 
the exposure -response relationship of JNJ -64304500 in the treatment of Crohn’s disease.
[IP_ADDRESS]. Ustekinumab
Results from the 2Phase 3 induction studies of IVustekinumab (Study CNTO1275CRD3001 in 
subjects with Crohn’s disease who failed 1 or more TNFα antagonists, and Study  
CNTO1275CRD3002 in subjects who failed conventional therap y with immunomodulators 
and/or corticosteroids) and 1 Phase 3 maintenance study  with SC ustekinumab 
(Study CNTO1275CRD3003 , which enrolled clinical responders from the 2IV induction 
studies) were used to determine the appropriate dose regimen of ustekinumab for t he treatment of 
Crohn’s disease. As a result, a single IV induction dose of 6 mg/kg ustekinumab (administered as 
body  weight -based tiered fixed doses, see Section 3.1.2 for details) at Week 0, followed by [CONTACT_887113] [ADDRESS_1241609] selection, refer to Section 11.1, 
Samp le Size Determination.
The following inclusion and exclusion criteria apply  to Part I and Part II within this protocol.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 100
Approved , Date: [ADDRESS_1241610] satisfy  all of the following criteria to be randomized in the study :
1.Be a man or woman [ADDRESS_1241611] Crohn’s disease or fistulizing Crohn’s disease of at least 3 months’ duration, with 
colitis, ileitis, or ileocolitis, confirmed at any time in the past by [CONTACT_485622] , histology , 
and/or endoscop y.
3.Have act ive Crohn’s disease, defined a s abaseline CDAI  score of 220 but450.
4.Have a t least one of the following at screening :
a.An abnormal CRP (>0.3 mg/dL [>3.0 mg/L ])
OR
b.Calprotectin >250 mg/kg.
5.Criterion modified per Amendment 2:
In Study 1of Part I, meet the following requirements for prior or current medications for 
Crohn’s disease:
a.Has previously  demonstrated inadequate response, loss of response, or intolerance to 1 
or more approved biologic therapi[INVESTIGATOR_014] (eg, infliximab, adalimumab, certolizumab pegol,
or vedolizumab) as outlined in Attachment 1.
In Study 2of Part I, meet the following requirements for prior or current medications for 
Crohn’s disease:
b.Has failed conventional therap y:
1)Is currentl y receiving corticosteroi ds and/or immunomodulators ( ie, AZA, 6-MP, or 
MTX) at adequate therapeutic doses (Attachment 2 ).
OR
2)Has a history  of failure to respond to or tolerate an adequate course of 
corticosteroids and/or immunomodulators (ie, AZA, 6-MP, or MTX)
(Attachment 2).
OR
3)Is corticosteroid dependent or has had a history  of corticosteroid dependency
(Attachment 2 ).
6.In Part II,meet the following requirement for prior or current medications for Crohn’s 
disease:
a.Has previously  demonstrated inadequate response, loss of response, or intolerance to 1 
or more approved biologic therapi[INVESTIGATOR_014] (eg, infliximab, adalimumab, certolizumab pegol, 
or vedolizumab) as outlined in Attachment 1.
OR
b.Has failed conventional therap y:
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 101
Approved , Date: 4 June [ZIP_CODE])Is currentl y receiving corticosteroids and/or immunomodulators (ie, AZA, 6 -MP, or 
MTX) at adequate therapeutic doses ( Attachment 2 ).
OR
2)Has a history  of failure to respond to or tolerate an adequate course of 
corticosteroids and/or immunomodulators (ie, AZA, 6-MP, or MTX) 
(Attachment 2).
OR
3)Is corticosteroid dependent or has had a history  of corticosteroid dependency  
(Attachment 2 ).
7.Adhere to the following requirements for concomitant medication for the treatment of 
Crohn's disease , which are permitted provided that doses meeting theserequirements are 
stable, or have been discontinued, for at least 3 weeks before baseline (Week 0), unless 
otherwise specified :
a.Oral 5-aminosalicy lic acid ( 5-ASA )compounds.
b.Oral corticosteroids at a prednisone -equivalent dose at or below 40 mg/day ,or 9 mg/day  
of budesonide , or 5 mg/day  beclomethasone dipropi[INVESTIGATOR_16847] .
c.Antibiotics being used as a primary  treatment of Crohn's disease.
d.Conventional immunomodulators (ie, AZA, 6-MP, or MTX): subjects must have been 
taking them for at least [ADDRESS_1241612] with a family  history of colorectal cancer, personal history  of increased colorectal 
cancer risk, age >[ADDRESS_1241613] be up-to-date on colorectal 
cancer surveillance (may  be performed during screening). Adenomatous polyps must be 
removed before the first administration of study  agent.
9.A subject who has had extensive colitis for ≥8 years, or disease limited to the left side of the 
colon for ≥[ADDRESS_1241614] results within the following parameters:
a.Hemoglobin ≥8.0g/dL.
b.White blood cell count ≥3.0×103/µL.
c.Neutrophils ≥1.5× 103/µL.
d.Platelets ≥100× 103/µL.
e.Serum creatinine <1.7 mg/dL.
f.Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) concentrations 
must be within 2 times the upper limit of the normal (ULN )range for the laboratory  
conducting the test.
g.Direct (conjugated) bilirubin <1.0 mg/dL.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 102
Approved , Date: 4 June 202111.Are considered eligible according to the following tuberculosis ( TB)screening criteria:
a.Have no history  of latent or active TB before screening. Exceptions are made for 
subjects currentl y receiving treatment for latent TB, if there is no evidence of active TB, 
or who have a history  of latent TB and documentation of having completed adequate 
treatment for latent TB within [ADDRESS_1241615] administration of study agent. It is 
the responsibility  of the investigator to verify  the adequacy  of previous TB treatment 
and provide appropriate documentation.
Note : The exceptions outlined above exclude subjects in countries with high 
multidrug -resistant TB burden (eg, Braz il, China, India, the Russian Federation, and 
South Africa) , due to potent ial concerns for multi -drug-resistant TB.
b.Have no signs or symptoms suggestive of active TB upon medical history  and/or 
physical examination.
c.Have had no recent close contact [CONTACT_4490] a person with active TB or, if there has been such 
contact, will be referred to a physician specializing in TB to undergo additional 
evaluation and, if warranted, receive appropriate treatment for latent TB before or 
simultaneously  with the first administrat ion of study  agent.
d.Criterion modified per Amendment [ADDRESS_1241616] administration of study  agent (except in countries 
with high multidrug -resistant TB burden [eg, Brazil, China, India, the Russian 
Federation, and South Africa ]), where subjects with a newl y identified positive 
QuantiFERON -TB test result are excluded). Indeterminate results should be 
handled as outlined in Section 9.1.[ADDRESS_1241617] 
(Attachment 3)is additionally  required if the QuantiFERON -TB test is not 
approved/registered in that country .A tuberculin skin test is recommended but not 
required for study  centers in countries where tuberculin is not available. The 
QuantiFERON -TB test is not required at screening for subjects with a history  of 
latent TB and appropriate treatment as described above in Inclusion Criterion 11a.
e.Have a chest radiograph (posterior -anterior and lateral views ), taken within [ADDRESS_1241618] a negative highl y sensitive serum (β-human 
chorionic gonadotropin [β-hCG]) pregnancy test result at screening and a negative urine 
pregnancy  test result at Week 0.
13.Before randomization, a female subject must be either:
a.Not of childbearing potent ial,defined as:
1)Premenarchal: A premenarchal state is one in which menarche has not yet occurred.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 103
Approved , Date: 4 June [ZIP_CODE])Postmenopausal : A postmenopausal state is defined as no menses for 12 months 
without an alternative medical cause. A high follicle -stimulating hormone level 
(>40 IU/L or mIU/mL )in the postmenopausal range may be used to confirm a 
postmenopausal state in women not using hormonal contraception or hormonal 
replacement therapy ; however, in the absence of 12 months of amenorrhea, a single 
follicle -stimulati ng hormone measurement is insufficient.
3)Permanently  sterile : Permanent sterilization methods include hysterectom y, 
bilateral salpi[INVESTIGATOR_8820] y, bilateral tubal occlusion/ligation procedures, and bilateral 
oophorectom y.
OR
b.Of childbearing potential and :
1)Practicing a highl y effective method of contraception (failure rate of <1% per year 
when used consistently  and correctl y), consistent with local regulations regarding 
the use of contraceptive methods for subjects participating in clinical studies.
Examples of highly  effective contraceptives include user-independent methods
such as implantable progestogen -only hormone contraception associated with 
inhibition of ovulation; intrauterine device (IUD); intrauterine hormone -releasing 
system (IUS); vasectomized partner; or sexual abstinence (considered a highly 
effective method only if defined as refraining from heterosexual intercourse during 
the entire period of risk associated with the study  drug, and if in line with the 
preferred and usual lifesty le of the subject); or user-dependent methods such as 
combined (estrogen -and progestogen -containing) hormonal contraception 
associated with inhibition of ovulation (oral, intravaginal, transdermal); or 
progestogen -only hormone contraception associated with inhibition of ovulation 
(oral, injectable). If using a hormone birth control method, a second method of 
birth control, such as a condom or diaphragm, must be used.
2)Agrees to remain on a highl y effective method of contraception throughout the 
study  and for at least 16weeks after the last administration of study  agent .
Note : If a subject’s childbearing potential changes after start of the study  (eg, a 
premenarchal woman experiences menarche) or the risk of pregnancy  changes (eg, a 
woman who is not heter osexually  active becomes active ),a woman must begin a highl y 
effective method of contraception, as described throughout the inclusion criteria.
14.A woman must agree not to donate eggs (ova, oocy tes) for the purposes of assisted 
reproduction during the study  and for a period of [ADDRESS_1241619] agree to use a 
barrier method of contraception (eg, condom with spermicidal 
foam/gel/film/cream/suppository ).
b.who is sexually  active with a pregnant woman must use a condom .
c.must agree not to donate sperm .
16.Be willing and able to adhere to the prohibitions and restrictions specified in this protocol.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 104
Approved , Date: [ADDRESS_1241620] sign an informed consent form (ICF) indicating that he or she understand sthe purpose 
of and procedures required for the stud y and is willing to participate in the study .
18.Criterion modified per Amendment 1.
18.[ADDRESS_1241621] who meets any  of the following criteria will be excluded from participating 
in the study :
1.Has complications of Crohn’s disease such as symptomatic strictures or stenoses, short gut 
syndrome, or any other manifestation that might be anticipated to require surgery , could 
preclude the use of the CDAI  to assess response to therapy , or would possibl y confound the 
ability  to assess the effect of treatment with JNJ-[ADDRESS_1241622] 3 weeks before baseline, or 
8weeks before baseline for intra-abdominal abscesses, provided that there is no anticipated 
need for any further surgery . Subjects with active fistulas may be included if there is no 
anticipation of a need for surgery  and there are cur rently  no abscesses identified.
3.Has had any kind of bowel resection within 6months or any other intra-abdominal surgery 
within 3 months before baseline.
4.Has a draining ( ie, functioning) stoma or ostom y.
5.Has received any of the following prescribed medicat ions or therapi[INVESTIGATOR_393362]:
a.IV corticosteroids <3 weeks before baseline.
b.Other oral immunomodulatory  agents (eg, 6-thioguanine [6-TG], cyclosporine, 
tacrolimus, sirolimus, or mycophenolate mofetil, tofacitinib and other Janus kinase 
[JAK ] inhibitors) <6 weeks or within 5 half-lives of agent before baseline, whichever is 
longer.
c.Nonbiologic experimental or investigational agents <4weeks or within 5half-lives of 
agent before baseline, whichever is longer.
d.Nonautologous stem cell therap y (eg, Proch ymal), natalizumab, efalizumab, or biologic 
agents that deplete B or T cells (eg, rituximab, alemtuzumab, or visilizumab) 
<12months before baseline.
e.TNF α-antagonist biologic agents (eg, monoclonal antibody therapi[INVESTIGATOR_014]) or other agents 
intended to s uppress or eliminate TNF α<8weeks before baseline.
f.Vedolizumab <16 weeks before baseline.
g.Other immunomodulatory  biologic agents <12 weeks or within 5 half-lives of agent 
before baseline, whichever is longer.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 105
Approved , Date: 4 June 2021h.Treatment with apheresis ( eg, Adacolumn aphere sis)<3 weeks before baseline .
i.Initiation of total (complete) or partial (supplemental) parenteral nutrition administered 
through any indwelling catheter <3 weeks before baseline or anticipated to require 
parenteral nutrition administered through an indwel ling catheter during enrollment in 
the study .
j.Initiation of enteral therapy  for Crohn’s disease (liquid nutritional formula comprising 
≥80% of total caloric intake administered throug h the gastrointestinal tract) <3 weeks 
before baseline. Subjects who are on a stable regimen of enteral feeds ≥3 weeks before 
baseline may be considered for enrollment if they plan to continue enteral feeds as 
treatment for Crohn’s disease through the duration of the study  (Week 24, Part I or 
Part II).
6.Hasa stool culture or other examination positive for an enteric pathogen, including 
Clostridium difficile toxin, in the last 4 months unless a repeat examination is negative and 
there are no signs of ongoing infection with that pathogen.
7.Has previousl y received a biologic agent targeting IL-12 or IL-23, including but not limited 
to ustekinumab or briakinumab (ABT -874).
8.Has previousl y received JNJ -64304500 or NNC0142 -002.
9.Has received a Bacille Calmette -Guérin (BCG) vaccination within [ADDRESS_1241623] infection 
(eg, recurrent pyelonephritis or chronic nonremitting cystitis), or open, draining, or infected 
skin wounds or ulcers.
11.Has current signs or symptoms of infection. Established nonserious infections (eg, acute 
upper respi[INVESTIGATOR_2826], simple urinary tract infection) need not be considered 
exclusionary  at the discretion of the investigator.
12.Has a history  of serious infection (eg,sepsis, pneumonia, or pyelonephritis), including any 
infection requiring hospi[INVESTIGATOR_26109] I V antibiotics, for 8 weeks beforebaseline.
13.Has evidence of a Herpes zoster infection [ADDRESS_1241624] radiograph, unless definitively 
resolved surgically  or by [CONTACT_393388].
16.Has or ever has had a nontuberculous mycobacterial infection or serious opportunistic 
infection ( eg, cytomegalovirus colitis, Pneumocystis carinii , aspergillosis).
17.Hasa history  of human immunodeficiency  virus (HIV) antibody  positiv ity, or tests positive 
for HIV at screening.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 106
Approved , Date: 4 June 202118.Are seropositive for antibodies to hepatitis C virus (HCV) without a history of successful 
treatment, defined as being negative for HCV RNA at least [ADDRESS_1241625] undergo screening for hepatitis B virus (HBV). At a minimum, this includes 
testing for HBV surface antigen (HBsAg), HBV su rface antibody  (anti-HBs), and HBV core 
antibody  (anti -HBc) total:
a.Subjects who test negative for all HBV screening tests (ie, HBsAg -, anti-HBc-, and 
anti-HBs-) are eligible for this study .
b.Subjects who test positive for surface antigen (HBsAg+) are not eligible for this study , 
regardless of the results of other hepatitis B tests.
c.Subjects who test negative for surface antigen (HBsAg -) and test positive for core 
antibody  (anti -HBc+) and surface antibody  (anti -HBs+) are eligible for this study .
d.Subjects who test positive only for surface antibody  (anti-HBs+) are eligible for this 
study .
e.Subjects who test positive only for core antibody  (anti-HBc+) must undergo further 
testing for hepatitis B DNA acid (HBV DNA test). If the HBV DNA test is positive, the 
subject is not eligible for this study . If the HBV DNA test is negative, the subject is 
eligibl e for this study . In the event the HBV DNA test cannot be performed, the subject 
is not eligible for this study .
Note: For subjects who are not eligible for this study due to HIV, HCV, and HBV test 
results, consultation with a physician with expertise in the treatment of those infections is 
recommended.
20.Has severe, progressive, or uncontrolled renal, hepatic, hematological, endocrine, 
pulmonary , cardiac, neurologic, cerebral, or psychiatric disease, or signs and symptoms 
thereof.
21.Has a transplanted organ (with exception of a corneal transplant >12 weeks before
screening).
22.Has a known history  of lymphoproliferative disease, including monoclonal gammopath y of 
unknown significance (MGUS), lymphoma, or signs and symptoms suggestive of possible 
lymphoproliferative disease, such as l ymphadenopathy  and/or splenomegaly .
23.Has any known malignancy  or has a history  of malignancy  (with the exception of basal cell 
carcinoma; squamous cell carcinoma in situ of the skin; or cervical carcinoma in situ that 
has been treated with no evidence of recurrence; or squamous cell carcinoma of the skin that 
has been treated with no evidence of recurrence within 5 y ears before screening).
24.Is unable or unwilling to undergo multiple venipunctures because of poor tolerability  or lack 
of eas y access to veins.
25.Is known to have had a substance abuse (drug or alcohol) problem within the previous 
12months before baseline.
26.Has known allergies, hypersensitiv ity, or intolerance toJNJ-64304500 or ustekinumab or 
any of their excipi[INVESTIGATOR_840] (refer to I Bs).
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 107
Approved , Date: [ADDRESS_1241626] (eg, compromise the well-being) of the subject or that could prevent, limit, 
or confound the protocol -specified assessments.
30.Is an employ ee of the investigator or study  site, with direct involvement in the proposed 
study  or other studies under the direction of that investigator or study  site, as well as family 
members of the emplo yees or the investigator.
NOTE: Investigators should ensure that all study enrollment criteria have been met at screening. 
If a subject's clinical status changes (including any available laboratory  results or receipt of 
additional medical records) after screening but before the first dose of study  drug is given, such 
that he or she no longer meets all eligibility  criteria, then the subject should be excluded from 
participation in the study . Section 9.1.[ADDRESS_1241627] developed Crohn’s disease complications which may be 
anticipated to require surgery  in the next [ADDRESS_1241628] be willing and able to adhere to the following prohibitions and 
restrictions during the course of the stud y to be eligible for participation:
1.Subjects must agree to follow the contraceptive requirements noted in the Inc lusion Criteria.
2.Subjects must not receive ustekinumab outside of this protocol or participate in any other 
clinical study  with an investigational agent while in this study , and must terminate study  
participation if they do. A subject who intend sto partic ipate in any other clinical study  with 
an investigational agent should undergo an early  termination visit before he or she 
withdraws from stud y participation .
3.Subjects must agree not to receive a live virus or live bacterial vaccination, including a BCG 
vaccination, during the study  and for [ADDRESS_1241629] of prohibited therapi[INVESTIGATOR_443182] 8.2.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 108
Approved , Date: 4 June [ZIP_CODE]. TREA TMENT ALLOCA TION AND BLINDING
5.1. Treatment A llocation
Central randomization will be implemented in this study . Subjects will be randomly  assigned to 
1 of 2 treatment groups (1:1 ratio) inPart I andto1 of 5 treatment groups (1:1:1:1:1 ratio) in 
PartII,based on a computer -generated randomization schedule prepared before the study  by [CONTACT_170166]. Each of the 2studies will have separate randomizations . 
Each randomization will be balanced by [CONTACT_887114] (≤300 or >300) and SNP-positive status (yes or no)(Part II will also be 
stratified by [CONTACT_44313]-IR status [yes or no]). The interactive web response system (IWRS) will assign 
a unique treatment code, which will dictate the treatment assignment and matching study  drug kit 
for the subject. The requestor must use his or her own user identification and personal 
identification number when contact[CONTACT_170482], and will then give the relevant subject details 
to uniquely  identify  the subject.
5.2. Blinding
To maintain the study  blind, the study  agent container will have a label containing the study 
name [CONTACT_887140] . The label will not identi fy the study  agent in 
the container. The medication number or syringe number will be entered in the case report form 
(CRF) when the drug is dispensed. The study agents will be identical in appearance and 
packaging.
Planned efficacy  and safety  evaluations will be performed after thefollowing planned DBLs
(additional DBLs may  occur and would be described in the SAP):
Interim analysis lock for Part I:Occurs when 100 randomized subjects (Bio-IR and Bio-
NF)in Part I have completed their W eek [ADDRESS_1241630] terminated th eir study  participation 
before W eek 12.
Week 12 DBL for Part I:Occurs when all subjects inPart Ihave completed their W eek [ADDRESS_1241631] terminated th eir study  participation before W eek 12.
Final DBL for Part I:Occurs when all Part I subjects have completed their final efficacy 
and safet y visit or have terminated their study  participation before the final efficacy  and 
safet y visit.
Week 12 DBL for Part II:Occurs when all Part II subjects have completed their Week [ADDRESS_1241632] terminated their study  participation before Week 12.
Week 24 DBL for Part II:Occurs when all Part II subjects have completed their Week [ADDRESS_1241633] terminated their study  participation before Week 24.
Final DBL for Part II:Occurs when all Part II subjects who entered the Part II LTE have 
completed their final safet y visit in the Part II LTE or have terminated their study 
participation before the final safet y visit in the Part II LTE.
At the time ofthe interim analy sis lock for Part I,a limited number of sponsor personnel will 
become unblinded to treatment assignment. At the time of the Week [ADDRESS_1241634] interactions with the 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 109
Approved , Date: [ADDRESS_1241635] assessments.
Data that may  potentially unblind the treatment assignment ( ie, study  drug serum concentrations, 
anti-drug an tibodies, treatment allocation, and study  drug preparation/accountability  data) will be 
handled with special care to ensure that the integrity  of the blind is maintained and the potential 
for bias is minimized. In particular, before unblinding, this information will be available only to 
a limited number of data management staff for purposes of data cleaning, and if applicable, to 
quality  assurance re presentatives for the purposes of conducting independent drug audits.
The SNP status and postbaseline results of CRP, fecal lactoferrin, and fecal calprotectin tests will 
be blinded to the investigative site. If an investigative site requests these data, i t will be provided 
to them after the final analy ses have been completed.
The designated pharmacists, or other appropriately  licensed and authorized personnel, and 
independent drug monitors will be unblinded to study  agent. Placebo infusions/injections will
have the same appearance as the ustekinumab infusions/JNJ -[ADDRESS_1241636].
For bioanal ytical purposes, before the PK, anti-drug antibody , and PDbioanalysesare initiated , 
the unblinded data management team will provide the sponsor bioanal ysts with the information 
about which treatment (JNJ-64304500, ustekinumab, or placebo) the subjects receive d, but not 
the dose level to which the subjects are rando mized. For the purpose of performing PK, 
immunogenicit y, and PD bioanal yses, bioanal ysts in Biologics Clinical Pharmacology  at Janssen 
will be unblinded to treatment -level data (JNJ -64304500, ustekinumab, or placebo) at the time of 
analyzing serum samples for the determination of drug concentrations ,detection of antibodies to 
study  agents , or PD assessments . Samples will be separated based on treatment administered; 
subject identification and dose given will not be disclosed.
Additionally , a given subject’s treatment assignment may be unblinded to the sponsor, 
Institutional Review Board/Independent Ethics Committee (IRB/IEC), and site personnel to 
fulfill regulatory  reporting requirements for suspected unexpected serious advers e reactions 
(S[LOCATION_003]Rs).
The investigator will not be provided with randomization codes. The codes will be maintained 
within the IWRS, which has the functionality  to allow the investigator to break the blind for an 
individual subject.
Under normal circumstanc es, the blind should not be broken until the final analyses have been 
completed for all subjects. Otherwise, the blind should be broken only if specific emergency 
treatment/course of action would be dictated by [CONTACT_169762]. In 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 110
Approved , Date: [ADDRESS_1241637]'s source documents in a secure manner so as to not unblind the 
study site monitor. The investigators are advised not to reveal the study  treatment assignment to 
the study  site monitor or to sponsor personnel.
A separate code -break procedure will be available for use by [CONTACT_887115] y with specific requests from 
regulatory  or health authorities.
Subjects who have had their treatment assignment unblinded will be discontinued from further 
study  agent administration but should continue to return for scheduled evaluations (Section 10).
6. DOSA GE A ND A DMINISTR ATION
Subcutaneous injections of study  agent should be administered at different locations at each visit 
at which study  agent is administered to allow for assessment of potential injection -site reactions.
6.1. Part I
In Part I of the study  (Figure 2), all subjects will receive either placebo SC or JNJ-64304500 
400mg SC at Week 0 and placebo SC or JNJ-64304500 200mg SC at Weeks 2, 4,6, 8, 10, 12, 
14, 16, 18, 20, and 22, with the exception of placebo nonresponders at Week 12.Placebo 
nonresponders will receive JNJ -64304500 400 mg SC at Week 12 and JNJ -64304500 200 mg SC 
at Weeks 14, 16, 18, 20, and 22. Study  drug concentration in Part I is 100 mg/mL .
To maintain the blind in Part I, all subjects will receive 4 SC injections at Weeks 0 and 12, and 
2SC injections at Weeks 2, 4, 6, 8, 10, 14, 16, 18, 20, and 22.
6.2. Part II
In Part II of the study  (Figure 3), subjects will be randomly  assigned in equal proportions to 
receive placebo, 1of 3 dose regimens of JNJ -64304500, or ustekinumab, as follows:
Placebo : Placebo SC at Weeks 0, 2, 4, 8, 12, 16, and 20.Placebo nonresponders at Week 12 
will receive JNJ-64304500 150mg SC at Week 12 and JNJ-64304500 75 mg SC at 
Weeks 14, 16, and 20.
JNJ-64304500 high dose: 400 mg SC at Week 0 and 200 mg SC at Weeks 2, 4, 8, 12, 16, 
and 20 (study drug concentratio n=100 mg/mL ).
JNJ-64304500 middle dose: 150 mg SC at Week 0 and 75 mg SC at Weeks 2, 4, 8, 12, 16, 
and 20 (study drug concentration =75 mg/mL ).
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 111
Approved , Date: 4 June 2021JNJ-64304500 low dose: 50mg SC at Week 0 and 25 mg SC at Weeks 2, 4, 8, 12, 16, 
and20 (study drug concentration =25 mg/mL ).
Ustekinumab: tiered doses approximating 6mg/kg IV(Section 3.1.2 )at Week 0and 90mg 
SC at Weeks [ADDRESS_1241638] will be eligible to receive up 
to 52 weeks of additional study  drug (for a total of up to 72 weeks of study  drug in Part II). The 
first dose of study  drug within the Part II LTE will be administered after the Week [ADDRESS_1241639] been completed. The dose may be administe red on the same day as the 
Week 24 assessments, or may  be administered on a later date, as long as the dose is administered 
within the Week 24 visit window.
Subjects will continue to receive the same treatment regimen during the Part II LTE that they 
were receiving between Week 12 and Week 20 in the main study  phase of Part II (placebo, high, 
middle, low dose JNJ-64304500 ,or ustekinumab). To maintain the study  blind, all patients, 
investigators, and sites will remain blinded to treatment allocation during the Part II LTE until 
the last subject in the Part II main study  phase has completed the Week [ADDRESS_1241640]’s unblinding during the Part II LTE will depend upon his/her 
Part II enrollment date. Therefore, a portion of subjects will complete the entire Part II LTE in a 
blinded fashion before study  unblinding, while other subjects could be unblin ded to treatment 
allocation during their participation in the Part II LTE.
On [ADDRESS_1241641] dose of study  drug. For subjects that remain in the 
Part II LTE at the time of study  unblinding, continuation of study  drug during the Part II LTE 
will be dependent upon treatment allocation as follows:
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 112
Approved , Date: 4 June 2021JNJ-64304500: Subjects receiving JNJ-[ADDRESS_1241642] dose of study  drug.
Placebo: Subjects receiving placebo who remain in the Part II LTE at the time of study  
unblinding will have their final safet y follow -up visit subsequent to unblinding and will be 
discontinued from the study . No further follow -up visits will be performed.
Ustekinum ab:Subjects receiving ustekinumab will continue to receive it during the Part II 
LTE until unblinding occurs. After unblinding, based on the treating physician’s clinical 
judgment , subjects may  receive ustekinumab in a manner dependent on the country  in w hich 
they are located:
oIf a subject is not continuing on ustekinumab after unblinding, the subject will need 
to return for a final safety  follow -up visit that will be performed [ADDRESS_1241643] continues on ustekinumab in a country where commercial ustekinumab 
is available and approved forthe treatment ofadult Crohn’s disease, the treating 
physician is responsible for providing the subject with commercial ustekinumab, 
which should be administered according to the approved dosing regimen in each 
country . The final safet y follow -up visit should be performed after unblinding but 
before receiving the first dose of commercial ustekinumab.
oIf a subject continues on ustekinumab in countries where commercial ustekinu mab 
is not available or approved for adult Crohn’s disease, ustekinumab will continue to 
be provided to subjects through Week 72.
For eligible Part II subjects, participation in the Part II LTE is entirely  voluntary . Eligible 
subjects who do not wish to enter the Part II LTE will complete the Part II Week 24 safet y and 
efficacy  assessments, followed by  [CONTACT_887110] y assessments at Week 36.
During the Part II LTE, all concomitant medications, including Crohn’s disease -specific 
medications (except for the prohibited medications listed in Section 8.2) may be administered at 
the discretion of the investigator.
All subjects in the Part II LTE (before unbli nding for JNJ-64304500, ustekinumab, and placebo 
and after unblinding for JNJ 64304500) will be assessed according to the Time & Events 
Schedule (Table 3), which includes assessments, AEs, laboratory  analyses, and PK and 
immunogenicit y samples. Ustekinumab subjects in the Part II LTE (after unblinding for 
ustekinumab subjects in countries where ustekinumab is not commercially  available) will be 
assessed according to the Time & Events Schedule (Table 4), which includes assessments and 
AEs.
7. TREA TMENT COMPLIA NCE
Study  agent will be administered as an IV infusion or SC injection by [CONTACT_3436]. The details 
of each administration will be recorded in the CRF. For IV infusions, this will include date and 
start and stop times of the IV infusion and volume infused; for SC injections, this will include 
date and time of SC i njection.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 113
Approved , Date: [ADDRESS_1241644] study  visit.
All therapi[INVESTIGATOR_014] (prescription or over-the-counter medications, including vaccines, vitamins, herbal 
supplements; non-pharmacologic therapi[INVESTIGATOR_23719], acupuncture, special 
diets, exercise regimens) different from the study drug must be recorded in the CRF.Recorded 
information will include a description of thetype of therap y, treatment period, dosage, route of 
administration, and indication. Modification of an effective pre-existing therap y should not be 
made for the explicit purpose of entering a subject into the study .
8.1. Concomitant Medications
Subjects who are receiving oral 5-ASA compounds, oral corticosteroids, conventional 
immunomodulators (ie, AZA, 6-MP, orMTX ), enteral therapy ,and/or antibiotics for the 
treatment of Crohn’s disease at baseline should maintain a stable dose for a specified period 
before baseline , as defined in the Inclusion Criteria (Section 4.1).
With the exception of oral corticosteroids, subjects who are receiving these medications for 
Crohn’s disease at baseline should maintain a stable dose through the final efficacy  and safety  
visit.Corticosteroids m ust be maintained at baseline doses through Week 12(see Section 8.1.1 ).
Randomized subjects should not initiate any of the following Crohn’s disease -specific medical 
therapi[INVESTIGATOR_887068] :
Oral or rectal 5 -ASA compounds.
Immunomodulators ( ie, AZA, 6 -MP, or MTX).
Oral, parent eral, or rectal corticosteroids.
Antibiotics as a treatment for Crohn’s disease.
Total (complete) or partial (supplemental) parenteral nutrition administered through an 
indwelling catheter as a treatment for Crohn’s disease.
Enteral therapy  (liquid nutritional formula comprising ≥80% of total caloric intake) as 
treatme nt for Crohn’s disease.
If the above medications are initiated or medication doses are changed, subjects should continue 
to attend all study  visits and have all assessments. Ifdue to medical necessity  in the opi[INVESTIGATOR_13046], the above medicati ons are initiated or medication doses are changed, this does 
not represent a deviation from the study  protocol but may  be considered a treatment failure .
After Week 12, subjects may transiently  use (ie, for <4 weeks) increased doses of corticosteroids 
for reasons other than worsening of Crohn’s disease (eg, stress doses of corticosteroids for 
surgery , asthma, adrenocortical insufficiency ).
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 114
Approved , Date: 4 June 2021Subjects participating in the Part II LTE may continue receiving concomitant medications they 
were receiving at the time of Part II Week 24, including aminosalicy lates, immunomodulatory  
agents (including 6-MP/AZA, MTX), enteral therap y,and corticosteroids. During thePart II
LTE, these medications may be initiated, discontinued, or dose adjusted at the investig ator’s 
discretion.
8.1.1. Corticosteroid Tapering
In Part I and Part II, subjects who are receiving corticosteroids at Week 0 and who are in clinical 
response at Week 12 are encouraged to initiate corticosteroid tapering at the Week 12 visit, using  
the tapering schedules described below. Other subjects should remain on their original 
corticosteroid dose through Week 24unless a change in corticosteroid dose is considered 
medically  necessary  (eg, for corticosteroid side effects).
For subjects who experience a worse ning of disease activit y while tapering, further dose 
decreases may be suspended and/or their oral corticosteroid dose increased if deemed necessary  
by [CONTACT_093]. The oral corticosteroid dose, however, may not be increased above the 
baseline dose un less due to medical necessit y (Section 8.1).
During the Part II LTE, corticosteroids may be initiated, discontinued, or dose adjusted at the 
investi gator’s discretion.
Tapering Schedule for Oral Prednisone (or Equivalent)
Dose >15mg/day prednisone or equivalent: taper daily  dose by 5mg/week until receiving 
10 mg/day , then continue tapering at 2.5 mg/week until 0 mg/day .
Dose 11 to 15mg/day prednisone or equivalent: taper daily dose to 10mg/day for 1week, 
then continue tapering at 2.5 mg/week until 0 mg/day .
Dose ≤10mg/day  prednisone or equivalent: taper daily  dose b y 2.5 mg/week until 0 mg/day .
Tapering Schedule for Oral Budesonide or Bec lomethasone
Tapering of budesonide or beclomethasone dipropi[INVESTIGATOR_887069].
8.2. Prohibited Medications
Randomized subjects must not initiate any of the following prohibited medications at any time 
during Part I, Part II ,or the Part II LTE:
Immunomodulatory  agents other than 6-MP/AZA or MTX (including but not limited to 
6-TG, cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, tofacitinib ,and other 
JAK inhibitors).
Immunomodulatory  biologic agents (including but not limited to tumor necrosis factor 
[TNF ]antagonists, natalizumab, abatacept, vedolizumab).
Experimental Crohn’s disease medications (including but not limited to thalidomide, 
briakinumab, traficet, brodalumab [AMG 827]). Ustekinumab is permitted in Part II of this
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 115
Approved , Date: [ADDRESS_1241645] be notified in advance (or as soon as possible thereafter) of any instances in 
which prohibited therapi[INVESTIGATOR_23730].
9. STUDY EVA LUATIONS
9.1. Study Procedures
9.1.1. Overview
The Time and Events Schedule s summarize the freque ncy and timing of efficacy , PK, 
immunogenicit y, PD, pharmacogenomic, medical resource utilization, and safet y measurements 
applicable to this study (Table 1, Table 2,Table 3).The Time and Events Schedules for the LTE 
after unblinding for ustekinumab subjects in countries where ustekinumab is not commerciall y 
available ( Table 4) includes safet y assessments.
It is recommended that all visit-specific PRO assessments be conducted before any tests, 
procedures, or other consultations to prevent influencing subject perceptions .
The maximum amount of blood drawn from each subject in this study  will be approximately 
330mL.
9.1.2. Screening P eriod
At the screening visit, written informed consent must be obtained from the subject for this study  
by [CONTACT_458] [INVESTIGATOR_887070] -specific procedure.
Procedures to be performed at the screening visit are outlined in the Time and Events Schedules
(Table 1, Table 2).
The CDAI diary  will be completed by [CONTACT_887116]. The investigator or 
appropriate site personnel will use the hematocrit value obtained during screening to calcu late 
the CDAI score at Week 0.
The screening period should be a minimum of [ADDRESS_1241646] 
enough data to support CDAI calculation.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 116
Approved , Date: [ADDRESS_1241647] be reminded that they are required to use ahighly  effective method of 
contraception during the study  (as described in Inclusion Criterion 13) and must continue taking 
such precautions for 16weeks after receiving the last administration of study  agent. The 
method(s) of contraception used by  [CONTACT_41012].
Subject s must undergo testing for TB (Attachment 3) and their medical history  assessment must 
include specific questions about a history  of TB or known occupational or other personal 
exposure to individuals with active TB. The subje ct should be asked about past testing for TB, 
including chest radiograph results and responses to tuberculin skin or other TB testing.
Subjects with a negative QuantiFERON -TB test result (and a negative tuberculin skin test result 
in countries in which the QuantiFERON -TB test is not approved/registered or the tuberculin skin 
is mandated by [CONTACT_72952] ) are eligible to continue with prerandomization 
procedures. A tuberculin skin test is recommended but not required for study  centers in countries
where tuberculin is not available. Subjects with a newly  identified positive QuantiFERON -TB 
(or tuberculin skin) test result must undergo an evaluation to rule out active TB and initiate 
appropriate treatment for latent TB. Appropriate treatment for laten t TB is defined according to 
local country  guidelines for immunocompromised patients. If no local country  guidelines for 
immunocompromised patients exist, US guidelines must be followed , or the subject will be 
excluded from the study . Note: Subjects in countries with high multidrug -resistant TB burden 
(eg, Brazil, China, India, the Russian Federation, and South Africa ) identified with latent TB at 
screening will be excluded from participating in the study .
A subject whose first QuantiFERON -TB test result isindeterminate should have the test 
repeated. In the event that the second QuantiFERON -TB test result is also indeterminate, the 
subject may berandomized without treatment for latent TB if his/her chest radiograph shows no 
abnormality  suggestive of TB (active or old, inactive TB) and the subject has no additional risk 
factors for TB as determined by  [CONTACT_173875].
Note: Subjects in countries with high multidrug -resistant TB burden (eg, Brazil, China, India, 
the Russian Federation, and South Africa ) with a repeat indeterminate QuantiFERON -TB test 
result will be excluded from participating in the study , unless his/her chest radiograph shows no 
abnormality  suggestive of TB (active or old, inactive TB), there are no additional risk factors for 
TB as determined by [CONTACT_173875], and he/she has a negative tuberculin 
skin test result within the 2months before baseline, in which case he/she may be randomized 
without treatment for latent TB.
An assessment of all screening laboratory  test results, clinical data, and concomitant medication 
data will be made by  [CONTACT_458] [INVESTIGATOR_887071].
9.1.3. Double -Blind Treatment P eriod
In Par t I, the visit window should be ±4 day s for each visit. In Part II, the visit window should be 
±4days, from the Week 0 visit up to and in cluding the Week 12visit, and ± 7days from Week 16 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 117
Approved , Date: 4 June 2021until the end of the study . Procedures to be performed at each visit are outlined in the Time and 
Events Schedules (Table 1, Table 2). Unless otherwise specified, all procedures are to be 
conducted before stud y agent administration.
Study  agent should not be administered to a subject with a clinically  important, active infection.
Each subject must be instructed to complete the CDAI  diary card daily during the study , except 
during the Part II LTE .
9.1.4. Final Efficacy  and Safety Follow -up Visit
Subjects in Part I should complete the final efficacy  and safet y follow -up visit approximately  [ADDRESS_1241648] study  agent administration (Table 1). Subjects in Part II who are not 
continuing into the Part II LTE should comple te the final efficacy  and safet y follow -up visit 
approximately  [ADDRESS_1241649] dose of study  drug(Table 2). Subjects in the 
PartII LTE should complete the final safet y follow -up visit appro ximately  [ADDRESS_1241650] dose of study  drug(Table 3).Subjects in the Part II LTE on ustekinumab after 
unblinding will not require a safet y follow -up visit. Placebo subjects who remain in thePartII
LTE at the time of study  unblinding will have their final safet y follow -up visit subsequent to 
unblinding and will be discontin ued from the study .
9.2. Efficacy Evaluations
The CDAI  will be the primary  tool for assessing disease activity  response to JNJ-64304500 , 
along with PRO -2, PRO -3, Bristol stool form scale, abdominal pain based on NRS 0-10 scale , 
PGIS of Crohn’s disease , and PGIC of severit y of Crohn’s disease . The degree of inflammation 
will be assessed by [CONTACT_887097]. Stool samples will be collected and 
analyzed to evaluate changes in markers that may reflect JNJ-64304500 or ustekinumab 
treatment .The well-being of subjects will be measured using the IBDQ and the SF-36. 
Endos copic improvement will be assessed by [CONTACT_218758] . For subjects with fistulizing  
disease, fistula closure will also be assessed.
9.2.1. Crohn’s Disease A ctivity Index
The CDAI  will be assessed by [CONTACT_393396] 8 different Crohn’s disease -related 
variables (Attachment 4):1extra -intestinal manifestations, abdominal mass, weight, hematocrit, 
total number of liquid stools, abdominal pain/crampi[INVESTIGATOR_007], use of antidiarrheal drug(s) and/or 
opi[INVESTIGATOR_858], and general well-being. The last [ADDRESS_1241651]. The PRO -2 score is based on the CDAI  components of the total number of liquid 
stools and abdominal pain/crampi[INVESTIGATOR_007]. The PRO -[ADDRESS_1241652] sare to comple tea dail y diary 
entry  and bring the diary  to each visit .
9.2.2. Bristol Stool Form Scale
The Bristol stool form scaleis a medical aid to classify  the form (or consistency ) of human feces
into 7 categories.8It has been used as a research tool to evaluate the effectiveness of treatments 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 118
Approved , Date: 4 June 2021for various diseases of the bowel (eg, irritable bowel syndrome).4Subject swill complete the 
Bristol stool form scale as a daily  diary  entry  and bring the diary  to each visit up to Week 12 .
9.2.3. Abdominal Pain Numerical Rating Scale
The NRS for pain is a unidimensional meas ure of pain intensit y in adults .5An 11-point (0-10) 
NRS will be used to evaluate abdominal pain. The score of 0 represents “no abdominal pain” and 
the score of 10 represents the “worst possible abdominal pain”,with greater scores indicating 
greater pain severity  and intensity . Subjects will select only one number that best reflects their 
pain at its worst in the past 24 hours . The abdominal pain NRS will be assessed daily.Subjects 
will complete the NRS at approximately  the same time each day before going to bed and bring 
the diary  to each visit.
9.2.4. Patient’s Global Impression of Severity of Crohn’s Disease
The PGIS of Crohn’s disease is a 5-point scale (“None”, “Mild”, “Moderate”, “Severe” and 
“Ver y Severe”) to rate Crohn’s disease intensity . Subjects will rate their PGI S of Crohn’s disease
at Weeks 0, 4, 8, 12, and 24 .
9.2.5. Patient’s Global Impression of Change of Severity of Crohn’s Disease
The PGIC of severit y of Crohn’s disease is a 7-point scale ranging from “a lot better now” to “a 
lot worse now” with a neutral center point (“neither better nor worse”) to measure perceived 
change (improvement or deterioration) in severity  of Croh n’s disease . Subjects will assess their 
PGIC of severit y of Crohn’s disease at Weeks 4, 8, 12, and 24.
9.2.6. C-Reactive Protein
C-reactive protein has been demonstrated to be useful as a marker of inflammation in patients 
with inflammatory  bowel disease (IBD). In Crohn’s disease, elevated CRP concentrations have 
been associated with severe clinical activity , elevated sedimentation rate, and active disease as 
detected by [CONTACT_887117] y.10,11Blood samples for the measurement of CRP will be collected from 
all subjects at visits indicated in the Time and Events Schedule. CRP will be assay ed using a 
validated, high sensitivity  CRP assay . Results of postbaseline CRP measurement will not be 
released to the investigators by  [CONTACT_2237] .
9.2.7. Fecal Lactoferrin and Calprotectin
Fecal lactoferrin and fecal calprotectin have been demonstrated to be sensitive and specific 
markers in identify ing intestinal inflammation and response to treatment in patients with I BD.2,3,7
Stool samples for fecal lactoferrin and calprotectin concentrations will be collected from all 
subjects at visits indicated in the Time and Events Schedule s. Assay s for fecal lactoferrin and 
calprotectin concentrations will be performed using a validated method. Additional tests may 
also be performed on the stool samples for additional markers related to intestinal inflammation 
and treatment response such as the microbiome. Results of postbaseline fecal lactoferrin and 
calprotectin tests will not be released to the investigators b y the central laboratory .
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 119
Approved , Date: 4 June [ZIP_CODE].2.8. Inflammatory  Bowel Disease Questionnaire
The IBDQ6is a 32-item self-report questionnaire for subjects with IBD to evaluat e the PROs 
across 4 dimensions: bowel symptoms (loose stools, abdominal pain), systemic symptoms 
(fatigue, altered sleep pattern), social function (work attendance, need to cancel social events), 
and emotional function (anger, depression, irritability ). Scores range from 32 to 224 with higher 
scores indicating better outcomes.
9.2.9. 36-Item Short Form Health Survey
The SF -36 was developed to measure the general health status with 8 functional domain scales.
Limitations in phy sical functioning due to health proble ms.
Limitations in usual role activities due to phy sical health problems.
Bodily  pain.
General mental health (psy chological distress and well -being).
Limitations in usual role activities due to personal or emotional problems.
Limitations in social function ing due to ph ysical or mental health problems.
Vitality  (energy  and fatigue).
General health perception.
Based on the [ADDRESS_1241653] deviations (SD)
of 10, based on general US population norms.12The concepts measured by [CONTACT_20763]-36 are not 
specific to any age, disease, or treatment group, allowing comparison of relative burden of 
different diseases and the relative benefit of different treatments .13
9.2.10. Fistula A ssessment
Subjects will be assessed for fistulas. For subjects with fistulizing disease, fistula closure will be 
assessed. Enterocutaneous fistulas (eg, perianal and abdominal) will be considered no longer 
draining (ie, closed) when there is absence of drainage despi[INVESTIGATOR_393368]. Rectovaginal 
fistulas will be considered closed based on either physical examination or absence of relevant 
symptoms ( eg, passag e of rectal material or flatus from the vagina).
9.2.11. Endoscopic Endpoints
Endoscopic improvement will be assessed during endoscop y (ileocolonoscopy ). A video 
ileocolonoscopic examination will be performed to determine the presence or absence of 
mucosal inflamm ation and ulceration at screening and Week 12, and Week 24(optional in 
PartI), according to the Study Reference Manual provided to each site; if the video 
ileocolonoscopic examination is not performed on the day of the visit, it must be performed at 
least 8 days before the Week 0 visit and no more than 8 days before the Week 12 visit. The 
Week 24 video ileocolonoscop y in Part I is suggested but not required ; if performed, it should 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 120
Approved , Date: 4 June 2021occur not more than 8 days before the Week 24 visit.The video ileocolonoscopy will not be 
performed at Week 24 in Part II. Video endoscopi[INVESTIGATOR_887072] a central facility  that 
will be blinded to treatment group and study  visit. A complete video endoscopic examination 
does not require assessment of the terminal ileum if it cannot be visualized.
The SES-CD score is based on the evaluation of 4 endoscopic components (presence/size of 
ulcers, proportion of mucosal surface covered by [CONTACT_722561], proportion of mucosal surface affected 
by [CONTACT_887118], and presence/t ype of narrowing/strictures) across 5 ileocolonic segments. 
Each endoscopic component is scored from 0 to 3 for each segment , and a total score is derived 
from the sum of all the component scores (range, 0 to 56). The SES-CD score will be evaluated 
by a central reader.
In addition to the evaluation of the SES-CD score , endoscopic healing, which is traditionally  
defined as the resolution (absence) of mucosal ulcers in response to a therapeutic intervention, 
will also be assessed by [CONTACT_9251] .
9.2.12. Histologic Assessment
Histologic assessment will be performed using biops y samples collected during endoscop y. 
Biopsy  samples will be collected at screening, Week 12, and Week 24 from each of 3 predefined 
anatomic locations: the terminal ileum, splenic flexure, and rectum. The biops y samples 
collected at Week 12 and Week 24 will be obtained near where the biopsy  samples at screening 
were collected from each of the 3 predefined locations. Histologic assessment will be conducted 
by a central reader who is blinded to treatment groups. The GHAS will be used to evaluate 
histologic improvement. Additional details will be provided in the Stu dy Reference Manual.
9.3. Pharmacokinetics and Immunogenicity Evaluations
9.3.1. Evaluations
Serum samples used to evaluate the PK and immunogenicity  of JNJ-64304500 and ustekinumab 
(antibodies to JNJ-64304500 and antibodies to ustekinumab) will be collected according to the 
Time and Events Schedule s. Samples collected for analy ses of serum concentration of 
JNJ-[ADDRESS_1241654] be 
recorded on the laboratory  requisition form.
At visits where only serum concentration of study  agent will be evaluated (ie,no antibodies to 
study  agent will be evaluated), 1 venous blood sample of sufficient volume should be collected, 
and each serum sample should be divided into 2 aliquots (1 for serum concentration of study 
agent, and a back -up). At visits where serum concentration of study  agent and antibodies to study 
agent will be evaluated, 1 venous blood sample of sufficient volume should be collected . Each 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 121
Approved , Date: 4 June 2021serum sample will be divided into 3 aliquots (1 each for serum concentration of study  agent,
antibodies to study  agent, and a back -up).
9.3.2. Serum Concentration
Serum samples will be analy zed to determine concentrations of JNJ-64304500 and ustekinumab 
using a validated, specific, and sensitive method by [CONTACT_43754].
9.3.3. Immunogenic ity Assessments (A ntibodies to Study  Agent )
The detection and characterization of antibodies to JNJ-64304500 and ustekinumab will be 
performed using a validated assay  method by [CONTACT_43754]. All 
samples collected for detection ofantibodies to JNJ-64304500 or ustekinumab will also be 
evaluated for JNJ-64304500 or ustekinumab serum concentration to enable interpretation of the 
antibody  data.
Serum samples will be screened for antibodies binding to JNJ-64304500 or ustekinumab and the 
titer of confirmed positive samples will be reported. Other analyses may be performed to verify 
the stability  of antibodies to JNJ-64304500 or ustekinumab and/or further characterize the 
immunogenicit y of JNJ-64304500 or ustekinumab. Antibodies to JNJ-64304500 or ustekinumab 
will be evaluated on blood drawn from all subjects according to the Time and Events Schedule. 
Additionally , samples should also be collected at the final visit for subjects who terminate from 
the study . These samples will be tested by [CONTACT_4209]'s designee.
9.4. Biomarker and Other Pharmacody namic Evaluations
Biomarker assessments will be made to examine the biological response to treatment and to 
identify  biomarkers that are relevant to JNJ-64304500 treatment and/or Crohn’s disease. 
Assessments will include the evaluation of relevant biomarkers in serum, whole blood, stool, and 
mucosal biopsy  samples collected according to the Time and Events Schedule.
9.4.1. Serum -based Biomarkers
Blood samples for serum -based biomarker anal yses will be collected from all subjects. Assay s to 
be performed may include the following: measurement of proteins associated with the NKG2D 
pathway , including but not limited to, MICA, MICB,and UBPs 1-6, as well as proteins 
associated with Crohn’s disease such asserum amyloid A,interferon gamma, or matrix 
metalloproteinases.
9.4.2. Whole Blood -based Biomarkers
Whole blood samples will be collected from all subjects to study  the effect of study  agent on 
RNA expression. Whole blood analy ses may also examine RNA expression associated with the 
pathogenesis of Crohn’s disease. An additional blood sample will be obtained for analysis of the 
T-cell receptor repertoire.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 122
Approved , Date: [ADDRESS_1241655] of 
study  agent on gene and protein expression and for the histologic assessment of disease and 
healing (refer to Study  Reference Manual for further details). Mucosal biopsy  analyses may also 
examine gene and protein expression associated w ith the pathogenesis of Crohn’s disease.
9.4.4. NKG2D Receptor Occupancy
NKG2D ROassessments will be performed at the time points specified in the Time and Events 
Schedule. NKG2D ROwill be determined using a validated flow cy tometry assay .
9.4.5. Immunophenotypi[INVESTIGATOR_887073] (including NK cells and CD8+ T cells) will be performed at 
the time points specified in the Time and Events Schedule. Immunophenoty pi[INVESTIGATOR_887074] .
9.5. Pharmacogenomic (DNA ) Evaluations
All subjects will be tested for the NKG2D SNP rs2255336 and the MICB (NKG2D ligand) SNP 
rs2239705 at screening. For subjects who have signed a separate ICF, complete genomic testing 
will be done to search for links of specific genes to disease or response to drug. Only  DNA 
research related to JNJ-64304500 or ustekinumab or to the diseases for which this drug is 
developed will be performed. A 10 mL blood sample will be collected from all subjects for this 
testing; in the event of DNA extraction failure, a replacement pharmacog enomic blood sample 
will be requested from the subject.
Further, a subject may withdraw his/her optional DNA consent for complete genomic testing at 
any time without affecting their participation in other aspects of the study , or their future 
participation in the study .
9.6. Medical Resource Usage
Crohn's disease -related hospi[INVESTIGATOR_887075]’s disease -related surgeries will be collected in 
the study .
9.7. Safety  Evaluations
Details regarding the DMC are provided in Section 11.[ADDRESS_1241656] be recorded on the Adverse 
Event section of the CRF.
Any clinically  significant abnormalities persisting at the end of the study/earl y withdrawal will 
be followed b y the investigator until resolution or until a clinically  stable endpoint is reached.
The study  will include the following evaluations of safet y and tolerability  according to the time 
points provided in the Time and Events Schedule s:
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 123
Approved , Date: [ADDRESS_1241657] (or, when appropriate, by a caregiver, surrogate, 
or the subject's legall yacceptable representative) for the duration of the study . Adverse events 
will be followed b y the investigator as specified in Section 12, Adverse Event Reporting.
Clinical Laboratory Tests
Blood samples for serum chemistry  and hematology will be collected. The investigator must 
review the laboratory  results, document this review, and record any clinically  relevant changes 
occurring during the study  in the Adverse Event section of the CRF. Clinical hemat ology  and 
chemistry  laboratory  test results will be graded by[CONTACT_887119] (NCI-CTCAE )toxicity  criteria. The laboratory  reports 
must be filed with the source documents.
The following tests will be performed by [CONTACT_887120] b y the medical monitor :
Hematology assessments :hematocrit, hemoglobin, platelet count, total and differential 
white blood cell count.
Blood chemistry assessments :ALT, AST, alkaline phosphatase, albumin, total and direct 
bilirubin, blood urea nitrogen, calcium, chloride, creatinine, phosphate, potassium, total 
protein, and sodium .
A medical monitor or delegate and the clinical site will be notified if prespecified abnormal 
laboratory  values defined in the Laboratory  Manual are identified in any subject during the 
conduct of the stud y.
Pregnancy testing: Female subjects of childbearing potential will undergo a serum β-hCG 
pregnancy  test at screening, and a urine pregnancy  test before each study agent 
adminis tration visit, at an earl y termination visit, and at the final efficacy  and safet y visit.
Serology  (HIV antibody , HBsAg, and HCV antibody )
Abnormal liver function tests: If laboratory  testing for a subject randomized in the study 
and receiving study  drug reveals an increase of serum aminotransferases (ALT or AST ) to 
>3x the ULN and an increase of bilirubin to >2x ULN, study  agent should be suspended 
immediately . In addition, laboratory  tests for ALT, AST, alkaline phosphatase, and total 
bilirubin should be confirmed by a retest within [ADDRESS_1241658] results. See Attachment 5(Liver Safet y Monitoring 
and Assessment) for additional information on monitoring and assessment of abnormal liver 
function tests.
Electrocardiogram (ECG)
A 12 -lead ECG will be performed at screening.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 124
Approved , Date: 4 June 2021Vital Signs
Vital signs including temperature, pulse/heart rate, respi[INVESTIGATOR_2842], and blood pressure will be 
collected at all study  visits before and [ADDRESS_1241659] etion of the infusion (at approximately  
30-minute intervals).
Physical Examination
Physical examinations will be performed as specified in the Time and Events Schedules. Height 
and weight will be recorded at screening; weight will also be recorded at timep oints specified in 
the Time and Events Schedules.
Early Detection of Active Tuberculosis
To aid in the early  detection of TB reactivation or new TB infection during study  participation, 
subjects must be evaluated for signs and symptoms of active TB at scheduled visits (refer to 
Time and Events Schedule). The following series of questions is suggested for use during the 
evaluation:
“Have you had a new cough of >14 day s’ duration or a change in a chronic cough?”
“Have you had an y of the following s ymptoms:
Persistent fever?
Unintentional weight loss?
Night sweats?”
“Have you had close contact [CONTACT_41022]?” (If there is uncertaint y as 
to whether a contact [CONTACT_41023] “close,” a physician specializing in TB should be 
consulted.)
Ifthe evaluation raises suspi[INVESTIGATOR_40958] a subject may have TB reactivation or new TB infection, 
an immediate investigation should be undertaken, including, where possible, consultation with a 
physician specializing in TB.
Investigators should be aware that T B reactivation in immunocompromised subjects may  present 
as disseminated disease or with extrapulmonary  features. Subjects with evidence of active TB 
must discontinue further study  agent administrations and should be referred for appropriate 
treatment.
Subjects who experience close contact [CONTACT_402558] a repeat chest radiograph, a repeat QuantiFERON -TB test, a repeat 
tuberculin skin test in countries in which the QuantiFERON -TB test is not appro ved/registered, 
and, if possible, referral to a physician specializing in TB to determine the subject’s risk of 
developi[INVESTIGATOR_40959]. A tuberculin skin test is 
recommended but not required for study  centers in countries where tuberculin is not available. A 
positive QuantiFERON -TB (or tuberculin skin) test result should be considered detection of 
latent TB. If the QuantiFERON -TB test result is indeterminate, the test should be repeated as 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 125
Approved , Date: [ADDRESS_1241660] immediately  
discontinue further administration of study  agent and be encouraged to return for all subsequent 
scheduled stud y visits.
Concomitant Medication Review
Concomitant medications will be reviewed at each visit.
Infusion Reactions
An infusion reaction (Part II of the study ) is defined as an AE that occurs during or within 1 hour 
after the infusion of study  agent, with the exception of laboratory  abnormalities. Minor infusion 
reactions may be managed by [CONTACT_247915]/or treating with 
antihistamines and/or acetaminophen (paracetamol) as clinically  indicated. If an IV infusion of 
study  agent is stopped because of an infusion reaction and the reaction, in the opi[INVESTIGATOR_1070], is not severe or does not result in a serious adverse event (SAE; Section 12.3.2 ), the 
infusion may be restarted with caution.
Injection -Site Reaction
An injection -site reaction (in Part I or Part II) is any adverse reaction at an SC study  agent 
injection -site. Injection sites will be evaluated for reactions and any injection -site reactions will 
be recorded as an AE.
Allergic Reactions
Before any SC injection or IV infusion, appropriately  trained personnel and medications must be 
available to treat allergic reactions, including anaphy laxis. Appropriate medical personnel must 
be in attendance at the time of the injection or infusion and for at least [ADDRESS_1241661] be observed carefully  for symptoms of an 
allergic reaction ( eg, urticaria, itching, hives).
If a mild or moderate allergic reaction is observed, acetaminophen, nonsteroidal anti-
inflammatory  drugs (NSAIDs ), and/or diphenh ydramine may be administered. In the case of a 
severe allergic reaction (eg, anaph ylaxis), SC aqueous epi[INVESTIGATOR_238], corticosteroids, respi[INVESTIGATOR_72788], andother proper resuscitative measures are essential and must be available at the 
study  site where the injections or infusions are being given.
For severe reactions related to an injection or infusion, the subject may be permanentl y 
discontinued from further study  injections at the discretion of the investigator (Section 10.2).
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 126
Approved , Date: 4 June 2021Subjects who experience serious adverse reactions related to an injection or infusion should be 
discontinued from further study agent administrations (Section 10.2).
Subjects who experience reactions after an injection or infusion (Part II) that result in 
bronchospasm with wheezing and/or dyspnea that requires ventilatory support OR that 
result in symptomatic hypotension with a decrease in systolic blood pressure >40 mmHgor 
blood pressure <90/[ADDRESS_1241662] with a clinically  important, active 
infection. Investigators are required to evaluate subjec ts for any signs or symptoms of infection, 
and also review subjects’ diary  cards for signs of infection, at scheduled visits (see Time and 
Events Schedule). If a subject develops a serious infection, including but not limited to sepsis or 
pneumonia, discon tinuation of study  treatment (ie, no further study  agent administrations) must 
be considered.
9.8. Sample Collection and Handling
The actual dates and times of sample collection must be recorded in the CRF or laboratory 
requisition form.
Refer to the T ime and Events Schedule for the timing and frequency  of all sample collections.
Instructions for the collection, handling, storage, and shipment of samples are found in the 
laboratory  manual that will be provided. Collection, handling, storage, and shipment of samples 
must be under the specified, and where applicable, controlled temperature conditions as indicated 
in the laboratory  manual .
10. SUBJECT COMPLETION/ DISCONTINUA TION OF S TUDY TREATMENT/ 
WITHDRA WALFROM THE STUDY
10.1. Completion
Main Study Phase ( Part I and Part I I)
A subject will be considered to have completed the study  if he or she has completed assessments 
through the final efficacy  and safet y visit (ie,Week 38in Part I and Week 36in Part II), as 
specified in the Time and Events Schedule sfor Part I or Part II.
Subjects who prematurely  discontinue study  treatment for any reason can be considered to have 
completed the study  if they  have completed scheduled assessments as follows:
Subjects who discontinue study  agent in Part Ibefore Week [ADDRESS_1241663] dose of study  drug .
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 127
Approved , Date: 4 June 2021Subjects who discontinue study  agent at or after Week [ADDRESS_1241664] dose of study  drug.
Subjects who discontinue study  agent in Part II before Week [ADDRESS_1241665] dose of study  drug.
Subjects who discontinue study  agent at or after Week [ADDRESS_1241666] study  agent 
administration for all subjects who received JNJ-64304500 or ustekinumab . Following the study  
unblinding, any remaining ustekinumab subjects in the LTE (in countries were ustekinumab is 
not commerciall y available) will not have a final safet y visit du e to the well -known safety  profile 
of ustekinumab. If the investigator decides that the patient should continue ustekinumab 
treatment after completing the Part II LTE, the investigator or the subject’s treating physician is 
responsible for providing the subject with commercial ustekinumab, which should be 
administered according to the approved dosing regimen in each country .
Subjects who received placebo will be consider ed to have completed the extens ion phase of the 
studyif they complete [ADDRESS_1241667]'s study  treatment must be discontinued if:
The investigator believes that for safet y reasons or tolerability  reasons (eg,AE),it is in the 
best interest of the subject to discontinue study treatment .
The subject becomes pregnant or plans a pregnancy  within the study period or within 
16weeks after the last study  agent administration.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 128
Approved , Date: 4 June 2021The subject is deemed ineligible according to the following TB screening criteria:
A diagnosis of active TB is made.
A subject has symptoms suggestive of active TB based on follow -up assessment 
questions and/or physical examination, or has had recent close contact [CONTACT_4490] a person 
with active TB, and cannot or will not continue to undergo additional evaluation.
A subject undergoing continued evaluation has a chest radiograph with evidence of 
current active TB and/or a positive QuantiFERON -TB test result and/or a positive 
tuberculin skin test result in countries in which the QuantiFERON -TB is not 
approved/registered (recommended but not required for study  centers in countries where
tuberculin is not available) unless active TB can be ruled out and appropriate treatment 
for latent TB can be initiated either prior to or simultaneously  with the next 
administration of study  agent and continued to completion. (Note: Study  agent must be 
discontinued for all subjects diagnosed with latent TB in countries with high 
multidrug -resistant TB burden [eg, Brazil, China, India, the Russian Federation, and 
South Africa ]).
A subject receiving treatment for latent TB discontinues this treatment prematurely  or is 
noncompliant with the therap y.
A serious adverse reaction occurs that is related to an injection or an infusion, including an 
injection -site or infusion reaction, resulting in bronchospasm with wheezing and/or dyspnea 
that requires ventilatory  support ORthat results in sy mptomatic hy potension with a decrease 
in systolic blood pressure >40mmHg or blood pressure <90/60 mmHg.This may include 
events of NCI -CTCAE toxicity  grade ≥3.
Adverse events of NCI-CTCAE grade ≥3 will be evaluated by  [CONTACT_887121] a determination on discontinuation of study  agent. Discontinuation 
of study  agent should be considered in subjects with worsening Crohn’s disease where 
continuation of the study  drug is not in the best interest of the subject .
Malignancy  including squamous cell skin cancer. Consideration may be given to allowing 
subjects who develop ≤2 basal cell skin cancers that are adequately  treated with no evidence 
of residual disease to continue to receive stud y agent.
Total (com plete) or partial (supplemental) parenteral nutrition is initiated through an 
indwelling catheter at any  time during the study .
The initiation of the following protocol -prohibited medications at any  time during the study :
Immunomodulatory  agents other than 6-MP, AZA, or MTX (including but not limited 
to 6-TG, cyclosporine, tacrolimus, sirolimus, mycophenolate mofetil, tofacitinib, and 
other JAK inhibitors).
Immuno modulatory  biologic agents (including but not limited to TNF antagonists, 
natalizumab, abatacep t, vedolizumab ).
Experimental Crohn’s disease medications (including but not limited to thalidomide, 
briakinumab, traficet, AMG -827). Ustekinumab is permitted in Part II of this study  only 
in subjects randomly  assigned to ustekinumab and only  as stipulated per protocol.
A systemic opportunistic infection.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 129
Approved , Date: 4 June 2021Severe hepatic function abnormalities as described in Section 9.7.
The subject (or the subject’s representative) withdraws consent for administration of study 
agent.
Crohn’s disease -related surgeries that represent a lack of efficacy  of study  agent or will 
preclude the future ability  to assess efficacy  through the CDAI.
Note : Other permitted Crohn’s disease -related surgeries (eg, to resolve long-standing 
complications such as strictures or for symptomatic nonhealing fistulas, in subjects 
experiencing improve ment on study  agent) other than minor procedures (eg, placement of a 
seton or cutaneous drainage of an abscess) should be postponed until after the final efficac y 
and safet y visit, unless necessary  to ensure subject well -being and/or safety .
In the event of any serious infection, severe injection -site or infusion reaction, the study  drug 
must be held and dosing may not be resumed until the investigator has discussed the case with 
the study medical monitor .
A subject will not be automatically  withdrawn from the study  if he or she has to discontinue 
treatment before the end of the treatment regimen. If a subject discontinues study  treatment for 
any reason before the end of the treatment period , assessments should be obtained as specified in 
Section 10.1.
10.3. Withdrawal From the Study
A subject will be withdrawn from the stud y for any of the following reasons:
Lost to follow -up
Withdrawal of consent
Death
Sponsor decision ( eg, participating in any  other clinical study  with an investigational agent)
Subjects who terminate study  participation will not be required to return for any follow -up 
assessments; however, these subjects should complete the safety  and efficacy evaluations 
specified for the Early  Termination Visit in the appropriate Time and Events Schedule at the 
time they  terminate study participation.
If a subject is lost to follow -up, every  reasonable effort must be made by  [CONTACT_887122]/withdrawal. The measures 
taken to follow -up must be documented.
When a subject withdraws before completing the study , the reason for withdrawal is to be 
documented in the CRF and in the source document. Study agent assigned to the withdrawn 
subject may  not be assigned to another subject. Subjects who withdraw will not be replaced .
10.4. Withdrawal From the Use of Research Samples
A subject who withdraws from the study  will have the following options regarding the optional
research samples :
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 130
Approved , Date: 4 June 2021The collected sample swill be retained and used in accordance with the subject's original 
separate informed consent for optional research samples .
The subject may withdraw consent for optional research samples , in which case the sample s
will be destroy ed and no further testing will take place. To initiate the sample destruction 
process, the investigator must notify  the sponsor study  site contact [CONTACT_244538]. The sponsor study  site 
contact [INVESTIGATOR_1318], in turn, contact [CONTACT_90805]. If 
requested, the investigator will receive written confirmation from the sponsor that the 
sample s have been destroy ed.
Withdrawal From the Optional Research Samples While Remaining in the Main Study
The subject may  withdraw consent for optional research samples while remaining in the study . In 
such a case, the optional research samples will be destroy ed. The sample destruc tion process will 
proceed as described above.
Withdrawal From the Use of Sample s in Future Research
The subject may  withdraw consent for use of sample sfor research ( refer to Section 16.2.5 , Long -
Term Retention of Samples for Additional Future Research). In such a case, samples will be 
destroy ed after they are no longer needed for the clinical study . Details of the sample retention
for research are presented in the main I CF and in the separate IC F for optional research samples .
10.5. Withdrawal From Pharmacogenomic Research Only
The subject may withdraw from the optional consent for pharmacogenomic research related to 
the drug while remai ning in the clinical study . As noted in Section 9.5, however, any testing to 
be performed on all subjects consented as part of the main study  can only be withdrawn if the 
subject withdraws from the study . In the case of withdrawal from the optional 
pharmacogenomics testing and request for sample destruction, the investigator must notify  the 
sponsor site contact [CONTACT_350935]. The spon sor site contact [INVESTIGATOR_1318], in turn, contact 
[CONTACT_90805]. If requested, the investigator will 
receive written confirmation from the sponsor that the sample has been destroy ed.
11. STATISTICA L METHODS
Statistical analy sis will be done by [CONTACT_43758]. A general 
description of the statistical methods to be used to anal yze the efficacy  and safet y data is outlined 
below. Specific details will be provided in the SAP.
Descriptive statistic s (eg, mean, median, SD, interquartile range, minimum, and maximum) will 
be used to summarize continuous variables. Counts and percentages will be used to summarize 
categorical variables. Graphic data display s (eg, line plots) may also be used to summarize the 
data.
Analy ses suitable for categorical data (eg, chi-square tests or Cochran -Mantel -Haenszel 
chi-square tests as appropriate) will be used to compare the proportions of subjects achieving 
selected endpoints ( eg, clinical remission). In cases of rare events, Fisher ’sexact test will be used 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 131
Approved , Date: 4 June 2021for treatment comparisons. Continuous response parameters will be compared using an analysis 
of variance or covariance (ANCOVA) model on the van der Waerden normal scores.
All statistical testing will be performed at a significance level of 0.05 (2-sided) unless otherwise 
specified. Nominal p -values will be display ed for all treatment comparisons.
11.1. Sample Size Determination
Sample size calculations for Part I were determined by [CONTACT_676464] a significant 
difference in the change from baseline in the CDAI  score at Week 8 (primary  endpoint for Part I )
between JNJ-[ADDRESS_1241668] a dose-response signal for the change from baseline in 
CDAI at Week 12 (primary  endpoint for Part II) using the Multiple Comparison Procedures with 
modeling techniques (MCP -Mod) method.
11.1.1. Sample Size in Part I
Part I is powered based on the combined data from Study  [ADDRESS_1241669] differences between JNJ -64304500 and placebo.
The assumptions for the sample size calculations in Part I were based on data from 
CNTO1275CRD3001 (a study  conducted by [CONTACT_887089]’s disease who 
had failed or were intolerant to TNF -antagonist therap y) and CNTO1275CRD3002 (a study 
conducted by [CONTACT_887089]’s disease who had failed or were intolerant to 
corticosteroids or immunomodulators but who had not failed TNF -antagonist therapy ).In 
CNTO1275CRD3001, the mean CDAI change from baseline at Week 8 was -25.1 (SD=91.41) 
and -78.7 (SD=91.79) for the placebo and ustekinumab 6 mg/kg groups, respectivel y. These 
assumptions incorporated the impact of 6% of subjects being noncompleters (in 
CNTO1275CRD3001). In CNTO1275CRD3002, the mean CDAI change from baseline at 
Week 8 was -66.3 (SD=97.81) and -116.3 (SD=102.88) for the placebo and ustekinumab 
6mg/kg groups, respectively . These assumptions incorporated the impact of 4% of subjects 
being noncompleters (in CNTO1275CRD3002).
ForPart I, assuming the mean CDAI  change from baseline at Week 8 is -98in the JNJ -64304500 
group and -46in the placebo group with a common SD of 96 (these values are derived assuming 
1:1 ratio of Bio-IR and Bio-NF subjects) ,60 subjects per treatment group (a total of 120 
subjects) will provide 84% power to detect a treatment difference between JNJ-64304500 and 
placebo at an overall Ty pe 1 error of 0.05 (2 -sided; Table 6).
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 132
Approved , Date: 4 June 2021Table 6: Power to detect a treatm ent difference and sample size com binations at an overall 
Type 1 error of 0.05 (2 -sided) for Part I
Sample size per group Placebo JNJ-64304500 Difference Power*
Mean change from  baseline in CDAI score at Week 8
Based on data from CNTO1275CRD3001 a nd CNTO1275CRD3002 (assuming 1: 1 of Bio -IR and Bio -NF 
subjects)
55 -46 -68 32 41%
55 -46 -78 42 62%
55 -46 -98 52 80%
55 -46 -108 62 92%
55 -46 -118 72 97%
60 -46 -68 32 44%
60 -46 -78 42 66%
60 -46 -98 52 84%
60 -46 -108 62 94%
60 -46 -118 72 98%
*Assuming a standard deviation of 96 (derived from CNTO1275CRD3001 and CNTO1275CRD3002) for each 
group. 
11.1.2. Sample Size in Part II
The assumptions for the sample size calculations in Part II were based on the Part I Week 12 
analysisresults . For Bio-IR subjec tsin Part I, the mean CDAI change from baseline at Week 12 
was -30.9 (SD=85.15) and -77.4 (SD=103.68) for the placebo and JNJ-[ADDRESS_1241670] sin Part I, the mean CDAI change from baseline at Week 12 
was -70.9 (SD=93.59) and -144.7 (SD=92.50) for the placebo and JNJ-64304500 groups, 
respectivel y.
For Part II, assuming the mean CDAI change from baseline at Week 12 is -111 in the 
JNJ-64304500 high dose group and -51 in the placebo group (these values are derived assuming
a1:1ratio of Bio-IR and Bio-NF subjects) with a common SD of 102, 50 subjects per treatment 
group will provide a mean power of 85% to detect a dose-response signal forthechange from 
baseline in CDAI at Week 12 based on 7 candidate dose-response models (to be detailed in the 
SAP) at an overall Type 1 error rateof 0.05 (2-sided). Fifty  subjects per treatment group will 
also provide 83% power to detect a treatment difference between the JNJ-[ADDRESS_1241671] dose and the placebo treatme nt group for change from baseline in CDAI 
at Week 12based on a 2-sample t-testat a Type I error rate of 0.05 (2-sided; Table 7). This will 
result in a total sample size of 250 subjects in PartII (incorporating an additional 50 subjects for 
the ustekinumab treatment group).
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 133
Approved , Date: 4 June 2021Table 7: Power to detect a treatm ent difference and sample size com binations at an overall 
Type 1 error of 0.05 (2 -sided) for Part II
Sample size per group PlaceboJNJ-64304500 
high dose Difference Power*
Mean change from  baseline in CDAI score at Week 12
Based on data from Part I (assuming 1:1 of Bio -IR and Bio -NF subjects)
45 -51 -91 40 45%
45 -51 -101 50 63%
45 -51 -111 60 79%
45 -51 -121 70 90%
45 -51 -131 80 96%
50 -51 -91 40 49%
50 -51 -101 50 68%
50 -51 -111 60 83%
50 -51 -121 70 92%
50 -51 -131 80 97%
*Assuming a standard deviation of 102 (based on JNJ -64304500 group at Week 12) for each group. 
11.2. Efficacy  Analyses
This protocol is comprised of 2separate parts (Part I [Study 1: Bio-IR subjects and Study 2: Bio-NF 
subjects] and Part II [Bio-IR and Bio-NF subjects]) . Part I and Part II will be analyzed separatel y 
with separate Type I error control for the primary  endpoint (at the 0.05 level of significance ). 
The other endpoints within each partwill not be controlled for multiplicity .
For each part, the analysis set is all randomized subjects who received study  agent. Efficacy 
analyses will be based on amodified intent -to-treat principle. Therefore, the efficacy  data for 
each subject who received study  agent will be analyzed according to the assigned treatment 
regardless of the actual treatment received.
11.2.1. Part I
[IP_ADDRESS]. Primary  Endpoint Analysis
The primary  endpoint for Part I  is the change from baseline in the CDAI score at Week 8.
The change from baseline in the CDAI score will be compared between the JNJ-64304500 
treatment group and the placebo treatment group for all subjects in Part I. For the comparison , an 
ANCOVA model on the van der Waerden normal scores will be used with treatment as a fixed 
factor and baseline CDAI score ,SNP-positive status (y es or no), and Bio -IRstatus (yes or no)as 
covariates. For this analy sis, treatment failure rules and missi ng data rules as specified in 
Section [IP_ADDRESS] will be applied.
Part I will be considered to be positive if a significant improvement is detected inthe change 
from baseline in the CDAI score at Week 8 in the JNJ-64304500 group compared with the 
placebo group at the 0.05 level of significance .
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 134
Approved , Date: 4 June 202111.2.1.2. Other Efficacy  Endpoint Analyses
The following endpoints will be compared between the JNJ-64304500 treatment group and the 
placebo treatment group for all subjects in Part I and by  [CONTACT_44313]-IR status (y es or no):
Change in CDAI from baseline at all postbaseline visits.
Clinical remission based on CDAI  at all postbaseline visits.
Clinical response based on CDAI  at all postbaseline visits.
Change in PRO -2 from baseline at all postbaseline visits.
Change in abdominal pain score (daily average based on the CDAI assessment) from 
baseline at all postbaseline visits.
Change in stool frequency  score (daily  average based on theCDAI assessment) from 
baseline at all postbaseline visits.
Clinical remission based on PRO -2 at all postbaseline visits.
Clinical response based on PRO -2 at all postbaseline visits.
Change in PRO -3 from baseline at all postbaseline visits.
Clinical remiss ion based on CDAI  at Week 24 among subjects in clinical response at 
Week 12.
Clinical remission based on CDAI  at Week 24 among subjects in clinical remission at 
Week 12.
Change in SES -CD score from baseline at Weeks 12 and 24.
Endoscopic improvement at Weeks 12 and 24 based on a reduction from baseline in 
SES-CD score ≥3.
At least 50% improvement from baseline in SES -CD at Weeks 12 and 24.
Endoscopic healing (defined as the absence of mucos al ulcerations) at Weeks 12 and 24.
Endpoint(s) for histologic assessment based on the GHAS (to be detailed in the SAP).
Fistula response at all postbaseline visits, defined as a ≥50% reduction from baseline in the 
number of draining fistulas.
Endpoint (s)based on Bristol stool form scale (to be detailed in the SAP) .
Change in abdominal pain from baseline at all postbaseline visits based on a 0 -10 NRS .
Change in IBDQ score from baseline at Weeks 8, 12, and 24.
Clinical remission based on IBDQ ( ≥170) at Weeks 8, 12, and 24.
A ≥16-point improvement in IBDQ from baseline at Weeks 8, 12, and 24.
Change from baseline in the PCS and MCS scores of the SF -36 at Weeks 8, 12, and 24.
A ≥5-point improvement in PCS or MCS scores of the SF -36 at Weeks 8, 12, and 24.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 135
Approved , Date: 4 June 2021Change in biomarkers (CRP, fecal calprotectin, fecal lactoferrin) from baseline at Weeks 8, 
12, and 24.
Clinical remission based on CDAI at Week 12by [CONTACT_887082]. Subjects who are positive in at 
least 1 of 2 SNPs (NKG2D or MI CB) will be considered to be SNP -positive.
Other efficacy  endpoints may  be examined by  [CONTACT_887082] (to be detailed in the SAP).
11.2.2. Part II
[IP_ADDRESS]. Primary  Endpoint Analysis
The primary  endpoint is the change from baseline in the CDAI  score at Week 12.
Aunified strategy  that combines Multiple Comparison Procedures with modeling (MCP -Mod) 
techniques ,will be used to analy ze the dose-response relationship for the JNJ-64304500 doses 
(the efficacy  measurement for the dose-response analy sis is the change from baseline in the 
CDAI  score at Week 12). This approach consists of [ADDRESS_1241672] describes 
the observed data and use it to estimate adequate doses with associated precision. The details of 
the dose -response analy sis will be provided in the SAP.
Part II will be considered positive if a dose -response signal for the primary  endpoint is detected.
In addition to the dose-response analy sis, pairwise comparisons of the JNJ-64304500 treatment 
groups versus the placebo group will be performed for the change from baseline in the CDAI 
score at Week 12; these comparisons will not be adjusted for multiplicity . For these comparison s, 
an ANCOVA model on the van der Waerden normal scores will be used with treatment as a 
fixed factor and baseline CDAI score ,SNP-positive status (yes or no), and Bio-IRstatus (yes or 
no) as covariates. Pairwise comparisons of the ustekinumab treatment group with the 
JNJ-64304500 treatment groups or with placebo are not planned; however, summary  statistics 
will be provided for the ustekinumab treatment group.
For the analy ses described above, subjects who meet [ADDRESS_1241673] an y of the following events before the Week 12visit will be considered to be treatment 
failure sfor the primary  endpoint analy sis, regardless of the actual CDAI score:
Specified changes in concomitant Crohn’s disease medications (to be detailed in the SAP).
A Crohn’s disease -related surgery  (with the exception of drainage of an abscess or seton 
placement).
Discontinuation of study  agent due to lack of effica cy or due to an AEof worsening Crohn’s 
disease.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 136
Approved , Date: [ADDRESS_1241674] insufficient data to calculate their 
CDAI  score at Week 12(ie, <4 components of the CDAI are available) will have their last 
available CDAI score carried forward for Week 12.
To examine the robustness of the primary  endpoint analy sis, sensitivity  analyses of the primary 
endpoint will be conducted using different missing data approaches; these analyses will be 
described in the SAP. In addition, sensitivity  analyses excluding subjects who do not meet 
predefined threshold values of stool frequency and abdominal pain at study  entry will be 
performed for the primary  endpo int; thethreshold values and analyses will also be described in 
the SAP .
To evaluate the consistency  of the efficacy , subgroup analysis of the primary  endpoint by  [CONTACT_44313]-IR 
status (y es or no) will be performed.
[IP_ADDRESS]. Major Secondary  Endpoint A nalyses
The major sec ondary  endpoints are:
Clinical remission at Week 12as measured b y CDAI (CDAI <150).
Clinical response at Week 12as measured by [CONTACT_82274] (≥100 -point reduction from baseline in 
CDAI  or CDAI <150).
Change in PRO -2 from baseline at Week 12.
Clinical remission at Week 12as measured b y PRO -2 (PRO -2 <75).
Clinical response at Week 12as measured by [CONTACT_96553]-2 (≥50-point reduction from baseline in 
PRO -2 or PRO -2 <75).
Change in SES -CD from baseline at Week 12.
The major secondary  endpoints of clinical remission and clinical response at Week 12(defined 
by [CONTACT_887123] -2)will be compared between each of the JNJ-[ADDRESS_1241675] (2-sided) 
stratified by [CONTACT_887109] (≤300 or >300) , SNP-positive status (yes or no), and Bio-IR 
status (yes or no).In addition, for the endpoint of clinical remission at Week 12as measured by 
[CONTACT_82274] , the MCP -MOD strategy  will be used to examine the dose-response relationship for the 
JNJ-64304500 doses.
Subjects who meet 1 or more treatment failure rules (as specified for the primary  endpoint) 
before Week 12will be considered not to be in clinical remission or clinical response. Subjects 
who have a missing CDAI  score (ie, <4 components of the CDAI  score) at Week 12will be 
considered not to be in clinical remission or clinical response , as measured by [CONTACT_887124]. 
Subjects who have a missing PRO -2 score (ie, at least one component score of the PRO -2 is 
missing) at Week 12will be considered not to be in clinical remission or clinical response as 
measured b y the PRO -2 score .
The change in PRO -2 from baseline at Week 12will be compared between each of the 
JNJ-64304500 treatment groups and the placebo group using an ANCOVA model on the van der 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 137
Approved , Date: 4 June 2021Waerden normal scores with treatment as a fixed factor and baseline PRO -2 score, SNP-positive 
status (y es or no) , and Bio -IR status (y es or no) as covariates.
Subjects who meet [ADDRESS_1241676] to 
Week 12.
The change in SES-CD score from baseline at Week 12 will be compared between each of the 
JNJ-64304500 treatment groups and the placebo group using an ANCOVA model on the van der 
Waerden normal scores with treatment as a fixed factor and baseline SES-CD score, SNP-
positive status (yes or no), and Bio-IR status (yes or no)as covariates. Data -handling rules for 
the SES-CD score will be provided in the SAP.
For the major secondary endpoints, pairwise comparisons of the ustekinumab treatment group 
with the JNJ-64304500 treatment groups or with placebo are not planned; however, summary 
statistics will be provided for the ustekinumab treatment group.
Sensitivity  analyses excluding subjects who do not meet predefined threshold values of stool 
frequency  and abdominal pain at study  entry will be performed for the major secon dary 
endpoints ; the threshold values and analy ses will be described in the SAP .
To evaluate the consistency  of the efficacy , subgroup analy ses ofthemajor secondary  endpoints 
by [CONTACT_44313]-IR status (y es or no) will be performed.
No adjustments for multiple comp arisons will be made for the major secondary  endpoints.
[IP_ADDRESS]. Other Efficacy  Endpoint A nalyses
Comparisons between each of the JNJ-64304500 treatment group sand the placebo treatment 
group will also be made for each of the endpoints specified in Section [IP_ADDRESS] and for the 
following endpoints.
Change in PGIS of Crohn’s disease from baseline at Weeks 4, 8 , 12and 24.
A ≥1-point improvement in PGIS of Crohn’s disease from baseline at Weeks 4, 8, 12, 
and 24.
Improvement in PGI C of severit y of Crohn’s disease at Weeks 4, 8, 12, and 24.
Pairwise comparisons of the ustekinumab treatment group with the JNJ-64304500 treatment 
groups or with placebo are not planned for these endpoints, however summary  statistics will be 
provided for the ustekinumab group.
11.3. Pharmacokinetic A nalyses
Descriptive statistics of the serum JNJ-64304500 and ustekinumab concentrations will be 
calculated at each sampling time point. Serum JNJ-64304500 and ustekinumab concentrations 
over time will be summarized for each treatment group.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 138
Approved , Date: [ADDRESS_1241677] 
appropriate samples for detection of antibodies to JNJ-64304500 or antibodies to ustekinumab 
(ie, subjects with at least [ADDRESS_1241678] dose of JNJ-64304500 or 
ustekinumab).
Alisting of subjects who are positive for antibodies to JNJ-[ADDRESS_1241679] 
response to JNJ-64304500. Biomarker analyses of ustekinumab will be performed as 
comparisons but not to identify  novel biomarkers for ustekinumab.
Results of serum, whole blood analyses, stool, and mucosal biops y analyses will be reported in 
separate technical reports.
11.6. Pharmacokinetic/Pharmacody namic A nalyses
The relationship between serum concentrations of JNJ-64304500 and PD and/or clinical 
endpoints will be examined .
NKG2D RO(%) over time will be summarized for each treatment group.
The absolute numbers and percentages of peripheral blood NK cells and T cells (including CD4+ 
and CD8+) over time will be summarized for each treatment group.
11.7. Pharmacogenomic A nalyses
Exploratory  genetic analy ses on DNA collection from subjects who signed the optional DNA 
consent will be presented in a separate technical report.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 139
Approved , Date: 4 June 202111.8. Medical Resource Utilization
Crohn’s disease -related hospi[INVESTIGATOR_887076]’s disease -related surgeries will be 
descriptivel y summarized by [CONTACT_1570].
11.9. Safety  Analyses
Adverse Events
The verbatim terms used in the CRF by [CONTACT_43760] . Treatment -emergent AEs are AEs with onset 
during the treatment phase orthat are a consequence of a pre-existing condition that has
worsened since baseline .All reported treatment -emerg ent AEs will be included in the analysis. 
For each AE, the percentage of subjects who experience at least 1occurrence of the given event 
will be summarized by  [CONTACT_1570] .
The following anal yses of AEs will be used t o assess the safet y of subjects :
The incidence and t ype of AEs.
The incidence and t ype of SAEs.
The incidence and t ype of reasonably related AEs.
The incidence and t ype of AEs leading to discontinuation of study agent.
The incidence and t ype of infections.
The incidence and t ype of infusion or injection -site reactions.
Summaries, listings, datasets, or subject narratives may be provided, as appropriate, for those 
subjects who die, who discontinue study  agent due to an AE, or who experience a severe or a 
serious AE.
Clinical Laboratory Tests
The following summaries of clinical laboratory  tests will be used to assess the safet y of subjects:
Laboratory  parameters and change from baseline in laboratory  parameters (hematology  and 
chemistry ).
Summary  of maximum NCI-CTCAE toxicity  grade for postbaseline laboratory  values
(hematology  and chemistry ).
Listings of subjects with any abnormal postbaseline laboratory  values of CTCAE grade ≥2 will 
also be provided.
11.10. Interim A nalysis
An interim analysis is planned inPart Iwhen 100 randomized subjects (Study  1: Bio-IRand 
Study  2: Bio-NF)have completed their Week [ADDRESS_1241680] the 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 140
Approved , Date: [ADDRESS_1241681] tothe change in CDAI  from baseline (inthe combined Bio-IR and Bio-NF subjects ). 
Other selected efficacy analyses (eg,clinical remission , clinical response , and change in 
SES-CD)will also been performed; details will be provided in the Interim Analysis Plan.
A sponsor committee independent of the study  team will be established to review the interim 
data and formulate recommended decisions/actions in accordanc e with predefined decision rules
that will be defined in the Interim Anal ysis Plan .
11.11. Data Monitoring Committee
An external DMC will be established to monitor safet y data on an ongoing basis to ensure the 
continuing safet y of the subjects randomized inPart I and Part II. The committee will meet 
periodicall y to review interim data. After the review, the DMC will make recommendations 
regarding the continuation of thesestudies. The details will be provided in a separate DMC
charter.
The DMC will consist of at least one medical expert [INVESTIGATOR_154991]. The DMC responsibilities, authorities, and procedures will be documented in its 
charter .
12. ADVERSE EVENT REPORT ING
Timely , accurate, and complete reporting and analy sis of safety  information from clinical studies 
are crucial for the protection of subjects, investigators, and the sponsor, and are mandated by 
[CONTACT_23824]. The sponsor has established Standard Operating Procedures in 
conformity  with regulato ry requirements worldwide to ensure appropriate reporting of safet y 
information; all clinical studies conducted by [CONTACT_43765].
12.1. Definitions
12.1.1. Adverse Event Definitions and Classification s
Adverse Event
An AE is any untoward medical occurrence in a clinical study  subject administered a medicinal 
(investigational or non-investigational) product. An AE does not necessarily  have a causal 
relationship with the treatment. An AE can therefore beany unfavorable and unintended sign 
(including an abnormal finding), symptom, or disease temporally  associated with the use of a 
medicinal (investigational or non-investigational) product, whether or not related to that 
medicinal (investigational or non-investigational) product (definition per International 
Conference on Harmonisation [I CH]) .
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 141
Approved , Date: [ADDRESS_1241682] 
abnormalities.
Note: The sponsor collects AEs starting with the signing of the ICF(refer to Section 12.3.[ADDRESS_1241683] AE recording).
Serious Adverse Event
An SAE based on ICH and European Union Guidelines on Pharmacovigilance for Medicinal 
Products for Human Use is any  untoward medical occurrence that at an y dose:
Results in death
Is life-threatening (ie, the subject was at risk of death at the time of the event ; itdoes not 
refer to an event that hy pothetically  might have caused death if it were more severe)
Requires inpatient hospi[INVESTIGATOR_1081]
Results in persistent or significant disability /incapacity
Is a congenital anomal y/birth defect
Is a suspected transmission of an y infectious agent via a medicinal product
Is medicall y important*
*Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
also appropriate in other situations, such as important medical events that may not be
immediately  life-threatening or result in death or hospi[INVESTIGATOR_23738]. 
These should usually  be considered serious.
Unlisted (Unexpected) Adverse Event/Reference Safety Information
An AE is considered unlisted if the nature or severit y is not consist ent with the applicable 
product reference safet y information. For JNJ-64304500 and for ustekinumab, the expectedness 
of an adverse event will be determined by [CONTACT_887125]-64304500 
or for ustekinumab, respectively .
Advers e Event Associated With the Use of the Drug
An AEis considered associated with the use of the drug if the attribution is pos sible, probable, or 
very likely by [CONTACT_23826] 12.1.2 , Attribution Definitions .
Adverse Events Associated with the Study Population
Anticipated events will be recorded and reported as described in Attachment 6 .
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 142
Approved , Date: 4 June 202112.1.2. Attribution Def initions
Not Related
An AE that is not related to the use of the drug.
Doubtful
An AE for which an alternative explanation is more likely , eg,concomitant drug(s), concomitant 
disease(s), or the relationship in time suggests that a causal relationship is unlikely .
Possible
An AE that might be due to the use of the drug. An alternative explanation, eg,concomitant 
drug(s), concomitant disease(s), is inconclusive. The relationship in time is reasonable; therefore, 
the causal relationship cannot be excluded.
Probable
An AE that might be due to the use of the drug. The relationship in time is suggestive 
(eg,confirmed by [CONTACT_23827]). An alternative explanation is less likely, eg,concomitant 
drug(s), concomitant disease(s).
Very Likely
An AE that is listed as a possible adverse reaction and cannot be reasonably  explained by [CONTACT_43767], eg,concomitant drug(s), concomitant disease(s). The relationship in time 
is very  suggestive ( eg,it is confirmed by  [CONTACT_35719] ).
12.1.3. Severity Criteria
An assessment of severity grade will be made using the following general categorical descriptors
as outlined in Section [IP_ADDRESS] and by  [CONTACT_12134]-CTCAE toxicity  grade outlined in Section [IP_ADDRESS] .
[IP_ADDRESS]. Severity Criteria: General Categorical Descriptors
Mild : Awareness of symptoms that are easily tolerated, causing minimal discomfort and not 
interfering with every day activities.
Moderate : Sufficient discomfort is present to cause interference with normal activity .
Severe : Extreme distress, causing significant impairment of functioning or incapacitation. 
Prevents normal every day activities.
The investigator should use clinical judgment in assessing the severit y of events not directly  
experienced b y the subject ( eg,laboratory  abnormalities).
Note : Seriousness and severit y should not be confused. A subject could experience a severe 
heada che that would not qualify  as aSAE, while another might experience a mild stroke that, 
while not severe, would be considered serious.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 143
Approved , Date: 4 June 202112.1.3.2. Severity Criteria Based on National Cancer Institute Common 
Terminolog y Criteria for A dverse Events Toxicity  Grade
An assessment of severity grade will also be made using the following NCI-CTCAE categorical 
descriptors. The NCI-CTCAE Grade refers to the severit y of the AE. The NCI-CTCAE display s 
Grades 1 through 5 with uniqu e clinical descriptions of severity  for each AE based on this 
general guideline:
Grade 1:Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.
Grade 2:Moderate; minimal, local or noninvasive interventi on indicated; limiting  
age-appropriate instrumental Activities of Daily  Living (ADL)*.
Grade 3:Severe or medically  significant but not immediately  life-threatening; hospi[INVESTIGATOR_8942]; disabling; limiting self -care ADL**.
Grade 4: Life-threatening consequences; urgent intervention indicated.
Grade 5: Death related to AE.
*Instrumental ADL refer to preparing meals, shoppi[INVESTIGATOR_3112], using the 
telephone, managing money , etc.
**Self -care ADL refer tobathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden.
12.2. Special Reporting Situations
Safety  events of interest on a sponsor study  drugthat may require expedited reporting and/or 
safet y evaluation include, but are not limited to:
Overdose of a sponsor study  drug
Suspected abuse/misuse of a sponsor study  drug
Accidental or occupational exposure to a sponsor study  drug
Medication error involving a sponsor product (with or without subject/patient exposure to 
the sponsor study  drug , eg, name [CONTACT_2976])
Exposure to a sponsor study  drug from breast -feeding
Special reporting situations should be recorded in the CRF. Any speci al reporting situation that 
meets the criteria of a n SAE should be recorded on the SAE page of the CRF.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 144
Approved , Date: [ADDRESS_1241684]'s last study -related 
procedure ,which may include contact [CONTACT_20687] -up of safet y.Serious AEs, including those 
spontaneously  reported to the investigator within 16weeks after the last dose of study  drug, must 
be reported using the Serious Adverse Event Form. The sponsor will evaluate any safet y 
information that is spontaneously reported by [CONTACT_887126].
All event s that meet the definition of an SAE will be reported asSAEs , regardless of whether 
they are protocol -specific assessments. Anticipated events will be recorded and reported as 
described inAttachment [ADDRESS_1241685] be 
recorded using medical terminology  in the source document and the CRF. Whenever possible, 
diagnoses should be given when signs and symptoms are due to a common etiology  (eg,cough, 
runny  nose, sneezing, sore throat, and head congestion should be reported as "upper respi[INVESTIGATOR_28945]"). Investigators must record in the CRF their opi[INVESTIGATOR_762418] y. All measures required for AE management must be recorded in the source 
document and reported according to sponsor instructions.
The sponsor assumes responsibility  for appropriate reporting of AEs to the regulatory  authorities. 
The sponsor will also report to the investigator (and the head of the investigational institute 
where required) all S[LOCATION_003]Rs . The investigator (or sponsor where required) must report S[LOCATION_003]R s 
to the appropriate IEC/IRBthat appro ved the protocol unless otherwise required and documented 
by [CONTACT_6179]/IRB .A S[LOCATION_003]R will be reported to regulatory  authorities unblinded. Participating 
investigators and IEC/I RB will receive a blinded S[LOCATION_003]R summary , unless otherwise specified.
For all studie s with an outpatient phase, including open -label studies, subject smust be provided 
with a "wallet (study )card" and instructed to carry  this card with them for the duration of the 
study  indicating the following:
Study number
Statement, in the local langua ge(s), that the subject is participating in a clinical study
Investigator's name [INVESTIGATOR_1238] [ADDRESS_1241686] telephone number
Local sponsor's name [INVESTIGATOR_1238] [ADDRESS_1241687] telephone number (for medical staf f onl y)
Site number
Subject number
Any other information that is required to do an emergency  breaking of the blind
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 145
Approved , Date: [ADDRESS_1241688] be completed and signed by  a physician from the study site and transmitted to 
the sponsor within 24 hours. The initial and follow -up reports of an SAE should be made by 
[CONTACT_6972] (fax) .
All SAEs that have not resolved by [CONTACT_2054] , or that have not resolved upon 
discontinuation of the subject's participation in the study , must be followed until any of the 
following occurs:
The event resolves
The event stabilizes
The event returns to baseline, if a baseline value/status is available
The event can be attributed to agents other than the study  drug or to factors unrelated to 
study  conduct
It becomes unlikely  that any additional information can be obtained (subject or health care 
practitioner refusal to provide additional information, lost to follow -up after demonstration 
of due diligence with follow -up efforts)
Suspected transmission of an infectious agent b y a medicinal product will be reported as a n SAE .
Any event requiring hospi[INVESTIGATOR_059] (or prolongation of hospi[INVESTIGATOR_059]) that occurs during the 
course of a subject's participation in a study  must be reported as an SAE , except hospi[INVESTIGATOR_111074]:
Social reasons in the absence of an AE.
Hospi[INVESTIGATOR_43717] (eg, social reasons such as 
pending placement in long -term care facility ).
Surgery  or procedure planned before entry  into the study  (must be documented in the CRF ). 
Note: Hospi[INVESTIGATOR_23743], and where the 
underly ing condition for which the hospi[INVESTIGATOR_23744] ,will not 
be considered SAEs . Any AE that results in a prolongation of the originall y planned 
hospi[INVESTIGATOR_23745] a new SAE .
The cause of death of a subject in a study , whether or not the event is expected or associated with 
the study  drug , is considered a SAE .
12.3.3. Pregnancy
All initial reports of pregnancy  in female subjects or partners of male subjects must be reported 
to the sponsor by [CONTACT_41032] 24 hours of their knowledge of the event using 
the appropriate pregnancy  notification form. Abnormal pregnancy  outcomes (eg, spontaneous 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 146
Approved , Date: 4 June 2021abortion, fetal death, stillbirth, congenital anomal ies, ectopic pregnancy ) are considered SAEs 
and must be reported using the Serious Adverse Event Form. Any subject who becomes pregnant 
during the stud y must discontinue further study  treatment .
Because the effect of the study  drug on sperm is unknown, pregnancies in partners of male subjects 
included in the study  will be reported as noted above.
Follow -up information regarding the outcome of the pregnancy  and any  postnatal sequelae in the 
infant will be required .
12.3.4. Events of Special Interest
Any newly  identified malignancy  or case of active TB occurring after the first administration of 
study  agent in subjects participating in this clinical study  must be reported by [CONTACT_887127] 9.1.[ADDRESS_1241689] countries. These events are t o be considered serious only 
if they  meet the definition of an SAE.
12.4. Contact[CONTACT_23830] (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_23831] y issues or questions regarding the study  are listed in the Contact [CONTACT_23832](s), which will be provided as a separate document.
13. PRODUCT QUA LITY COMPLA INT HA NDLING
A product qualit y complaint (PQC) is defined as any suspi[INVESTIGATOR_1884] a product defect related to 
manufacturing, labeling, or packaging, ie, any dissatisfaction relative to the identity , quality , 
durability , or reliabilit y of a product, inc luding its labeling or package integrity . A PQC may  have 
an impact on the safet y and ef ficacy  of the product. T imely , accurate, and complete reporting and 
analysis of PQC information from studies are crucial for the protection of subjects, investigators, 
and the sponsor , and are mandated by [CONTACT_23824]. The sponsor has 
established procedures in conformity  with regulatory  requirements worldwide to ensure 
appropriate reporting of PQC information; all studies conducted by [CONTACT_111168].
13.1. Procedures
All initial PQCs must be reported to the sponsor by  [CONTACT_41032] [ADDRESS_1241690] report the PQC to the 
sponsor according to the SAE reporting timelines (refer to Section 12.3.2 ,Serious Adverse 
Events). A sample of the suspected product should be maintained for further investigation if 
requested b y the sponsor .
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 147
Approved , Date: [ADDRESS_1241691] Quality
The names (and corresponding telephone numbers) of the individuals who should be contact[CONTACT_887128](s), which will be 
provided as a separate document.
14. STUDY DRUG INFORMA TION
14.1. Physical Description of Study Drug s
In Part I and Part II, theJNJ-[ADDRESS_1241692] 
which , upon reconstitution with 1.1 mL of water for injection, contains 100 mg/mL 
JNJ-64304500 in 34mM L-histidine, 8.6% (w/v) sucrose, and 0.03% (w/v) polysorbate 80, pH 
6.0in a [ADDRESS_1241693] of excipi[INVESTIGATOR_840].
Placebo for JNJ-64304500 consists of a 9 mL solution of 34 mM L-histidine, 8.6% (w/v) sucrose, 
and 0.03% (w/v) pol ysorbate 80, pH 6.0 in a 10 mL glass vial.
In Part II, ustekinum ab 5 mg/mL final vialed product for IVinfusion and placebo to match will be 
supplied as a single -use, sterile solution in 30 mL vials with 1 dose strength (ie, 130mg in 26 mL 
nominal volume).
Ustekinumab SC will be supplied as a sterile solution in a single-use prefilled syringe (PFS) at a 
volume of 1 mL(90 mg dose) that contains ustekinumab 90mg, L-histidine, L-histidine 
monohy drochloride monohy drate, sucrose, and polysorbate 80 at pH 6.0 in 1.0 mL nominal 
volume. No preservatives are present. The needle cover on the PFS contains dry natural rubber 
(aderivative of latex), which may cause allergic reactions in individuals sensitive to latex. Liquid 
placebo will be supplied in a [ADDRESS_1241694] be stored at controlled temperatures ranging from 2°C to 8°C (36°F to 46°F) .
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 148
Approved , Date: 4 June 2021Refer to the pharmacy  manual/ study site investigational product and procedures manual for 
additional guidance on study  drug preparation ,handling , and storage .
14.5. Drug A ccountability
The investigator is responsible for ensuring that all study  drug received at the site is inventoried 
and accounted for throughout the study . The study  drug administered to the subject must be 
documented on the drug accountability  form. All study  drug will be stored and disposed of 
according to the sponsor's instructions. Study site personnel must not combine contents of the 
study  drug containers.
Study  drug must be handled in strict accordance with the protocol and the container label and
must be stored at the study  site in a limited -access area or in a locked cabinet under appropriate 
environmental conditions. Unused study  drug must be available for verification by [CONTACT_456]'s 
study  site monitor during on-site monitoring visits. The return to the sponsor of unused study 
drug will be documented on the drug return form. When the study  site is an authorized 
destruction unit and study  drug supplies are destroy ed on-site, this must also be documented on 
the drug return form.
Potentially  hazardous materials such as used ampules, needles, syringes ,and vials containing 
hazardous liquids should be disposed of immediately  in a safe manner and therefore will not be 
retained for drug accountability  purposes. The immediate destruction of these drug supplies 
should be documented in the drug accountability  records on -site.
Study  drug should be dispensed under the supervision of the investigator or a qualified member 
of the study site personnel , or b y a hospi[INVESTIGATOR_307]/clinic pharmacist. Study  drug will be supplied onl y to 
subjects participating in the study . Returned study drug must not be dispensed again, even to the 
same subject. Study  drug may not be relabeled or reassigned for use by [CONTACT_23837]. The 
investigator agrees neither to dispense the study  drug from, nor store it at, any site other than the 
study  sites agreed upon with the sponsor.
15. STUDY -SPECIFIC MATER IALS
The investigator will be provided with the following supplies:
Investigator Site File (includes protocol and IB)
Investigational Product Binder
Central Laboratory  Manual
CRF completion instructions
Patient recruitment materials
Subject study  information
Informed consent form
CDAI  diary
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 149
Approved , Date: 4 June 2021Bristol stool form scale diary
Abdominal pain NRS diary
IWRS Manual
Worksheets for data collection
16. ETHICA L ASPECTS
16.1. Study -Specific Design Considerations
Potential subjects will be fully informed of the risks and requirements of the study  and, during the 
study , subjects will be given any new information that may affect their decision to continue 
participation. They  will be told that their consent to participate in the study  is voluntary  and may  be 
withdrawn at any time with no reason given and without penalt y or loss of benefits to which they 
would otherwise be entitled. Only subjects who are fully able to understand the risks, benefits, and 
potential AEs of the study, and provide their consent voluntaril y will be randomized .
The total blood volume to be collected is considered to be an acceptable amount of blood to be 
collected over this time period from the population in this study  based upon the standard of the 
American Red Cross (1 pi[INVESTIGATOR_11731]/473 mL  of blood for donation).
16.2. Regulatory  Ethics Compliance
16.2.1. Investigator Responsibilities
The investigator is responsible for ensuring that the study  is performed in accordance with the 
protocol, current ICH guidelines on Good Clinical Practice (GCP), and applicable regulatory  and 
count ry-specific requirements.
Good Clinical Practice is an international ethical and scientific qualit y standard for designing, 
conducting, recording, and reporting studies that involve the participation of human subjects. 
Compliance with this standard provide s public assurance that the rights, safety , and well -being of 
study  subjects are protected, consistent with the principles that originated in the Declaration of 
Helsinki ,and that the study  data are credible.
16.2.2. Independent Ethics Committee or Institutional R eview  Board
Before the start of the study , the investigator (or sponsor where required) will provide the 
IEC/IRB with current and complete copi[INVESTIGATOR_23747] (as required by [CONTACT_13125]) :
Final protocol and, if applicable, amendments
Sponsor -approved ICF(and any  other written materials to be provided to the subjects)
Investigator's Brochure (or equivalent information) and amendments/addenda
Sponsor -approved subject recruiting materials
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 150
Approved , Date: 4 June 2021Information on compensation for study -related injuries or payment to subjects for 
participation in the study , if applicable
Investigator's curriculum vitae or equivalent information (unless not required, as 
documented b y the IEC/IRB)
Information regarding funding, name [CONTACT_8152], institutional affili ations, other potential 
conflicts of interest, and incentives for subjects
Any other documents that the I EC/IRB requests to fulfill its obligation
This study will be undertaken only after the IEC/I RB has given full approval of the final 
protocol, amendment s (if any, excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct , unless required locall y), the ICF, applicable 
recruiting materials, and subject compensation programs, and the sponsor has received a copy of 
this approval. This approval letter must be dated and must clearl y identify the IEC/IRB and the 
documents being approved.
Approval for the collection of optional samples for research and for the corresponding ICFmust 
be obtained from the IEC/IRB. Approval for the protocol can be obtained independent of this 
optional research component .
During the study  the investigator (or sponsor where required) will send the following documents 
and updates to the IEC/IRB for their review and approval, where appropr iate:
Protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study  conduct)
Revision(s) to ICFand any  other written materials to be provided to subjects
If applicable, new or revised subject recr uiting materials approved by  [CONTACT_456]
Revisions to compensation for study -related injuries or payment to subjects for participation 
in the study , if applicable
New edition(s) of the IBand amendments/addenda
Summaries of the status of the study at intervals stipulated in guidelines of the IEC/IRB (at 
least annuall y)
Reports of AEs that are serious, unlisted/unexpected, and associated with the study  drug
New information that may adversel y affect the safet y of the subjects or the conduct of the 
study
Deviations from or changes to the protocol to eliminate immediate hazards to the subjects
Report of deaths of subjects under the investigator's care
Notification if a new investigator is responsible for the study  at the site
Development Safet y Update Repor t and Line Listings, where applicable
Any other requirements of the IEC/I RB
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 151
Approved , Date: 4 June 2021For all protocol amendments (excluding the ones that are purel y administrative, with no 
consequences for subjects, data or study conduct) , the amendment and applicable ICFrevision s 
must be submitted promptly  to the IEC/I RB for review and approval before implementation of 
the change(s).
At least once a year, the IEC/I RB will be asked to review and reapprove this study , where 
required.
At the end of the study , the investigator (or sponsor where required) will notify  the IEC/I RB 
about the study  completion.
16.2.3. Informed Consent
Each subject must give written consent according to local requirements after the nature of the 
study  has been fully  explained. The ICF(s) must be signed before perfo rmance of any study -
related activity . The ICF(s) that is/areused must be approved by [CONTACT_887129]/I RB and be in a language that the subject can read and understand. The informed 
consent should be in accordance with principles that originated in the Declaration of Helsinki, 
current ICH and GCP guidelines, applicable regulatory  requirements, and sponsor policy .
Before enrollment in the study , the investigator or an authorized member of the study site 
personnel must explain to potential subjects the aims, methods, reasonably anticipated benefits, 
and potential hazards of the study ,and any discomfort participation in the study  may entail. 
Subjects will be informed that their participation is voluntary  and that they may withdraw 
consent to participate at any time. They  will be informed that choosing not to participate will not 
affect the care the subject will receive for the treatment of his or her Crohn ’s disease . Subjects 
will be told that alternative treatments are available if they refuse to take part and that such 
refusal will not prejudice future treatment. Finally , they will be told that the investigator will 
maintain a subject identification register for the purposes of long-term follow -up if needed and 
that their records may be accessed by [CONTACT_43772], to the extent permitted by [CONTACT_43773](s) or regulations. By [CONTACT_12568],the subject is authorizing such access , and agrees to 
allow his or her study  physician to recontact [CONTACT_66882] y evaluations , if needed.
The subject will be given sufficient time to read the ICF and the opportunity  to ask questions. 
After this explanation and before entry  into the study , consent should be appropriatel y recorded 
by [CONTACT_19720]'s personall y dated signature. After having obtained the consent, a copy  of 
the ICFmust be given to the subject.
Subjects will be asked for consent toprovide optional samples for research where local 
regulations permit). After informed consent for the study  is appropriatel y obtained, the subject 
will be asked to sign and personall y date a separate ICFindicating agreement to participate in the 
optional research component . Refusal to participate in the optional research will not result in 
ineligibility  for the stud y.A cop y of this signed ICF will be given to the subject.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 152
Approved , Date: [ADDRESS_1241695] includes explicit consent for the processing of 
personal data and for the investigator /institution to allow direct access to his or her original 
medical records (source data/do cuments) for study -related monitoring, audit, IEC/IRB review, 
and regulatory  inspection. This consent also addresses the transfer of the data to other entities 
and to other countries.
The subject has the right to request through the investigator access to his or her personal data and 
the right to request rectification of any data that are not correct or complete. Reasonable steps 
will be taken to respond to such a request, taking into consideration the nature of the request, the 
conditions of the study , and the applicable laws and regulations.
Exploratory  DNA,PD,biomarker ,PK,and immunogenicit y research is not conducted under 
standards appropriate for the return of data to subjects. In addition, the sponsor cannot make 
decisions as to the significance of any findings resulting from exploratory  research. Therefore, 
exploratory  research data will not be returned to subjects or investigators, unless required by  [CONTACT_307509] . Privacy  and confidentiality  of data generated in the future on stored samples 
will be protected b y the same standards applicable to all other clin ical data.
16.2.5. Long -Term Retention of Samples for Additional Future Research
Samples collected in this study  may be stored for up to 15 years (or according to local 
regulations) for additional research. Samples will only be used to understand JNJ-64304500 and 
ustekinumab , to understand Crohn’s disease , to understand differential drug responders, and to 
develop tests/assay s related to JNJ-64304500 and ustekinumab and Crohn’s disease . The 
research may  begin at any  time during the study  or the post -study  storage period.
Stored samples will be coded throughout the sample storage and analysis process and will not be 
labeled with personal identifiers. Subjects may withdraw their consent for their samples to be 
stored for research ( refer to Section 10.4, Withdrawal From the Use of Research Samples ).
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 153
Approved , Date: [ADDRESS_1241696] not be implemented without prior IEC/IRB 
approval, or when the relevant competent authority  has raised any grounds for non-accept ance, 
except when necessary to eliminate immediate hazards to the subjects, in which case the 
amendment must be promptly  submitted to the IEC/I RB and relevant competent authority . 
Documentation of amendment approval by  [CONTACT_23846]/IRB must be provided to the 
sponsor. When the change s involve only logistic or administrative aspects of the study , the 
IEC/IRB ( where required) only  needs to be notified.
During the course of the study , in situations where a departure from the protocol is unavoidable , 
the investigator or other physician in attendance will contact [CONTACT_307510] (s), which will beprovided as a separate
document . Except in emergency  situations, this contact [CONTACT_887130]. In all cases, contact [CONTACT_233869]. The data recorded 
in the CRF and source documents will reflect any departure from the protocol, and the source 
documents will describe this departure and the circumstances requiring it.
17.2. Regulatory  Documentation
17.2.1. Regulatory  Approval/Notification
This protocol and any amendment(s) must be submitted to the appropriate regulatory  authorities 
in each respective country , if applicable. A study may not be initiated until all local regulatory 
requirements are met.
17.2.2. Required Prestudy  Documentation
The following documents must be provided to the sponsor before shipment of study  drug to the 
study site:
Protocol and amendment(s), if an y, signed and dated by [CONTACT_458]
A copy of the dated and signed (or sealed, where appropriate per local regulations) , written 
IEC/IRB approval of the protocol, amendments, ICF, any recruiting materials, and if 
applicable, subject compensation programs. This approval must clearly  identify  the specific 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 154
Approved , Date: [ADDRESS_1241697] be signed (or sealed, where appropriate per local 
regulations) by [CONTACT_887131] e.
Name [CONTACT_23875]/IRB, including a current list of the IEC/IRB members and 
their function, with a statement that it is organized and operates according to GCP and the 
applicable laws and regulations. If accompanied by a letter of explanation, or equivalent, 
from the IEC/I RB, a general statement may be substituted for this list. If an investigator or a 
member of the study site personnel is a member of the IEC/I RB, documentation must be 
obtained to state that this person did not participate in the deliberations or in the 
vote/opi[INVESTIGATOR_23748] .
Regulatory  authority  approval or notification, if applicable
Signed and dated statement of investigator ( eg,Form FDA 1572), if applicable
Documentation of investigator qualifications ( eg,curriculum vitae)
Completed investigator financial disclosure form from the principal investigator, where 
required
Signed and dated Clinical Trial Agreement, which includes the financial agreement
Any other documentation required by  [CONTACT_887132] d ocuments must be provided to the sponsor before enrollment of the first subject:
Completed investigator financial disclosure forms from all subinvestigators
Documentation of subinvestigator qualifications ( eg,curriculum vitae)
Name [CONTACT_23876] , and a dated copy  of 
current laboratory  normal ranges for these tests, if applicable
Local laboratory  documentation demonstrating competence and test reliability 
(eg,accreditation/license), if applicable
17.3. Subject Identification, Enrollment, and Screening Logs
The investigator agrees to complete a subject identification and enrollment log to permit easy 
identification of each subject during and after the study . This document will be reviewed by [CONTACT_887133].
The subject identification and enrollment log will be treated as confidential and will be filed by 
[CONTACT_23854]. To ensure subject confidentiality , no copy  will be made. All 
reports and communications relating to the study  will identify  subjects by [CONTACT_23855]. In cases where the subject is not randomized into the study , the date seen and 
date of birth will be used.
The investigator must also complete a subject screening log, which reports on all subjects who 
were seen to determine eligibility  for inclusion in the study .
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 155
Approved , Date: [ADDRESS_1241698] be available for the following: 
subject identification, eligibility , and study  identification; study  discussion and date of signed 
informed consent; dates of visits; results of safety and efficacy  parameters as required by [CONTACT_12695]; record of all AEs and follow -up ofAEs; concomitant medication; drug 
receipt/dispensing/return records; study  drug administration information ; and date of study  
completion and reason for early discontinuation of study  drug or withdrawal from the study, if 
applicable.
The author of an entry  in the source documents should be identifiable.
At a minimum, the type and level of detail of source data available for a subject should be 
consistent with that commonly  recorded at the study  site as a basis for standard medical care. 
Specific details required as source data for the study  and source data collection methods will be 
reviewed with the investigator before the study  and will be described in the monitoring 
guidelines (or other equivalent document).
The minimum source documentation requirements for Section 4.1,Inclusion Criteria ,and 
Section 4.2,Exclusion Criteria ,that specify  a need for documented medical history  are as 
follows:
Referral letter from treating ph ysician or
Complete history  of medical notes at the site
Discharge summ aries
Inclusion and exclusion criteria not requiring documented medical history must be verified at a 
minimum by [CONTACT_41047] (eg, physical examination, 
laboratory  assessment) and documented in the source document s.
An electronic source system may be utilized, which contains data traditionally  maintained in a 
hospi[INVESTIGATOR_23749] (eg, electronic source documents) as well as 
the clinical study -specific data fields as determined by [CONTACT_760]. This data is electronicall y 
extracted for use by [CONTACT_456]. If an electronic source is utilized, references made to the CRF 
in the protocol include the electronic source system but information collected through the 
electronic source may not be limited to that found in the CRF. Data in this system may be 
considered source documentation.
17.5. Case Report Form Completion
Case report forms are prepared and provided by [CONTACT_66888].
All data relating to the study  must be recorded in the CRF. All CRF entries, corrections, and 
alterations must be made by [CONTACT_130438]. The investigator 
must verify  that all data entries in the CRF are accurate and correct.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 156
Approved , Date: [ADDRESS_1241699]'s source document s. Data must be entered into 
CRF in English . The CRF must be completed as soon as possible after a subject visit and the 
forms should be available for review at the next scheduled mo nitoring visit.
All subjective measurements (eg, pain scale information or other questionnaires) will be 
completed by [CONTACT_23856].
If necessary , queries will be generated in the electro nic data capture (eDC)tool. If corrections to 
a CRF are needed after the initial entry  into the CRF, this can be done in either of the following
ways:
Investigator and study site personnel can make corrections in the eDC tool at their own 
initiative or as a response to an auto query  (generated by  [CONTACT_66832]) .
Sponsor or sponsor delegate can generate a query  for resolution by [CONTACT_887134].
17.6. Data Quality  Assurance/Quality  Control
Steps to be taken to ensure the accuracy  and reliability  of data include the selection of qualified 
investigators and appropriate study  sites, review of protocol procedures with the investigator and 
study sitepersonnel before the study , periodic monitoring visits by [CONTACT_456], and direct 
transmission of clinical laboratory  data from a central laboratory into the sponsor's data base. 
Written instructions will be provided for collection, handling, storage, and shipment of samples.
Guidelines for CRF completion will be provided and reviewed with study sitepersonnel before 
the start of the stud y.
The sponsor will review CRF for accuracy  and completeness during on -site monitoring visits and 
after transmission to the sponsor; any discrepancies will be resolved with the investigator or 
designee, as appropriat e. After upload of the data into the study database they  will be verified for 
accuracy  and consistency with the data sources.
17.7. Record Retention
In compliance with the ICH/GCP guidelines, the investigator/institution will maintain all CRF 
and all source docu ments that support the data collected from each subject, as well as all study  
documents as specified in ICH/GCP Section 8, Essential Documents for the Conduct of a 
Clinical Trial, and all study  documents as specified by [CONTACT_887135] t(s). 
The investigator/institution will take measures to prevent accidental or premature destruction of 
these documents.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 157
Approved , Date: [ADDRESS_1241700]. These documents will be 
retained for a longer period if required by [CONTACT_43785]. It is the responsibility  of the sponsor to inform the 
investigator/institution as to when these documents no longer need to be retained.
If the responsible investigator retires, relocates, or for other reasons withdraws from the 
responsibi lity of keepi[INVESTIGATOR_13274], custody  must be transferred to a person who will 
accept the responsibility . The sponsor must be notified in writing of the name [CONTACT_23877]. Under no circumstance shall the investigator relocate or dispose of any study  
documents before having obtained written approval from the sponsor .
If it becomes necessary  for the sponsor or the appropriate regulatory  authority  to review any 
documentation relating to this study , the investigator /institution must permit access to such 
reports.
17.8. Monitoring
The sponsor will perform on-site monitoring visits as frequentl y as necessary . The monitor will 
record dates of the visits in a study  site visit log that will be kept at the study  site, as allowed by 
[CONTACT_1295] .The first post-initiation visit will be made as soon as possible after enrollment 
has begun. At these visits, the monitor will compar e the data entered into the CRF with the 
source documents (eg,hospi[INVESTIGATOR_307]/clinic/phy sician’s office medical records) . The nature and 
location of all source documents will be identified to ensure that all sources of original data 
required to complete the CRF are known to the sponsor and study site personnel and are 
accessible for verification by [CONTACT_130441]. If electronic records are maintained 
at the study site, the method of verification must be discussed with the study site personnel .
Direct access to source document s(medical records) must be allowed for the purpose of 
verify ing that the recorded data are consistent with the original source data. Findings from this 
review will be discussed with the study site personnel . The sponsor expects that, during 
monitoring visits, the relevant study site personnel will be available, the source document swill 
be access ible, and a suitable environment will be provided for review of study -related 
documents. The monitor will meet with the investigator on a regular basis during the study to 
provide feedback on the study conduct.
In addition to on-site monitoring visits, remote contacts can occur. It is expected that during 
these remote contacts, study site personnel will be available to provide an update on the progress 
of the study  at the site.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 158
Approved , Date: 4 June 202117.9. Study Completion/Termination
17.9.1. Study Completion /End of Study
The study  is consider ed completed with the last efficacy  and safet y follow -up visit for the last 
subject participating in the study . The final data from the study site will be sent to the sponsor
(ordesignee) after completion of the final subject visit at that study  site, in the time frame 
specified in the Clinical Trial Agreement.
17.9.2. Study Termination
The sponsor reserves the right to close the study site or terminate the study  at any time for any 
reason at the sole discretion of the sponsor .Study sites will be closed upon study completion. 
Astudy site is considered closed when all required documents and study  supplies have been 
collected and a study site closure visit has been performed.
The investigator may initiate study site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earlyclosure of astudy site by [CONTACT_11004]:
Failure of the investigator to comply  with the protocol, the requirements of the IEC/I RB or 
local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitment of subjects by  [CONTACT_093]
Discontinuation of further study  drug development
17.10. On-Site A udits
Representatives of the sponsor's clinical quality  assurance department may visit the study  site at 
any time during or after completion of the study  to conduct an audit of the study  in compliance 
with regulatory  guidelines and company  policy . These audits will require access to all study 
records, including source documents, for inspection. Subject privacy  must, however, be 
respected. The investigator and study site personnel are responsible for being present and 
available for consultation during routinely  scheduled study site audit visits conducted by [CONTACT_170192].
Similar auditing procedures may also be conducted by [CONTACT_23865], either as 
part of a national GCP compliance program or to review the results of this study  in support of a 
regulatory  submission. The investigator should immediately  notify  the sponsor if he or shehas
been contact[INVESTIGATOR_530] b y a regulatory agency  concerning an upcoming inspection.
17.11. Use of Information and Publication
All information, including but not limited to information regarding JNJ-64304500 or the 
sponsor's operations (eg,patent application, formulas, manufacturing processes, basic scientific 
data, prior clinical data, formulation information) supplied by [CONTACT_887136], and any data, including pharmacogenomic orexploratory  biomarker
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 159
Approved , Date: 4 June 2021research data, generated as a result of this study , areconsidered confidential and remain the sole 
propert y of the sponsor. The investigator agrees to maintain this information in confidence and 
use this information only to accomplish this study  andwill not use it for other purposes without 
the sponsor's pri or written consent.
The investigator understands that the information developed in the study will be used by [CONTACT_244548]-[ADDRESS_1241701] identifiers will not be used in publication of results. Any work created in 
connection with performance of the study  and contained in the data that can benefit from 
copy right protection (except any publication by [CONTACT_40999] ) shall be 
the propert y of the sponsor as author and owner of cop yright in such work.
Consistent with Good Publication Practices and International Committee of Medical Journal 
Editors guidelines, the sponsor shall have the right to publish such primary  (multicenter) data 
and information without approval from the investigator. The investigator has the right to publish 
study  site-specific data after the primary  data are published. If an investigator wishes to publish 
information from the study ,a copy of the manuscript must be provided to the sponsor for review 
at least 60days before submission for publication or presentation. Expedited reviews will be 
arranged for abstracts, poster presentations, or other materials. If requested by [CONTACT_170196], the investigator will withhold such publication for up to an additional 60days to allow 
for filing of a patent application. In the event that issues arise regarding scientific integrity  or 
regulatory  compliance, the sponsor will review these issues with theinvestigator. The sponsor 
will not mandate modifications to scientific content and does not have the right to suppress 
information. Formulticenter study  designs and substudy  approaches, secondary  results generall y 
should not be published before the prima ry endpoints of a study  have been published. Similarly , 
investigators will recognize the integrity  of a multicenter study by [CONTACT_41055], within 12 months of the availability  of the final data (tables, 
listings, graphs), or the sponsor confirms there will be no multicenter study  publication. 
Authorship of publications resulting from this study  will be based on the guidelines on 
authorship, such as those described in the Uniform Requirements for Manuscripts Submitted to 
Biomedical Journals, which state that the named authors must have made a significant 
contribution to the design of the study  or analy sis and in terpretation of the data, provided critical 
review of the paper, and given final approval of the final version.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 160
Approved , Date: 4 June 2021Registration of Clinical Studies and Disclosure of Results
The sponsor will register and disclose the existence of and the results of clinical studies as 
required b y law.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 161
Approved , Date: [ADDRESS_1241702] WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National 
Cooperative Crohn’s Disease Study. Gastroenterol ogy. 1976; 70(3):439 -444.
2. Buderus S, Boone J, Lyerly D, Lentze M J. Fecal lactoferrin: a new parameter to monitor infliximab therapy. 
Dig Dis Sci. 2004; 49(6):1036 -1039.
3. Costa F, Mumolo MG, Ceccarelli L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative 
colitis than in Crohn’s disease. Gut. 20 05;54:364 -368.
4. Dove LS, Lembo A, Randall CW, et al. Eluxadoline benefits patients with irritable bow el syndrome with 
diarrhea in a Phase 2 study. Gastroenterology. 2013; 145:329 –338.
5. Hawker GA, Mian S, Kendzerska T, et al. Measures of adult pain: Visual Analog Scale for Pain (VAS Pain), 
Numeric Rating Scale for Pain (NRS Pain), McGill Pain Questionnaire (MPQ), Short -Form McGill Pain 
Questionnaire (SF -MPQ), Chronic Pain Grade Scale (CPGS), Short Form -36 Bodily Pain Scale (SF -36 BPS), 
and Measure of Intermi ttent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res (Hoboken) 2011; 
63: S240 –S252.
6. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the 
treatment of inflammatory bowel disease. Ca nadian Crohn’s Relapse Prevention Trial Study Group. 
Gastroenterol ogy. 1994; 106(2):287 -296.
7. Kane SV, Sandborn WJ, Rufo PA et al. Fecal lactoferrin is a sensitive and specific marker in indentifying 
intestinal inflammation. Am J Gastroenterol. 2003; 98(6); 1309 -1314.
8. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 
1997; 32(9):920 –924.
9. Shah DK, Betts AM. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal 
antibodies based on the plasma concentrations in several preclinical species and human. mAbs. 2013; 
5(2):297 –305.
10. Solem CA, Loftus EV, Tremaine WJ, et al. Correlation of C -reactive protein with clinical, endoscopic, 
histologic, and radiographic activity in inflammato ry bow el disease. Inflamm Bowel Dis. 2005; 11(8):707 -712.
11. Verm eire S, Van Assche G, Rutgeerts P. C -reactive protein as a marker of inflammatory bow el disease. 
Inflamm Bow el Dis. 2004; 10(5):661 -665.
12. Ware JE, Kosinski M, Keller SD. Interpretation: Norm -Base d. In: SF -36 Phy sical and Mental Health Summary 
Scales: A User’s Manual. [LOCATION_011], MA: The Health Institute; 1994; 8:1-8:42.
13. Ware JE Jr, Sherbourne CD. The MOS 36 item short form health survey (SF 36), I. Conceptual framework and 
item selection. Med Care. 19 92;30(6):473 483.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 162
Approved , Date: 4 June 2021ATTACHMENTS
Attachment 1: Definition of Inadequate Initial Response, Loss of Response, or Intolerance to TNF -
Antagonist Therapi[INVESTIGATOR_014] (Infliximab, A dalimumab, or Certolizumab Pegol ) or
Vedolizumab
The criteria for inadequate initial response, response followed b y loss of response, or intoleran ce 
to infliximab, adalimumab, certolizumab pegol , or vedolizumab are described in items I , II, and 
III, below.
I. Inadequate initial response to current or prior therapy with infliximab, 
adalimumab, certolizumab pegol (primary nonresponse) , or vedolizumab (primary 
nonresponse)
Eligible subjects must satisfy  criteria A, B, and C.
A. Have received induction doses of:
 Infliximab (2 or 3 doses of 5 mg/kg)
or
 Adalimumab (at a dose of 160 mg followed by a dose 80mg orat a 
dose of 80 mg followed by  a dose 40 mg)
or
 Certolizumab pegol (2 or 3 doses of 400 mg)
or
 Vedolizumab (3 or 4 doses of 300 mg)
AND
B. Did not initially respond to these induction doses ofinfliximab, adalimumab, 
certolizumab pegol , or vedolizumab, as evidenced by [CONTACT_76478] 
1 of the following signs or symptoms related to persistence of Crohn’s 
disease, as assessed by a treating physician:
 Lack of improvement or worsening in s tool frequency
 Lack of improvement or worsening in daily  abdominal pain
 Occurrence, lack of improvement, or worsening of fever thought to be 
related to Crohn’s disease
 Lack of improvement or worsening in a draining fistula or devel opment of 
a new draining fistula
 Lack of improvement or worsening in rectal bleeding
 Initiation or incre ase in antidiarrheal medication
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 163
Approved , Date: 4 June 2021These signs and s ymptoms of Crohn’s disease must have occurred 2weeks after 
receiving the last induction dose of infliximab, adalimumab, certol izumab pegol , 
or vedolizumab, and are offered only  as a benchmark of the minimally  acceptable 
criteria required to designate a subject as having had an inadequate initial 
respo nse to infliximab, adalimumab, certolizumab pegol , or vedolizumab therap y. 
This benchmark acknowledges that the CDAI is not routinely  recorded in clinical 
practice.
AND
C. Have documentation available to the investigator that meets the following 2 
requirements:
 Provide the dates and doses of the failed infliximab, adalimumab, 
certolizum ab pegol , or vedolizumab induction therapy.
 Documents that the subject had persistence of disease activity  following 
infliximab, adalimumab, certolizumab pegol , or vedolizumab induction
therap y.
Examples of acceptable documents include: medical records, letter provided by  a 
referring ph ysician, or other “reason for referral” documents (eg, insurance 
authorization form).
II. Initial response followed by [CONTACT_887137], adalimumab, certolizumab pegol , or vedolizumab (secondary 
nonresponse)
Eligible subjects must satisfy  criteria A, B, C, and D.
A. Initially responded to induction therapy
AND
B. Have received at least 2 maintenance doses of:
 Infliximab (at a dose of 5 mg/kg)
or
 Adalimumab (at a dose of 40 mg)
or
 Certoli zumab pegol (at a dose of 400 mg)
or
 Vedolizumab (at a dose of 00 mg)
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 164
Approved , Date: [ADDRESS_1241703] 1 of the following signs or symptoms related to 
recurrence of Crohn’s disease, as assessed by a treating physician:
 Worsening in stool frequency
 Worsening in dail y abdominal pain
 Occurrence or worsening in fever thought t o be related to Crohn’s disease
 Recurring drainage from a previously  nondraining fistula or development 
of a new dr aining fistula
 Worsening in rectal bleeding
 Initiation or incre ase in antid iarrheal medication
These signs and s ymptoms of Crohn’s disease must have occurred 2weeks after 
receiving the last maintenance dose of infliximab, adalimumab, certolizumab 
pegol , or vedolizumab, and are offered onl y as a benchmark of the minimally 
accept able criteria required to designate a subject as having lost response to 
infliximab, adalimumab, certolizumab pegol , or vedolizumab therapy . This 
benchmark acknowledges that the CDAI is not routinely  recorded in clinical 
practice.
AND
D. Have documentation available to the investigator that meets the following 2 
requirements:
 Provide the dates and doses of the failed infliximab, adalimumab, 
certolizumab pegol , or vedolizumab maintenance therap y.
 Documents that the subject had recurrence of disease activity  despi[INVESTIGATOR_887077], adalimumab, certolizumab pegol , or vedolizumab maintenance 
therap y.
Examples of acceptable documents include: medical records, letter provided by  a 
referring ph ysician, or other “reason for referral” documents (eg, insurance 
authorization form).
III. Current or prior intolerance to therapy with infliximab, adalimumab, certolizumab 
pegol , or vedolizumab
Eligible subjects must satisfy  criteria A and B.
A. Have had an adverse reaction that meets 1 of the following 3criteria: 1) 
significant acute infusion/administration reaction; 2)significant delayed 
infusion/administration reaction (for example, delayed hypersensitivity or 
serum -sickness like reactio n); or 3) significant injection -site reaction. 
Definitions of these 3 criteria are provided below . Adverse reactions also 
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 165
Approved , Date: [ADDRESS_1241704] followed 1 dose of infliximab, adalimumab, certolizumab pegol , 
or vedolizumab, and, in the treating physician’s opi[INVESTIGATOR_1649], precluded 
continued use of the therapy.
1) A significant acute infusion/administration reaction is defined as an 
adverse reaction that was:
 Manifested through 1 of the following s ymptoms.
a. Fever greater than 100 F (37.8 C)
b. Chills or rigors
c. Itching
d. Rash
e. Flushing
f. Urticaria or angioedema
g. Breathing difficulties (dyspnea, chest paint or tightness, 
shortnes sof breath, wheezing, stridor)
h. Clinical hypotension (pallor, diaphoresis, faintness, 
syncope), blood pressure less than 90 mm Hg systolic and 
60 mm Hg diastolic, or a systemic or orthostatic drop in 
systolic blood pr essure of greater than 20 mm Hg
AND
 Occu rred 24 hours after infusion/administration of infliximab, 
adalimumab, certolizumab pegol , or vedolizumab
AND
 Was considered related to the infusion/administration of 
infliximab, adalimumab, certolizumab pegol , or vedolizumab .
2) A significant delayed infusi on/administration reaction is defined as an 
adverse reaction that:
 Was manifested through 1 or more of the following s ymptoms:
a. Myalgias
b. Arthralgias
c. Fever greater than 100 F (37.8 C)
d. Malaise
e. Rash
AND
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 166
Approved , Date: 4 June 2021 Occurred >24 hours and <15 days after infusion/administration of 
infliximab, adalimumab, certolizumab pegol , or vedolizumab
AND
 Was considered related to the infusion/administration of 
infliximab, adalimumab, certolizumab pegol , or vedolizumab .
3) A significant injection -site reaction is defined as an adverse reaction 
that:
 Was manifested through 1 or more of the following s ymptoms:
a. Significant bruising
b. Erythema
c. Hemorrhage
d. Irritation
e. Pain
f. Pruritus
g. “Injection -site reaction ”
AND
 Occurred within 24 hours of an SC injection of adalimumab or 
certolizumab pegol.
AND
 Was considered related to the injection.
B. Have documentation available to the investigator that meets the following 2 
requirements:
 Provides the date of discontinuation of infliximab, adalimumab, 
certolizumab pegol , or vedolizumab .
 Documents that the subject had intolerance to infliximab, adalimumab, 
certolizumab pegol , or vedolizumab .
Examples of acceptable documents include: medical records, letter provided by  a 
referring ph ysician, or other “reason for referral” documents (eg, insu rance 
authorization form).
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 167
Approved , Date: 4 June 2021Attachment 2: Definition sof Inadequate Response to or Intolerance of Corticosteroids or 
AZA/6-MP/MTX and Corticosteroid Dependence
CORTICOSTEROIDS
Subjects have failed to respond to corticosteroids ifthey have had evidence of an initial inadequate 
response, recurrent disease, or a relapse despi[INVESTIGATOR_837614] 0.75 mg/kg/ day or >40mg/day of 
prednisone (or corticosteroid equivalent, given orally or intravenously) for 2 weeks; or ≥9 mg/day of 
bude sonide or ≥5 mg/day of beclomethasone dipropi[INVESTIGATOR_676442] 4 weeks.
Subjects are intolerant of corticosteroids if:
They have developed clinically significant adverse events (eg, osteonecrosis or osteoporosis, 
psychosis, uncontrolled diabetes) unresponsive to dose reduction that, in the judgment of the 
investigator, precluded the use of corticosteroids to treat Crohn’s disease .
OR
They have a medical condition that precludes the use of corticosteroids as a treatment for Crohn’s 
disease .
Subjects are corticosteroid dependent ifthey have failed to successfully taper their corticosteroid (ie, 
had a flare of disease) within 3 months of starting therapy, or if a relapse occurs within 3 months after 
stoppi[INVESTIGATOR_887078] 3 months 
after starting them.
6-MERCAPTOPURINE (6 -MP), AZATHIOPRINE (AZA) , OR METHOTREXATE 
(MTX) :
Subjects have failed to respond to 6-MP, AZA , or MTX ifthey have had evidence of an initial 
inadequate response, recurrent disease, or a relapse despi[INVESTIGATOR_338466]:
At least 3 months of therapy with 1 mg/kg/day of 6-MP, 2 mg/kg/day of AZA, or 25 mg/week 
(intramuscular or subcutaneous) of MTX.
OR
A lower dosage of 6-MP, AZA , or MTX when country or local guidelines specify a different 
treatment regimen. (In such an event, the country or local guidelines needs to be included in the 
source document).
OR
The dosage of 6-MP, AZA, or MTX confirmed to be thera peutic for the subject with whole blood 
thioguanine nucleotide levels >200 pmole/8x1 08red blood cells .
OR
The highest tolerated dosage due to leukopenia, elevated liver enzymes, or nausea.
Subjects are intolerant of 6 -MP, AZA , or MTX if:
They have developed clinically significant adverse events (eg, pancreatitis, arthritis accompanied by 
[CONTACT_676508]/or rash, leukopenia, or persistently elevated liver enzymes) unresponsive to dose 
reduction that, in the judgment of the investigato r, precluded the use of 6 -MP, AZA, or MTX to treat 
Crohn’s disease within the past 5 years.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 168
Approved , Date: 4 June 2021OR
They have a medical condition th at precludes the use of 6 -MP, AZA , or MTX .
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 169
Approved , Date: 4 June 2021Attachment 3:Tuberculin Skin Testing
Administering the Mantoux Tuberculin Skin Test
The Mantoux tuberculin skin test (CDC, 2000) is the standard method of identifying persons infected with 
Mycobacterium tuberculosis . Multiple puncture tests (Tine and Heaf) should not be used to determine whether a 
person is infected because the amoun t of tuberculin injected intradermally cannot be precisely controlled. Tuberculin 
skin testing is both safe and reliable throughout the course of pregnancy. The Mantoux tuberculin test is performed 
by [CONTACT_269329] 0.1mL of tuberculi n into the inner surface of the forearm. The test must be 
performed with tuberculin that has at least the same strength as either 5tuberculin units (TU) of standard purified 
protein derivative ([COMPANY_003]) -S or 2TU of [COMPANY_003]-RT23, Statens Seruminstitut, as recomm ended by [CONTACT_67848]. [COMPANY_003] strengths of 1TU or 250TU are not acceptable (Menzies, 2000). Using a disposable tuberculin 
syringe with the needle bevel facing upward, the injection should be made just beneath the surface of the skin. This 
should produce a discrete, pale elevation of the skin (a wheal) 6mm to 10mm in diameter. To prevent needle -stick 
injuries, needles should not be recapped, purposely bent or broken, removed from disposable syringes, or otherw ise 
manipulated by [CONTACT_35681]. After they are used, disposable needles and syringes should be placed in puncture -resistant 
containers for disposal. Institutional guidelines regarding universal precautions for infection control (eg, the use of 
gloves) should be follow ed. A trained health care worker, preferably the investigator, should read the reaction to the 
Mantoux test [ADDRESS_1241705], tuberculin testing 
should be repeated. The area of induration (palpable raised hardened area) around the site of injection is the reaction 
to tuberculin. For standardization, the diameter of the induration should be measured transversely (perpendicular) to 
the long axis of the forearm. Erythema (redness) should not be measured. All reactions should be recorde d in 
millimeters, even those classified as negative.
Interpreting the Tuberculin Skin Test Results
In the US and many other countries, the most conservative definition of positivity for the tuberculin skin test is 
reserved for immunocompromised patients, and this definition is to be applied in this study to maximize the 
likelihood of detecting latent TB, even though the subjects may not be immunocompromised at baseline.
In the US and Canada, an induration of 5mm or greater in response to the intradermal tuberculin skin test is 
considered to be a positive result and evidence for either latent or active TB.
In countries outside the US and Canada, country -specific guidelines for immunocomprom ised patients should be 
consulted for the interpretation of tuberculi n skin test results. If no local country guidelines for 
immunocompromised patients exist, US guidelines must be follow ed.
Treatment of Latent Tuberculosis
Local country guidelines for immunocompromised patients should be consulted for acceptable antituberc ulous 
treatment regimens for latent TB. If no local country guidelines for immunocompromised patients exist, US 
guidelines must be follow ed.
NOTE: The tuberculin skin test is recommended but not required in countries where tuberculin is not available.
Refe rences
Centers for Disease Control and Prevention. Core curriculum on tuberculosis: What the clinician should know 
(Fourth Edition). Atlanta, GA: Department of Health and Human Services; Centers for Disease Control and 
Prevention; National Center for HIV, STD, and TB Prevention; Division of Tuberculosis Elimination; 2000:25 -86.
Menzies RI. Tuberculin skin testing. In: Reichman LB, Hershfield ES (eds). Tuberculosis, a comprehensive 
international approach . 2nd ed. New  York, NY: Marcel Dekker, Inc; 2000:279 -322.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 170
Approved , Date: 4 June 2021Attachment 4:Crohn’s Disease A ctivity Index
       DISEASE ACTIVITY INDEX                 SUM   X FACTOR     SUBTOTAL       
Total number of liquid or very soft stools in the 
previous 7 days x2 =
Sum abdominal pain/cramps ratings
(total for previous 7 days): x5 =
0 =none 2 = moderate
1 =mild 3 = severe
General well -being (total for previous 7 days): x7 =
0 =generally well 3 = very poor
1 =slightly under par 4 = terrible
2 =poor
Categories currently present and
presumed to be related to Crohn’s disease: 0 = no; 1 = yes 
 = arthritis/arthralgia x20 =
 = iritis/uveitis x20 =
 = erythema nodosum/pyoderma 
gangrenosum/aphthous stomatitis x20 =
 = anal fissure, fistula or abscess x20 =
 = other fistula x20 =
 = fever over 100° F (37.8° C) during the 
previous 7 days. x20 =
During the previous [ADDRESS_1241706] once:
OR x30 =
During the previous 7 days has subjec treceived
opi[INVESTIGATOR_887079] 7 days:
0 = no
1 = yes
Abdominal mass: x10 =
0 = none 2 = questionable 5 = definite
Hematocrit: x6 =
Males: ([ADDRESS_1241707]) = SUM (add or subtract by [INVESTIGATOR_652363])
Females: ([ADDRESS_1241708]) = SUM
(Standard Weight -Actual Body Weight) x 100 =*
x1 =
Standard Weight (add or subtract by [INVESTIGATOR_652363], round to 3 decimal places)
*If this value is less than -[ADDRESS_1241709] be in same units (kg or lb)
TOTAL = 
(round total to integer)
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 171
Approved , Date: 4 June 2021Attachment 5:Liver Safety Monitoring and A ssessment
If laboratory  testing for a subject enrolled in study  and receiving study  drug reveals an increase 
of serum aminotransferases ( ALT or AST ) to>3X ULN andbilirubin >2X ULN, laboratory  tests 
for ALT, AST, alkaline phosphatase, and total bilirubin should be confirmed by a retest within 
[ADDRESS_1241710]:
ALT o r AST Total Bilirubin
Moderate >3x UL N or >2x UL N
Marked >3x UL N and >2x UL N
In addition, the subject should be considered to have marked hepatic abnormalities for any  of the 
following:
ALT or AST >8x ULN.
ALT or AST >5x ULN for more than 2 weeks.
ALT or AST >3x ULN and international normalized ratio ( INR)>1.5.
ALT or AST >3x ULN with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).
The investigator may determine that abnormal liver function results, other than as described 
above, may qualify  as moderate or marked abnormalities and require additional monitoring and 
follow -up.
FOLLOW -UP PROCEDURES
Confirmed moderate and marked abnormalities in hepatic functions shou ld be thoroughl y 
characterized by [CONTACT_317257], detailed pertinent history , physical 
examination, and laboratory  tests. The site should complete the Liver Abnormality  Case Report 
Form (LA-CRF). Subjects with confirmed abnormal liver function testing should be followed as 
described below.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 172
Approved , Date: 4 June 2021Confirmed moderatel y abnormal liver function tests (LFTs) should be repeated [ADDRESS_1241711] is asy mptomatic.
Marked hepatic liver function abnormalities, in the absence of another etiology , may be 
considered an important medical event and reported as an SAE . The medical monitor should be 
contact[CONTACT_887138].
To further assess abnormal hepatic laboratory  findings, the investigator is expected to:
Obtain a more detailed history  of sy mptoms and prior or concurrent diseases. Symptoms and 
new onset -diseases should be recorded as ‘adverse events’ on the AE sheet. Illnesses and 
conditions such as hypotensive events, and decompensated cardiac disease than may lead to 
secondary  liver abnormalities should be noted. Non -alcoholic ste atohepatitis (NASH) is seen 
in obese hyperlipoproteinemic, and/or diabetic patients and may be associated with 
fluctuating aminotransferase levels. The investigator should ensure that the medical history 
form captures any illness that predates study  enroll ment that may be relevant in assessing 
hepatic function.
Obtain a history  of concomitant drug use (including nonprescription medication, 
complementary , and alternative medications), alcohol use, recreational drug use, and special 
diets. Medications, includ ing dose, should be entered on the concomitant medication form. 
Information on alcohol, other substance use, and diet should be entered on the LA -CRF.
Obtain a history  of exposure to environmental chemical agents.
Based on the subject’s history , other test ing may  be appropriate including:
acute viral hepatitis (A, B, C, D, E or other infectious agents).
ultrasound or other imaging to assess biliary  tract disease.
other laboratory  tests including INR, direct bilirubin.
Consider gastroenterology or hepatology consultations.
Submit results for any  additional testing and possible etiology  on the LA -CRF.
STUDY AGENT SUSPENSION and/or DISCONTINUATION
If laboratory  testing reveals an increase of serum aminotransferases (ALT or AST) to >3x ULN 
and an increase of bilirubin to >2x ULN, study  agent should be suspended immediatel y. 
Suspension of study  agent should also be considered if:
ALT or AST >8x ULN.
ALT or AST >5x ULN for more than 2 weeks.
ALT or AST >3x ULN and INR >1.5.
ALT or AST >3x ULN with the appearance offatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 173
Approved , Date: [ADDRESS_1241712]’s 
best interest to continue study  agent.
In addition, if close monitoring for a subject with moderate or marked hepatic laboratory  tests is 
not possible, study  agent should be discontinued.
Reference
Guidance for Industry  titled “Drug -Induced Liver Injury : Premarketing Clinical Evaluation” 
issued by  [CONTACT_29024]  2009.
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 174
Approved , Date: 4 June 2021Attachment 6:Anticipated Even ts
Anticipated Event
An anticipated event is an adverse event (serious or nonserious) that commonly occurs as a consequence 
of the underlying disease or condition under investigation (disease -related) or background regimen.
For the purposes of this study t he following events will be considered anticipated events:
Adverse events related to symptoms of Crohn’s disease
Adverse events related to worsening or progression of Crohn’s disease
Reporting of Anticipated Events
These events will be captured on the CRF and in the database, and will be reported to the sponsor as
described in Section 12.3.1 , All Adverse Events . Any event that meets serious adverse event criteria will 
be reported to the sponsor within the appropriate timeline as described in Section 12.3.2 , Serious Adverse 
Events. These anticipated events are exempt from exped ited reporting as individual single cases to Health 
Authorities. However, if based on an aggregate review, it is determined that an anticipated event is 
possibly related to study drug, the sponsor will report these events in an expedited manner.
Anticipate d Event Review Committee (ARC)
An Anticipated Event Review Committee (ARC) will be established to perform reviews of prespecified
anticipated events at an aggregate level. The ARC is a safety committee within the sponsor’s organization 
that is independent of the sponsor’s study team. The ARC will meet to aid in the recommendation to the 
sponsor’s study team as to whether there is a reasonable possibility that an anticipated event is related to 
the study drug.
Statistical Analysis
Details of statistical analysis of anticipated events, including the frequency of review and threshold to 
trigger an aggregate analysis of anticipated events will be provided in a separate Anticipated Events 
Safety Monitoring Plan (ASMP).
JNJ-64304500 Clinical Protocol 64304500CRD2001 Amendment 7
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 175
Approved , Date: 4 June 2021INVESTIGA TOR AGREEME NT
[COMPANY_003]
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 1
Status: Approved ,  Date: 27 April 2020Janssen Research & Development *
Clinical Protocol
COVID -19 Appendix
Protocol Title
A Phase 2b, Randomized, Double -blind, Placebo- controlled, Parallel -group, 
Multicenter Protocol to Evaluate the Safety and Efficacy of JNJ- 64304500 
inSubjects with Moderately to Severely Active Crohn’s Disease
TRIDENT
Protocol 64304500CRD2001; Phase 2b
JNJ-64304500
*Janssen Research & Development is a global organization that operates through different legal entities in 
various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development 
studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen Biologic s, 
BV; Janssen- Cilag International NV; Janssen, Inc; Janssen Pharmaceutica NV; Janssen Sciences Ireland
UC; Janssen Biopharma Inc.;or Janssen Research & Development, LLC. The term “sponsor” is used 
throughout the protocol to represent these various legal entities; the sponsor is identified on the Contact 
[CONTACT_12944].
[LOCATION_002] (U S)sites of t his study  will be conducted under US Food & Drug Administration
Investigational New Drug ( IND) regulations (21 CFR Part 312).]
Status: Approved   
Date: 27April 2020
Prepared by: [CONTACT_12945] & Development, LLC   
EDMS number: EDMS- RIM-[ZIP_CODE], 1.0
THIS APPENDIX APPLIES TO ALL CURRENT APPROVED VERSIONS OF 
PROTOCOL 64304500CRD2001
GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory 
requirements. 
Confidentiality Statement
The information provided herein contains Company trade secrets, commercial or financial information that the Company 
customarily holds close and treats as confidential.  The information is being provided under the assurance that t he recipi[INVESTIGATOR_12882], regulations, rules, protective orders or 
otherwise.
[STUDY_ID_REMOVED]
COVID -19 Appendix
JNJ-64304500 Clinical Protocol 64304500CRD2001
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 2
Status: Approved ,  Date: [ADDRESS_1241713] DURING THE COVID -19 PA NDEMIC
It is recognized that the Coronavirus Disease 2019 (COVID -19) pandemic may  have an impact on 
the conduct of this clinical study due to, for example, self -isolation/quarantine by  [CONTACT_90830] -site personnel; travel restrictions/limited access to public places, including hospi[INVESTIGATOR_600]; study 
site personnel being reassigned to critical tasks.
In alignment with recent health authority  guidance, the sponsor is providing options for 
study -related subject management in the event of disruption to the conduct of the study . This 
guidance does notsupersede any local or government guidelines or requirements or the clinical 
judgement of the investigator to protect the health and well-being of subjects and site staff. If,at 
any time,a subject’s safety  is considered to be at unacceptable risk, study intervention will be 
discontinued, and study  follow -up will be conducted.
Scheduled visits that cannot be conducted in person at the study  site will be performed to the extent 
possible remotel y/virtually  or delayed until such time that on-site visits can be resumed. At each 
contact, subjects will be interviewed to collect safet y data. Key efficacy endpoint assessments 
should be performed if required and as feasible. Subjects will also be questioned regarding general 
health status to fulfill any phy sical examination requirement. 
Every  effort should be made to adhere to protocol -specified assessments for subjects on study 
intervention, including follow -up. Modifications to protocol-required assessments may be 
permitted via COVID -19 Appendix after consultation between the participant and investigator, 
and with the agreement of the sponsor (see below). 
The sponsor will continue to monitor the conduct and progress of the clinical study , and any 
changes will be communicated to the sites and to the health authorities according to local guidance.
If a subject has tested positive for COVID -19, the investigator should contact [CONTACT_456]’s 
responsible medical officer to discuss plans for study  intervention and follow -up. Modifications 
made to the study  conduct as a result of the COVID -19 pandemic should be summarized in the 
clinical study  report.
COVID -19 Appendix
JNJ-64304500 Clinical Protocol 64304500CRD2001
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 3
Status: Approved ,  Date: 27 April 2020ADDITIONAL ELEMENTS, WHERE APPLICABLE:
Certain protocol -mandated visits to the study  site may not be possible during the COVID -[ADDRESS_1241714] care and study integrit y. Certain 
measures, such as those liste d below, ma y be necessar y and  should be instituted in accordance 
with applicable (including local) laws, regulations, guidelines, and procedures:
oremote (eg,by [CONTACT_648] / telemedicine) or in-person, off-site (eg,in-home) interactions 
between site staff (or designees) and participants for study  procedures ,eg,those related 
to safet y monitoring / efficacy  evaluation / study  intervention storage and 
administration (including training where pertinent)
olaboratory  assessments using a suitabl y accredited local laboratory ; for selected 
measures (eg ,urine pregnancy ), home testing may  be employ ed
Missed assessments/visits will be captured in the clinical trial management system for 
protocol deviations. Discontinuations ofstudy  interventions and withdrawal from the study 
should be documented with the prefix “COVID -19-related” in the case report form (CRF).  
oother relevant study  data elements impacted by [CONTACT_12948] / labeled as “COVID -19-related ” in CRFs and / or other study  systems, 
as directed by [CONTACT_12949]. These may include missed / delay ed / 
modified study  visits / assessments / dosing, and instances where temporary  
measures such as those above are implemented.  
The sponsor will evaluate the totalit y of impact of COVID -19 on collection of key study 
data and additional data analy ses will be outlined in study  SAP(s). 
Exclusion: a potential subject with the following features will be excluded from 
participating in the stud y protocol:
oDuring the [ADDRESS_1241715] had ANY of (a) confirmed SARS -CoV -2 
(COVID -19) infection (test positive), OR (b) suspected SARS -CoV -2 infection 
(clinical features without documented test results), OR (c) close contact [CONTACT_4490] a 
person with kn own or suspected SARS -CoV -2 infection 
Exception: may be included with a documented negative result for a 
validated SARS -CoV -[ADDRESS_1241716]
(i)obtained at least 2 weeks after conditions (a), (b), (c) above (timed from 
resolution of key  clinical features if present, e g,fever, cough, d yspnea)
AND
COVID -19 Appendix
JNJ-64304500 Clinical Protocol 64304500CRD2001
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 4
Status: Approved ,  Date: 27 April 2020(ii)with absence of ALL  conditions (a), (b), (c) above during the period 
between the negative test result and the baseline study  visit 
NOTES on COVID -related exclusion:
1.If a participant is excluded due to recent COVID -19-related features, the reason for 
screen failure should be documented in the case report form under the exclusion 
criterion of having a condition for which participation would not be in the participant’s 
interest or could confound study  assessments. 
2.The field of COVID -related testing (for presence of, and immunity  to, the SARS -
CoV -2 virus) is rapi[INVESTIGATOR_2478] y evolving. Additional testing may be performed as part of 
screening and/or during the study  if deemed necessary  by [CONTACT_887139] / guidance from authorities / standards of care. 
Precaution: for those who may  carry  a higher risk for severe COVID -19 illness (eg ,those 
aged over 65 years), follow guidance from local health authorities when weighing the 
potential benefits and ri sks of enrolling in the study , and during participation in the study . 
COVID -19 Appendix
JNJ-64304500 Clinical Protocol 64304500CRD2001
CONFIDENTIAL –FOIA Exemptions Apply in U.S. 5
Status: Approved ,  Date: 27 April 2020INVESTIGA TOR AGREEME NT
[COMPANY_003]